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Die vorliegende Dissertationsschrift befasst sich mit der Darstellung, Charakterisierung und 
Anwendung neuartiger (Metallo-)Dendrimere. Den Schwerpunkt der Arbeit bildet dabei die 
terminale Funktionalisierung (Poly)amidoamin-basierender Dendrimere kleiner Generationen. 
Durch Standardpeptid-Knüpfungsreaktionen von 1,1´-(Diphenylphosphino)ferrocen-
carbonsäure an dendritische (Poly)amidoamine ist eine Serie entsprechend funktionalisierter 
Metallodendrimere zugänglich. Die metallorganischen, Dendrimer-immobilisierten Engrup-
pen können durch Zugabe von [Pd(3-C3H5)Cl]2 in heterobimetallische Übergangsmetallkom-
plexe umgewandelt werden und finden Einsatz als katalytisch aktive Systeme in C,C-
Kreuzkupplungsreaktionen nach Heck.  
Ein weiterer Gegenstand der Arbeit ist die terminale Modifikation von (dendritischen) Ami-
nen mit (Sp)-2-(Diphenylphosphino)ferrocen-1-carbonsäure. Nach erfolgter Umsetzung mit 
[Pd(3-C3H5)Cl]2 werden die erhaltenen planar-chiralen Verbindungen als Katalysatoren in 
asymmetrischen allylischen Substitutionsreaktionen eingesetzt. 
Ferner ist die Darstellung (Oligo)ethylenglykolether-terminierter (Poly)amidoamin-
Dendrimere beschrieben. Diese werden als Stabilisatoren zur in-situ Generierung von Gold- 
sowie Magnetit-Nanopartikeln eingesetzt. Der Einfluss der dendritischen Template auf die 
Kolloidgrößen und Morphologien sowie die Eigenschaften der gebildeten Hybridmaterialien 
werden aufgezeigt. 
Darüber hinaus befasst sich die Arbeit mit der Verwendung biokompatibler 
(Oligo)ethylenglykolether-Dendrimere als Wirkstoffträger für Zytostatika bei der Krebsthera-
pie. Die im Rahmen von in vitro Untersuchungen erhaltenen Ergebnisse werden präsentiert. 
Stichworte:  (Poly)amidoamine, (Metallo-)Dendrimer, Ferrocen, Palladium, Kreuzkupplung, 
(Oligo)ethylenglykole, Stabilisator, Nanopartikel, Gold, Magnetit, Zytostatika. 
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Präambel 
Im Rahmen der im Zeitraum zwischen November 2007 und Oktober 2011 durchgeführten 
Promotionsarbeit an der Professur für Anorganische Chemie der Technischen Universität 
Chemnitz konnten bislang fünf das Thema der vorliegenden Promotionsschrift betreffende 
Publikationen erstellt werden. Diese veröffentlichten bzw. bei entsprechenden naturwissen-
schaftlichen Journalen zur Veröffentlichung eingereichten Arbeiten wurden vom Promoven-
den selbstständig unter Anleitung von Herrn Universitätsprofessor Dr. Heinrich Lang angefer-
tigt. Die vom Promovenden geleisteten Eigenanteile in Publikationen, die als Ergebnis einer 
arbeitsgruppenübergreifenden Kooperation entstanden sind, werden an entsprechender Stelle 
gesondert ausgewiesen. 
Alle diese Promotionsschrift betreffenden Manuskripte sind in englischer Sprache verfasst 
und in inhaltlich unveränderter Form als Kapitel C bis G eingefügt worden. Weiterhin wurden 
die Kapitel A Einleitung (Introduction), Kapitel B Kenntnisstand (State of Knowledge) und 
Kapitel H Zusammenfassung (Summary) sowie die Abschnitte Inhaltsverzeichnis (Table of 
Contents), verwendete Abkürzungen (List of Abbreviations) und Anhang (Appendix) in eng-
lischer Sprache erstellt.    
Die Nummerierung der in der Dissertationsschrift aufgeführten chemischen Verbindungen 
erfolgt gemäß der Bezeichnung des Manuskriptes, in welchem die wissenschaftlichen Ergeb-
nisse veröffentlicht wurden. 
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A Introduction 
1. Dendrimers 
In December 1953, the German chemist Hermann Staudinger was awarded with the Nobel 
Prize in Chemistry. Preceding to this award, he accomplished a pioneering research on the 
field of macromolecular chemistry and established the revolutionary concept of linking a 
large number of small monomer molecules by means of covalent bond formation to yield ma-
cromolecules. This certainly marked the beginning of a new era of molecular design of poly-
mers. 
[A1]  
Polymeric materials are exceptional with respect to their unique flexible and controllable 
preparation techniques as well as their extraordinary versatility of properties. Therefore, in the 
last decades, there was a tremendous development of various types of structural and function-
al macromolecular compounds like hyperbranched, star-shaped and radial symmetric poly-
mers (dendrimers) (Scheme A1). 
[A1] [A2]
 
 
Scheme A1. Schematic illustration of a hyperbranched polymer (A), a star-shaped polymer 
(B) and a dendrimer (C). 
[A2]
 
In 1978, Vögtle 
[A3]
 published a seminal "cascade-like" synthetic strategy making accessible 
a new class of fascinating macromolecules which are now-a-days known as dendrimers (C). 
The word "dendrimer" originates from Greek (combining dendron meaning tree and meros 
meaning part) and refers to regular highly branched macromolecules 
[A4]
 that are in particular 
reminiscent of natural branching tree tops, blood vessels, nerve cells, corals and snowflakes. 
[A5]
 Apart from the distinctive chemical elegance, dendritic networks pertain to flexible, versa-
tile and promising representatives of macromolecular chemistry. 
In general, dendrimers are monodisperse, fractal-like polymers of well-defined three-
dimensional globular shape, exhibiting a radial symmetry. 
[A6]
 Type C molecules are com-
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posed of a central multifunctional core, repetitive branching units (generations) and terminal 
functional groups (periphery) (Scheme A2). 
[A7]  
 
Scheme A2. Structure of a typical regular branched dendrimer.  
The number ni of repetitive units and terminal moieties, respectively, in the dendritic scaf-
fold increases exponentially as a function of the dendrimer´s generation (i) (Equation A1). 
When the dendrimer grows in size, the terminal groups reside closer and closer to each other, 
resulting in a surface congestion, a phenomena that prevents further uniform growth for a mo-
nodisperse dendrimer. 
[A8]
  
             –   
      
(Eq. A1) 
ni = number of repetitive units/terminal moieties;  fc = multiplicity of central core; 
f = multiplicity of branching units; i = generation number. 
 
In contrast to hyperbranched polymers (A), the precise dendritic architectures are con-
structed typically via iterative, consecutive synthesis processes, whereas the synthetic proto-
cols rely on two different approaches: the divergent and the convergent methodology, em-
ploying protection and deprotection steps (Scheme A3). The divergent approach is based on 
the sequential addition of monomers to a branched building block (core), thus forming layer 
by layer (generations) within the structure. The convergent method constructs dendritic archi-
tectures starting from the periphery, elaborating inwards and finally attaching to a core for 
dendrimer assembly. 
[A6] 
As a consequence of both hierarchical synthesis strategies, size, mo-
lecular mass, monodisperseity, shape, chirality, density, viscosity, polarity, solubility, flexibil-
ity and surface chemistry of the resulting dendritic macromolecules can be controlled in an 
unique manner. 
[A9] 
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Scheme A3. Schematic representation of (a) divergent and (b) convergent synthesis of den-
drimers. 
[A6]
 
Since Vögtle´s initial report about (poly)propyleneimine (PPI) dendrimers 
[A3]
,  numerous 
dendritic systems have been prepared. 
[A10]
 Accordingly, Tomalia´s (poly)amidoamine (PA-
MAM) 
[A11]
, Fréchet´s  (poly)aromatic ether 
[A12]
, Moore´s (poly)acetylene 
[A13]
 and Chap-
man´s (poly)silane dendrimers 
[A14]
 as well as Seebach´s (poly)ester 
[A15]
, Müllen´s 
(poly)phenylene 
[A16]
, Diederich´s (poly)etheramide 
[A17]
, Caminade´s (poly)phosphane 
[A18]
, 
Ford´s (poly)esteramide 
[A19]
 and Newkome´s "arborol"
 
systems
 [A20] 
have received widespread 
attention, clearly reflecting the structural and chemical diversity of dendritic macromolecules. 
In addition, whereas the dendrimer´s exterior provide an excellent platform for terminal at-
tachment of multiple close-packed functionalities, the present interior focal core, branching 
units as well as cavities around the focal core permit various opportunities for modification, 
e.g. to encapsulate both metal(ion)s as well as small organic molecule fragments (Scheme 
A4). 
[A21] 
 
Scheme A4. Different types of dendrimer functionalization: (a) central, (b) branched, (c) 
terminal and (d) in intrinsic cavities. 
During the last decade, the focus of the scientific interest in dendrimers shifted from initial 
synthetic directions towards various applications of these materials. 
[A8]
 Thus, different sized 
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dendrimers with tailored surface functionalities are becoming of interest from materials 
science perspective as these precise macromolecules facilitate unique novel chemical and 
physical properties, leading to promising potential applications including but not limited to 
catalysis 
[A22]
, optics 
[A23]
, sensors 
[A24]
, electronics 
[A25]
, cosmetics 
[A26]
, magnetic resonance 
imaging 
[A27]
, drug delivery systems 
[A28]
 and environmental remediation 
[A29]
. 
 
2. Nanomaterials 
In the 21
st 
century, new demands arise in terms of efficiency, selectivity and environmental 
compatibility for both established as well as prospective chemical processes. Whereas in the 
past century chemical industry mainly focused on a high productivity, nowadays it faces ris-
ing energy and disposal costs. Moreover, there is an increasing social interest for environmen-
tally compatible and sustainable chemistry. 
[A30, A31] 
One opportunity to overcome these cur-
rent challenges is to further improve chemical processes with respect to energy and resource 
usage and hence reaching the goal of a "Green Chemistry". 
[A32]
 Among others, this can be 
achieved by magnitude minimization and simultaneous reactivity activation of the applied 
reactants. 
 
In the last decades, a new direction of modern research has emerged, generally defined as 
"nanotechnology", wherein the term "nano" originates from Greek (nanos, meaning dwarf). 
 
It 
embraces research areas of chemistry, physics, biology, material science and mechanical en-
gineering and involves the ability to fabricate, manipulate and characterize artificial structures 
of atoms or molecules at the nanometer level. These nanomaterials are sized between 1 to 100 
nm in at least one dimension and exhibit new properties of matter at a level intermediate be-
tween macroscopic bulk solid and atomic/molecular systems. 
[A33] 
The unique physicochemi-
cal properties are strongly affected by the composition, size and shape of the appropriate na-
nometer-sized material. A significant feature of those nanoparticulate structures is the large 
surface-to-volume ratio. With decreasing particle diameter the unsaturated bonding and coor-
dination sites of the surface atoms result in an enhanced chemical reactivity. 
[A33, A34]  
In fact, the deliberate manufacturing and utilization of nanoparticles date back far in history. 
For example, the dying of glass by freshly precipitated colloidal gold solutions was already 
known in Roman times (e.g. the "Lycurgus Cup"). Dichroic hues have found wide application 
in glass and porcelain manufactories for several centuries. 
[A35]
 In the Middle Ages, Paracelsus 
postulated the health benefitting effect of "Aurum Potabile", a potable colloidal gold elixir. 
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Although nanoparticulate materials have been used throughout history, it was only in the 19
th
 
century when Faraday carried out initial systematic investigations on metal colloids. 
[A36]
 First 
scientific studies and descriptions on nanomaterials were established at the beginning of the 
20
th
 century by Zsigmondy, Ostwald, Mie and Feynman, resulting in many applied concepts 
in nanotechnology development. 
[A37 − A39] 
 
Scheme A5. Principle approaches for nanomaterials preparation. 
[A47]
 
The field of nanomaterial preparation has experienced an enormous progress to give a varie-
ty of anthropogenic nanoparticulate structures like fullerenes 
[A40]
, carbon nanotubes (CNTs) 
[A41]
, polymers 
[A42]
, dendrimers 
[A43]
, metals (homo- and bimetallic) 
[A44]
, (non-)metal oxides 
[A45]
 as well as metal sulfides and selenides 
[A46]
. In principle, there are two different ap-
proaches for the synthesis of the entire nanomaterials: the Top-Down and the Bottom-Up me-
thod (Scheme A5). 
[A47] 
Whereas the Top-Down approach utilizes mechanical and physical 
processes (e.g. grinding, laser ablation) to crush bulk material into nanometer-sized particles, 
the Bottom-Up method forms specific nanomaterials by linking atoms/molecules via applied 
self-assembling chemical techniques (e.g. liquid/gas phase method, sol-gel process, hydro-
thermal synthesis, thermolysis, photochemical process). 
[A34, A35, A48] 
Since small particles are thermodynamically unstable with respect to agglomeration to the 
bulk, a crucial aspect in colloid chemistry is the surface passivation of nanomaterials. Owing 
to the drastic increase in the chemical reactivity and attempts to minimize the surface, the 
nanoparticle exterior has to be saturated instantly after nucleation. The stabilization occurs by 
electrostatic repulsion and/or steric hindrance, 
[A37, A49]
 wherein prevention of the colloids to 
aggregate can be achieved by either surrounding with an electrical double layer formed by 
adsorbed ions (e.g. citrate, chloride) 
[A50]
 or by the adsorption of weakly bounded organic sur-
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factant molecules (e.g. long-chain alkyl compounds, tensides, polymers, dendrimers), 
[A51]
 
thus providing a protective layer (Scheme A6). 
[A33] 
 
Scheme A6. Schematic illustration of electrostatic (left) and steric (right) stabilization of 
nanoparticles. 
[A33]
 
Moreover, the association of colloids and appropriate (stabilizing) molecular units introduc-
es novel collective properties to the assembled composites that differ from the corresponding 
bulk materials. 
[A33] 
In correlation with the particle size, colloidal group-11 elements for ex-
ample exhibit a particular optical absorption phenomenon in the visible range of the spectrum. 
[A35]
 This surface plasmon resonance is the result of collective oscillation modes of the con-
fined electron-gas within the particles, initiated by the interaction of the electric field of the 
visible light (Scheme A7). 
[A52, A53]
 In consequence, the binding of substrates to the colloid´s 
surface
 
facilitates an amplification of the appropriate molecular vibration signals up to 10
5
-
fold due to an enhancement in sensitivity (e.g. surface-enhanced Raman scattering (SERS)). 
[A54] 
 
Scheme A7. Schematic surface plasmon resonance illustration. 
[A52, A53]
 
Nano-scaled assemblies are promising building blocks and hence provide a great variety of 
industrial applications due to their exceptional optical, electronic and catalytic properties, as-
sociated with manifold preparation methods available. Particularly, in modifying and upgrad-
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ing a wide range of materials, the usage of nanostructures ranges from hardening and self-
cleaning to antimicrobial surfaces, application in heterogeneous catalysis, ranging from clas-
sical synthesis chemistry to photocatalysis, includes the areas of luminescent, plasmonic and 
magnetic nanoparticles used in molecular biology as well as in medical diagnosis and therapy. 
In this respect, nanoparticulate pigments and luminophores, transparent conductive oxides and 
magnetic fluids also have to be mentioned. In terms of progressive miniaturization and ma-
terial economization, nanodevices are of essential importance for flexible (printed) electronic 
circuit elements, light-emitting diods and visual display units as well as dye-sensitized solar 
cells and magnetic data-storage media. 
[A35] 
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B State of Knowledge 
As the present work covers multiple aspects within the field of applied dendrimer, metalor-
ganic, organometallic and materials chemistry, the current Chapter B is subdivided into three 
sections giving an overview on significant fundamentals of related topics. In the first part, 
substantial synthesis methodologies and specific peculiarities of dendrimers are presented, 
followed by a selection of remarkable various functionalized dendritic architectures. Chapter 
B is complemented by a compilation focused on different characterization techniques which 
are essential for a complete material specification. However, as the entire paragraph provides 
a more general overview, the author would like to refer to the introduction sections of the re-
spective Chapters C to G. 
 
1. Dendrimers 
1.1. Synthesis and Characterization 
In 1941, Flory published a series of extensive monographs describing the theoretical evi-
dence for the formation of highly branched three-dimensional macromolecular (na-
no)architectures. 
[B1]
 However, it was not until the late 1970s when Vögtle first reported about 
a seminal "cascade-like" synthetic methodology for the construction of a new class of archi-
tecturally fascinating macromolecules possessing regular highly branched and well-defined 
structures. Employing an exhaustive Michael addition reaction of diverse primary amines to 
acrylonitrile and a subsequent co-mediated reduction afforded the appropriate first "genera-
tion cascade-molecule" (Scheme B1). 
[B2]
 Further generational assembly of 
(poly)propyleneimine was accomplished via thus simple repetitive transformation sequences, 
the archetype of the divergent synthesis methodology. 
 
Scheme B1. "Cascade-like" synthesis of (poly)propyleneimine. 
[B2] 
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In the mid of the 1980s, Newkome and Tomalia independently complemented the basic con-
cept of the divergent construction approach resulting in series of polyfunctional macromole-
cular architectures (synonymous "arborols" and "dendrimers"). 
[B3, B4] 
Whereas Newkome 
relied on the triester amidation for the assembly of polyols, 
[B5] 
Tomalia reported the first 
preparation of an entire series of "Starburst" (poly)amidoamine (PAMAM) dendrimers 
(Scheme B2). By applying addition and amidation cycles of primary amines to methacrylates, 
the formation of up to the 10
th
 dendrimer´s generation was realized, exhibiting a multiplicity 
of intrinsic and terminal amine functionalities. 
[B6]
  
 
Scheme B2. Architecture of a 2
nd
 generation (poly)amidoamine dendrimer. 
[B6] 
Although the divergent approach is conceptually straightforward in terms of extended den-
drimer constructions and multifunctional periphery modifications, synthetic problems occa-
sionally encounter due to incomplete transformations, inadequate removal of contaminations 
as well as statistical defects within the dendritic structure. 
[B7]
  
More recently, the preparation of (poly)aryl ether dendrimers were reported by Fréchet and 
Hawker (Scheme B3). 
[B8]
 The eloquent utilization of selective alkylation of phenolic hydrox-
yl groups and the conversion of a benzylic alcohol to a benzylic bromide to generate a reac-
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tive focal moiety established an alternate synthetic strategy, which was meant to overcome 
some of the problems associated with the divergent concept. 
[B9]
 In general, the convergent 
approach involves the synthesis of small "dendrons" (the later periphery), reacted to a multi-
functional core in the last reaction step to give the assembled dendrimer. Notable attributes of 
the convergent protocol include a small number of required transformations, a variety of suit-
able reaction types, improved purifications and statistically minimized defects in the dendritic 
structure. 
[B10]
 However, due to steric hindrance in the final reaction step, the approach is re-
stricted suitable for extended dendritic architectures formation. 
 
Scheme B3. Architecture of a Fréchet-type dendrimer. 
[B8] 
The procedure initially pioneered by Fréchet was followed shortly thereafter by Miller and 
Neenan, who published the first series of aromatic-based, all-hydrocarbon dendrimers. 
[B11]
 A 
high rigidity was inherent to these systems. Over the next decades, many further types of sig-
nificant and ecstatically pleasing dendrimer systems were developed and hence a great variety 
of dendritic scaffolds including amides, amines, silanes, carbosilanes (Scheme B4), siloxanes, 
carbosiloxanes, esters, ethers, carbohydrates and organometallic systems with defined nanos-
copic dimensions were accessible. 
[B12 – B16]
    
Concomitant to synthetic progresses in dendrimer chemistry, reliable full characterization 
techniques for dendritic architectures had to be developed. Due to the size and symmetry of 
the entire macromolecules, definite purity analyses are rather complex. Various NMR expe-
riments (
1
H, 
13
C, 
29
Si, 
31
P), elemental analysis, chromatography techniques (HPLC) and mass 
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spectrometries (MALDI, ESI) as well as microscopic examinations are implemented 
to identify potential imperfections in the dendrimer´s structure. 
 
Scheme B4. Example for a crown-ether functionalized carbosilane dendrimer as a chelating 
ligand for K
+
-ions, reported by Lang et al. in 2005. 
[B16] 
 
1.2. Functional Dendrimers 
Since Vögtle, Tomalia and Fréchet initially reported on dendrimers, research mainly focused 
on the preparation and characterization of a wide variety of dendritic macromolecules. 
[B13] 
Owing to the rising demand for materials with improved and novel properties, the emphasis in 
dendrimer research gradually shifted to investigate new classes of materials with highly con-
trollable architectures and specific functionalities. 
In principle, all of the functionalized dendrimer systems reported in literature can be catego-
rized into one of the following classes (Chapter A, Scheme A4): (a) dendrimers incorporating 
a functional core; (b) dendrimers featuring functional branching units; (c) dendrimers possess-
ing a functional periphery; and (d) dendrimers having loaded internal cavities. 
[B17] 
Core-functionalized dendrimers are accessible by applying a convergent self-organization 
synthesis strategy, representing a versatile approach to form precise and regular materials. As 
the inner functionalization occurs in the final assembling reaction step, even sensitive core 
units can be incorporated. Apart from its crucial impact on multiplicity, size and shape, the 
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applied core unit also determines the dendrimer´s functionality. In this respect, chromophores 
[B18]
, electrochemical/redox- 
[B19]
 and catalytic 
[B20, B21]
 active as well as chiral moieties 
[B17] 
were placed in the center of dendrimer architectures. 
Inside the dendritic structure, a unique and distinct (nano)environment is formed, suitable 
for the construction of dendrimer scaffolds by functional groups. Through specific incorpora-
tion of various active moieties (e.g. metal(ion)s, ammonium salts, amines, carbonyls, pyri-
dines, fullerenes, fluorescence labels, crown ethers, liquid crystalline and chiral groups) 
[B22 – 
B25]
 an internal manipulation of dendrimers can be achieved. The resulting multifarious capa-
bilities of appropriate intrinsic functionalized dendrimers were employed for example by Bal-
zani and Vögtle in dendritic light-harvesting effects 
[B26]
, by Hirsch in photo-induced electron 
transfer processes 
[B27]
, by Moore in observation of dendritic antenna effects 
[B28]
, by Takaha-
shi in a reversible morphological control of dendrimer structure by external chemical stimuli 
[B29]
, by Majoral in "burying" chiroptical properties 
[B30]
 and in biological systems as dendri-
mer protein mimetics 
[B31]
. 
 
Scheme B5. Structure of van Koten´s carbosilane "NCN" pincer nickel dendrimer. 
[B41] 
A range of studies certainly confirmed that the chemical and physical properties of dendritic 
(macro)molecules are highly affected by the peripheral moieties. Accordingly, terminal func-
tionalities influence the stability, solubility, viscosity, flexibility, aggregation and chemical 
reactivity as well as spatial and surface shape of the dendrimer. 
[B22]
 As the number of termin-
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al groups rises exponentially with the extension of generations, the periphery´s impact on the 
total molecule properties increases. Furthermore, multiplication of identical functional moie-
ties in terms of peripheral dendritic immobilization might reveal a tremendous amplification 
of the termini´s effect ("dendritic effect"). Therefore, a molecule periphery functionalization 
is the most promising and straightforward option in terms of creating novel dendrimer proper-
ties. 
 
Scheme B6. Structure of Astruc´s non-covalent bonded dendrimer. 
[B44]
 
The commercially available (poly)propyleneimine and (poly)amidoamine of Vögtle and 
Tomalia, respectively, are frequently utilized primary amine (-NH2) terminated dendrimers. 
Furthermore, divergent constructed dendritic scaffolds possessing CO2H, CHO, OH, P(X)R2 
(R = H, alkyl, aryl, Cl; X = S, O) and Si-H groups are extensively described in literature. 
[B22, 
B32]
 Due to the outstanding accessibility of the peripheral moieties, further functionalization 
of, for example, primary amines (-NH2) via applying appropriate coupling reactions with var-
ious carboxylic acid derivatives 
[B33]
, N-hydroxy succinimide esters 
[B34]
, sulfonic acid deriva-
tives 
[B35]
, iso(thio)cyanates 
[B36]
 and urea derivates 
[B37]
 are widely approved. Of particular 
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interest is the subsequent terminal incorporation of metalorganic as well as organometallic 
fragments, 
[B38]
 forming a new class of supramolecular "metallodendrimers" that possess a 
series of novel physical, optical, electrochemical, photochemical, biological and catalytic 
properties. 
[B21, B38, B39]
 
In 1994, Puddephatt reported about the first dendrimer, decorated by organometallic Pt
(IV)
 
functionalities used as integral structural features of each generation. 
[B40]
 One of the first or-
ganometallic dendrimers applied in a homogeneous catalysis (Kharasch addition) was re-
ported by van Koten and van Leeuwen in the same year. 
[B41]
 The periphery of a carbosilane 
dendrimer was adorned with "NCN" pincer supported Ni
(II) 
groups (Scheme B5).
 
  
 
Scheme B7. Togni´s adamantane-1,3,5,7-tetracarboxylic acid cored dendrimer equipped 
with chiral ferrocenyl diphosphine ligands. 
[B46] 
However, due to the high chemical and thermal stability as well as well-understood electro-
chemical properties, many reports deal with ferrocenyl moieties at dendrimer peripheries. In 
1999, Moss 
[B42]
 and Cuadrado 
[B43]
 reviewed on the major aspects. A few years later, Astruc 
employed a non-covalent hydrogen bonding synthetic pathway to construct dendrimers with 
terminal organometallic ferrocene units (Scheme B6). 
[B44]
 At the same time, Majoral studied 
the chiroptical and electrochemical properties of chiral ferrocene fragments within phospho-
rus containing dendrimers. 
[B30, B45]
 Togni reported about the attachment of chiral "Josiphos" 
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ferrocenyl diphosphine groups to an adamantane-1,3,5,7-tetracarboxylic acid cored dendritic 
skeleton, proved as an effective support for Rh-catalyzed asymmetric hydrogenation of al-
kenes (Scheme B7). 
[B46]
 Cuadrado used a terminal ferrocenyl modified carbosilane dendrimer 
to demonstrate the first example of unambiguous electronic coupling within a dendritic 
framework. 
[B47]
 The pioneering work in the field of electronic communication was forwarded 
by Kaifer 
[B48]
, Salmon and Jutzi 
[B49] 
using alkylamine dendrimers as support. Furthermore, 
Cuadrado utilized various alkylamine dendrimer backbones with ferrocene and cobaltocenium 
moieties in a mixed manner (Scheme B8). 
[B50]
 Another versatile functionalization method of 
dendrimer´s periphery was reported by Astruc. By applying the principle of "click-chemistry", 
a ferrocenyl temini was introduced by reacting an azide-terminated dendrimer with ferrocenyl 
acetylene in a [3+2]-cycloaddition. 
[B51]
 The selection of applied organometallic terminated 
dendrimers listed here clearly indicates the wide variety and great potential in this field of 
chemistry. 
 
Scheme B8. Structure of Cuadrado´s mixed ferrocene-cobaltocenium dendrimer. 
[B50] 
In the past decade, dendrimer-based therapeutics revolutionized the conventional health care 
and medical technology. 
[B52]
 Facilitating a great variety of biomedical applications, dendri-
mers can be employed as the drug itself or as the drug-carrier, in which the therapeutic agents 
are either encapsulated within the dendritic scaffold (host-guest) or conjugated to the dendri-
mer´s periphery in a (non-)covalent manner. In this respect, the construction of novel dendri-
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mers with well-established biocompatible surface modifications such as (poly)ethylene gly-
cols (PEG), amino acids, peptides and (poly)saccharides are propably the most effective strat-
egies in antimicrobial, antiviral and anticancer therapies as well as tissue engineering. 
[B53, B54]
   
 
Scheme B9. Schematic illustration of Kono´s PEG-grafted PAMAM dendrimer; green line 
represents PEG chain. 
[B55] 
In 2000, Kono synthesized a new biocompatible dendrimer using a PAMAM dendrimer as 
scaffold and PEG as surface terminals (Scheme B9). 
[B55] 
In vivo studies showed
 
the benefit of 
that functionalization, a prolonged circulation and retention in the bloodstream as well as 
lower accumulation in organs. By optimization of the dendrimer size (generation) and length 
of terminated PEG chains, biodegradation and bioresortion behaviors can be manipulated. 
However, PEGlation reduces the ability for further covalent attachment of bioactive agents. In 
a separate study, the PEG chain (50 %) and doxorubicin (50 %) were conjugated to a polyest-
er dendrimer using amino acids as spacers. The obtained bi-functionalized dendrimer was 
successfully applied in cancer chemotherapy investigations. 
[B56]
  
The concept of controlled release of bioactive compounds by covalent fragmentation of 
cleavable dendrimers is another promising emphasis in biochemistry. Shabat prepared a self-
immolative phenol/para-aminophenol dendrimer conjugated with cytotoxic drugs for cancer 
therapy. Activated by adaptors in the stimuli-responsive cleavable delivery system, a remark-
able drug release enhancement occurs accompanied with dendrimer degradation to excretable 
non-toxic compounds (Scheme B10). 
[B57] 
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Scheme B10. Cleavage mechanism of self-immolative dendrimers for stimuli-responsive 
drug delivery. 
[B57]
 
While magnetic resonance imaging (MRI) has become a widely used non-invasive technique 
in disease diagnostics, however, a major limitation of MRI remains its inherent low sensitivi-
ty. To increase the MRI sensitivity, non-toxic contrast agents are applied. Currently gadoli-
nium-complexes of precise structures are widely employed, as they are appreciated for a pre-
dominant signal enhancement. Unfortunately, a high dosage of the material is required due to 
non-specificity and fast renal excretion. One method to overcome these difficulties is to attach 
multiple MRI labels to a single dendritic scaffold. 
[B54]
 In a seminal work, Wiener conjugated 
several gadolinium chelating agents to different generations of Tomalia-type PAMAM den-
drimers. The corresponding Gd
(III)
 complexed dendritic structures have been successfully em-
ployed as multivalent MRI agents (Scheme B11). 
[B58 – B60]
 
 
Scheme B11. Dendritic MRI contrast agent with Gd
(III)
 complexes along the periphery. 
[B58] 
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Since the development of dendrimer chemistry, the peculiar interior cavities are regarded as 
suitable candidates for manifold applications in host-guest chemistry. Providing small loca-
lized and controlled microenvironments as well as conformational flexibility, dendrimers can 
serve as hosts for a non-covalent reversible intercalation of guest-molecules (e.g. drugs, pig-
ments) forming a "dendritic box" assembly. 
[B61]
 In this respect, it was demonstrated that wa-
ter-soluble dendrimers can "dissolve" small hydrophobic molecules within the interior scaf-
fold similar to micelles. 
[B62]
 Newkome applied aliphatic dendrimers with carboxylate termini 
to bind lipophilic probes. 
[B61] 
Fréchet constructed an amphiphilic (poly)aromatic ether den-
drimer with carboxylate end-groups to enhance solubility of pyrenes in water. 
[B63]
 In a similar 
manner, Martin utilized the hydrophobic interior of a dendritic micelle to catalyze reactions of 
guest molecules. 
[B64]
  
Beside the dendritic incorporation of small organic molecules, dendrimer cavities can be 
used to encapsulate metal, metal oxide as well as metal chalcogenide colloids. 
[B65]
 Based on 
the seminal work of Turkevich 
[B66]
 and Brust 
[B67] 
on colloidal gold stabilization techniques, 
in 1998, Tomalia, Crooks and Esumi independently implemented methodologies for metal 
nanoparticles (NPs) formation within hydroxy-terminated PAMAM dendrimer templates. 
Applying Na[BH4] as reducing agent to intrinsic coordinated metal ions, a wide range of ap-
propriate dendritic stabilized metal nanoparticles (e.g. Cu, Au, Pt, Pd, Fe, Co, Ru and Rh) 
were formed (Scheme B12), 
[B68]
 whereby the employed surfactants serve both the kinetic 
control of the NPs size and the prevention of unintended aggregation. 
 
Scheme B12. Schematic representation of the formation of metal nanoparticles. 
[B68] 
Once Reetz initial had showed the application of nanoparticulate Pd in homogeneous cataly-
sis, 
[B69]
 El-Sayed employed PAMAM dendrimer-stabilized NPs in Suzuki cross-coupling 
reactions in 2001, investigating the effect of the dendrimer´s generation on the catalytic ac-
tivity. 
[B70]
 The precise and predictable number of dendrimer-stabilized NPs offered the oppor-
tunity to study the influence of the NPs size and quantity on the catalytic efficiency. Regard-
ing the size of the applied dendritic templates, Astruc reported about different types of the 
NPs stabilization. Dendrimers possessing a small size entirely surround the NPs surface to 
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give interdendrimer-stabilized colloids, whereas larger dendritic architectures form intraden-
drimer-encapsulated NPs. 
[B71]
 Furthermore, the encapsulation strategy of NPs was extended 
to bimetallic catalysts. A 4
th
 generation PAMAM dendrimer with mixed Pd-Au and Pd-Pt 
NPs, respectively, proved to be more efficient in hydrogenation reactions than the analogous 
monometallic Pt or Pd catalyst. 
[B72 – B74]
 Due to dendrimer´s rigid open structure, substrates 
easily access to the NPs catalytic active sites. Moreover, dendritic templates are able to pro-
vide reactant and product selectivity as well as control of catalyst´s chemical composition, 
solubility and recovery, indicating the high potential of dendrimer nanocatalysts. 
[B74]
 
In addition, dendrimer architectures have attracted significant attention in surface coatings 
of metal oxide (e.g. NiO, ZnO, SiO2, TiO2,-Fe2O3, Fe3O4, Co3O4) as well as ferrite (e.g. 
MxFe2-xO3, MxFe3-xO4; M = Al, Zn, Mn, Co) colloids. According to relevant synthesis tech-
niques available, a substantial progress was made over the past decade, covering a wide range 
of compositions and tunable sizes. 
[B75 – B78]
 Numerous chemical methods can be applied for 
preparation, wherein the wet chemical co-precipitation technique is probably the simplest and 
most efficient pathway to obtain for example dendrimer coated iron oxide NPs (Scheme B13). 
[B79]
 Among various types of metal oxides, magnetite (Fe3O4) colloids are of particular inter-
est, due to remarkable size depending magnetic peculiarities of appropriate Fe3O4 nanostruc-
tures. According to Néel, the thermal fluctuations of magnetic moments cause a transition to 
superparamagnetism, when the diameter of magnetite particles is below a "critical size" (≈ 20 
– 30 nm). [B80] 
 
Scheme B13. Schematic illustration of magnetite (Fe3O4) NPs formation. 
[B79] 
Owing to a non-toxic biocompatible support of the applied dendritic stabilizer as well as a 
magnetic Fe3O4 colloid size comparable to biological entities, the appropriate superparamag-
netic magnetodendrimers emerged special interest in biomedical applications such as magnet-
ic hyperthermia treatment of cancer, controlled drug delivery, cell separation, magnetic reson-
ance imaging and biosensors. 
[B81]
 In this respect, Chandra demonstrated a facile approach for 
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the preparation of dendrimer coated magnetite NPs for drug delivery applications. 
[B82] 
Car-
boxylated
 
PAMAM dendrimers were applied as composites in order to form nanometer-sized 
water-soluble magnetodendrimers by Bulte. 
[B83]
 Recently, Taratula reported about a multi-
functional superparamagnetic iron oxide-(poly)propyleneimine dendrimer conjugate for en-
hanced cancer therapy. 
[B84]
  
As the above selection of multifunctional nano-sized dendritic assemblies clearly demon-
strates, the area of biological nanocomposites is a highly promising and fast developing field 
that will lead to a plurality of novel capabilities in years to come. It is time to transform so-
phisticated scientific findings into future applications. 
 
2. Characterization Techniques for Dendrimer-Nanomaterial Assemblies 
The extensive characterization of dendritic templates as well as dendrimer-nanomaterial 
composites is essential for a precise structure and function correlation. Therefore, a combina-
tion of qualitative and quantitative characterization techniques is necessary, since a single 
method employed cannot result in a defined specification of such complex systems. In gener-
al, the material characteristics like identity, (phase) purity, morphology, size, size distribution, 
shape, crystallinity and structural composition are examined by applying a great variety of 
spectroscopy, spectrometry, microscopy, scattering as well as separation techniques. In the 
selection given below, the most relevant methods are summarized.  
[B85] 
Nuclear magnetic resonance (NMR) spectroscopy measures the organic samples´ intrinsic 
magnetic moment of certain nuclei, typically for hydrogen (
1
H) and carbon (
13
C) as well as 
hetero-atoms like phosphorus (
31
P) and silicon (
29
Si). As one- and two-dimensional NMR 
spectroscopic methods provide physical, chemical, structural and environmental information 
about the species, NMR spectroscopy is definitely a versatile tool for the identity and purity 
characterization of dendrons and low-generation dendrimers. 
[B86]
 
In particular, for high-generation dendrimers purification and simultaneous characterization, 
on-line high-performance liquid chromatography (HPLC) techniques represent an exquisite 
ability. Based on physical and/or chemical interactions between the stationary phase in the 
column and a crude product mixture, elution is achieved to obtain separate product fractions. 
Distinct peaks within each HPLC trace provide the distribution and actual sample composi-
tion. 
[B86]
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X-ray (powder) diffraction (XRD) is commonly used to determine the identity of functiona-
lized nanoparticulated inorganic materials. By comparing the positions and intensities of ex-
perimental and reference peaks, one can establish the crystal structure of NPs, however, com-
pared to bulk materials in the nano-scale more complicated structures can be formed. The 
crystallite size can be estimated from the line broadening of the XRD profile by Scherrer equ-
ation, wherein the crystal size is not equal to the NPs size, if the NPs are not single crystals. 
[B85] 
Although XRD is often the method of choice, due to line broadening certain quite similar 
NPs structures (e.g. Fe3O4 and -Fe2O3) cannot be resolved. Therefore, X-ray photoelectron 
spectroscopy (XPS) can be employed, to estimate the elemental composition and electronic 
states of the elements contributing to the material composite. 
[B85] 
Transmission electron microscopy (TEM) imaging is a suitable common technique for the 
assessment of inorganic phases concerning crystallinity, atomic arrangements, lattice vacan-
cies and structural defects. However, as samples are typically imaged in vacuum or low-
pressure gas flow, in-situ liquid phase studies are excluded. Furthermore, due to extensive 
equipment, maintenance and sample preparation requirements, TEM is a relatively expensive 
examination method on an individual particle basis. Beside TEM further advanced microscop-
ic techniques such as scanning electron microscopy (SEM) and atomic force microscopy 
(AFM) are capable tools in ascertaining the size and morphology of nano-sized structures. 
[B87]
 
Dynamic light scattering (DLS), also known as photon correlation spectroscopy (PCS), is 
probably the most common technique for in-solution-determination of the NPs size, shape and 
size distribution. The method gives access to the hydrodynamic radius of the whole mono- or 
polydisperse colloidal sample in a simple, non-invasive, non-destructive and relatively eco-
nomical process. Due to the Brownian motion of particles, fluctuations in the scattered light 
intensity occur, that are used to determine the particle diffusion coefficient which is directly 
related to the hydrodynamic radius via the Stokes-Einstein relationship. 
[B86, B88] 
The colloidal stability is analyzed through zeta()-potential, in an indirect measurement of 
the surface charges that prevent the NPs aggregation by electrostatic repulsion. It corresponds 
to a potential difference between the outer Helmholtz plane and the particles surface, provid-
ing information on the nature of the nano-encapsulated material. 
[B87]
 
Among optical characterization techniques, UV/Vis spectroscopy is often used for in-situ 
observation of coordination processes between metal ions and dendrimers. Furthermore, the 
intrinsic UV/Vis absorbance features can be used to monitor pertinent nanomaterial properties 
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such as concentration, size, shape and aggregation state.  Metal NPs, in particular Au, Ag and 
Cu exhibit a strong absorption in the visible region termed as surface plasmon resonance 
band, which is sensitive to colloids size, shape and composition. 
[B85]
    
As Fourier transformed infrared spectroscopy (FT-IR) measures the distinctive absorption of 
IR radiation by an (in)organic sample, the method is frequently used to demonstrate the con-
jugation of an applied surfactant to a nano-scaled material through the appearance and shifting 
of characteristic spectral bands. Moreover, the complexation type and strength of dendritic 
functional groups to an appropriate metal species can by ascertained. 
[B86]
 
Recently, thermal characterization techniques like thermogravimetric analyses (TGA) and 
differential scanning calorimetry (DSC) are used for the quantitative determination of dendrit-
ic components grafted on nanocomposite surfaces. By utilization of a high-precision balance, 
changes in the sample´s weight relative to changes in temperature are revealed. Applying 
coupled TGA-MS (MS = mass spectrometry) systems, an accurate specification of stabiliza-
tion fragments can be achieved. 
[B85]
 
Mass spectrometric analyses comprise sample based mass-to-charge ratio technologies. In 
particular, inductively coupled plasma mass spectrometry (ICP-MS) techniques are suitable 
for determination of metal and metal oxide quantities in nano-structured composites. Howev-
er, application of ICP-MS is fairly limited due to costly instrumentations required and sample 
destruction during the analytic process. 
[B86] 
 
3. Motivation 
Within the macromolecular chemistry, dendrimers represent undeniably one of the most ver-
satile classes of molecules. The fascinating chemical elegance of dendritic architectures 
matched with the precise control of both the intrinsic scaffold´s structure as well as the 
straightforward terminal functionalization predestines dendrimers for a great variety of appli-
cations serving highest precision. However, sterically demanding high-generation dendrimers 
require multifarious and time consuming syntheses as well as extensive purification and cha-
racterization techniques, making these kinds of macromolecules less attractive for a wider 
area of applications due to economical reasons.  
That status resulted in the motivation for the research work introduced in the present doctor-
al thesis. The task was to develop a synthesis methodology making accessible series of com-
parable novel well-defined (poly)amidoamine-based dendrimers of low-generations, facilitat-
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ing a straightforward and more time efficient access to readily functionalizable and fully cha-
racterizable dendritic architectures. Furthermore, esteemed features like the monodisperse 
easy accessible open molecular structure and the plurality of capable donating moieties should 
likewise be integrated. Applying appropriate ligand, metal organic and organometallic mod-
ifications to the dendrimers´ periphery, the thus obtained promising oligomers were applied as 
templates in various fields of applications like (asymmetric) homogeneous catalyses (Chapter 
C + D), metal and metal oxide nanoparticles formations (Chapter E + F) as well as in biomed-
ical processes as drug-carriers (Chapter G). 
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1. Introduction 
Since the early work of G. van Koten 
[C1]
 on homogeneous catalysts immobilized on soluble 
inert silicon-based dendrimer supports there is a rapid development in this field of chemistry 
recognized which merges heterogeneous and homogeneous catalysis, respectively 
[C2]
. Metal-
lodendrimers depending on their size properties take advantage of a simple catalyst separation 
and recovery 
[C3]
. Furthermore, immobilization on a dendrimer support may influence the ac-
tivity (positive or negative dendritic effect) and/or selectivity of a catalytic reaction, when 
compared with their monomeric analogs. In addition to silicon-containing dendritic frame-
works, amidoamine dendrimers with their nitrogen and amide functionalities give advantage 
as high capacity chelating molecules for the stabilization of catalytic active species during the 
catalytic process 
[C4]
. So far, dendrimers with peripherally attached mononuclear organometal-
lic or metal-organic chiral and non-chiral units including nickel 
[C5]
, palladium 
[C6, C7]
, plati-
num 
[C8]
, cobalt 
[C9]
, rhodium 
[C10, C11]
 and ruthenium 
[C12]
 fragments have been applied in a 
variety of homogeneous catalyses. In this context, the utilization of ferrocenyl phosphine 
functionalized supports in combination with diverse palladium sources to in-situ generate cat-
alytic active species in carbon-carbon cross coupling reactions has widely been described 
[C13]
. 
About the use of individual heterobimetallic end-grafted organometallics featuring at least one 
catalytic active transition metal atom has to the best of our knowledge not been reported in 
dendrimer chemistry so far, however, very recently a method was reported to prepare the 
PAMAM-based dendrimer G4OH-(Pt
2+
)x(Ru
3+
)y by subsequent addition of K2[PtCl4] and 
[RuCl3], respectively, to dendrimer G4OH in an aqueous solution 
[C14]
. Nevertheless, the pro-
posed heterobimetallic Pt-Ru complexes were not isolated. 
With this in mind and as a continuation of our research in the field of dendrimers 
[C15]
 and 
carbon-carbon cross-coupling reactions 
[C16]
, we here describe the immobilization of catalytic 
active palladium ferrocenyl phosphines using amidoamine dendrimers. The use of the appro-
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priate supported heterobimetallic Fe-Pd systems as catalysts in the Heck-Mizoroki 
[C17 – C19]
 
(reaction of iodobenzene with tert-butyl acrylate) reaction is reported. 
 
2. Results and Discussion 
2.1. Synthesis of Amidoamine Dendrimers 
Amidoamine dendrimers were prepared by a divergent consecutive synthesis procedure 
firstly described by Tomalia and coworkers 
[C20]
. This synthesis methodology was applied to 
the preparation of 2 as depicted in Scheme C1. After appropriate work-up, this dendrimer 
with its five terminal amino functionalities could be isolated as a colorless oil in almost quan-
titative yield (Experimental Part). 
 
((i) CH2CHCO2Me, methanol, 25 °C, 72 hrs; (ii) H2NCH2CH2NH2, methanol, 25 °C, 72 hrs). 
Scheme C1. Synthesis of amidoamine dendrimer 2. 
Dendrimer 2 was characterized by elemental analysis, FT-IR and NMR (
1
H, 
13
C{
1
H}) spec-
troscopy. As for related amidoamine compounds 
[C21a]
 the NMR spectroscopic characteriza-
tion of 2 revealed single resonance patterns for the C(O)CH2CH2, C(O)CH2, HNCH2, 
CH2NH2 and NH2 fragments of which, as expected, the latter group appears as a broad signal 
(Experimental Part). Most characteristic in the FT-IR spectrum of 2 is the observation of three 
very distinctive absorptions at 3365 (NH), 1640 (C(O), amide I) and 1560 cm
-1
 (C(O), amide 
II) (Experimental Part). 
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2.2. Synthesis of Metallo- and Selenium-Phosphine Amidoamine Dendrimers 
The Iron-palladium organometallic moieties were attached to the dendrimer periphery via 
peptide coupling by treatment of (diphenylphosphino)ferrocenyl carboxylic acid (3) 
[C21b]
 with 
the NH2-functionalized amidoamine support (2) under standard peptide coupling conditions in 
presence of HOBT (= hydroxybenzotriazole) and EDC (= 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide), respectively, which was further reacted with [Pd(3-
C3H5)Cl]2 (4) 
[C21c]
 to give heterobimetallic 9-Fe-Pd (Scheme C2). Organometallic 9-Fe-Pd 
was obtained in an overall yield of 26 % (Experimental Part).  
 
((i) 2, HOBT (= hydroxybenzotriazole), EDC (= 1-ethyl-3-(3-dimethylaminopropyl)-
carbodiimide, dichloromethane, 0  25 °C, 12 hrs; (ii) [Pd(3-C3H5)Cl]2 (4), dichloro-
methane, 25 °C, 1 h). 
Scheme C2. Synthesis of heterobimetallic 9-Fe-Pd. 
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For comparison, the organometallic molecules 5-Fe-Pd − 8-Fe-Pd were synthesized in a 
consecutive reaction sequence using the same reaction conditions as described for the synthe-
sis of 9-Fe-Pd (Figure C1).  
 
Figure C1. Heterobimetallic amidoamines 5-Fe-Pd – 8-Fe-Pd. 
Compounds 9-Fe and 5-Fe-Pd – 9-Fe-Pd are odorless, stable to air and moisture, dissolve in 
polar organic solvents, e.g. in dichloromethane and tetrahydrofuran, while being poorly so-
luble in benzene and toluene. Dendrimer 9-Fe featuring as terminal group the ferrocenyl di-
phenylphosphine is an orange colored solid, whereas the defined coordination compounds Fe-
Pd (5-Fe-Pd – 9-Fe-Pd) are bright yellow. 
All ferrocenyl and heterobimetallic Fe-Pd metallodendrimers 9-Fe and 5-Fe-Pd – 9-Fe-Pd 
gave correct elemental analyses. As the unimolecular amidoamine molecule 2, the appropriate 
metallodendrimer 9-Fe-Pd shows separated and well-resolved signals with the expected 
coupling pattern in the NMR spectra (Experimental Part).  
The successful attaching of 3 to the amidoamine scaffold 2 can nicely be proofed by FT-IR 
and NMR spectroscopy. In FT-IR spectroscopy the absorption at ca. 1670 (C(O)) disappears, 
proofing complete consumption of the carboxylic acid (3). The formation of the amide con-
nectivity can best be figured with 
1
H NMR spectroscopy. For example, the signal of the ter-
minal NH2 moiety is shifted to lower field at 7.82 ppm in course of the reaction 
[C21a]
. In the 
13
C{
1
H} NMR spectra the resonance of the carbonyl carbon atom of the carboxylic acid (3) is 
shifted from 177 to ca. 170 ppm 
[C21b]
 (Experimental Part). 
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The presence of a diphenylphosphine ferrocenyl sandwich unit in 9-Fe is discernable by the 
appearance of a singlet at -17.9 ppm in the 
31
P{
1
H} NMR (Experimental Part). Through coor-
dination of the phosphorus atom to palladium as given in heterobimetallic compound 9-Fe-Pd 
a representative shift to lower field occurs (13.3 ppm). The chemical shift of the datively-
bonded Ph2P group is, as expected, almost independent of the appropriate amidoamine scaf-
fold 
[C22]
. The newly introduced [Pd(3-C3H5)Cl] organometallic fragment in 5-Fe-Pd – 9-Fe-
Pd can also be recognized in the 
1
H and 
13
C{
1
H} NMR spectra. In the 
1
H NMR spectra the 
allyl moieties give rise to three distinctive resonances at ca. 2.8 (CH-anti), 3.8 (CH-syn) and 
5.5 ppm (CH-centered) as a result of the different chemical environment within the allyl unit, 
while in 
13
C{
1
H} spectroscopy two signals can be assigned at ca. 62 (CH2) and 118 ppm (CH) 
(Experimental Part) 
[C23]
.
 
The  - donor properties of phosphines can be quantified by the phosphorus-selenium 
coupling constant 
1
J(31P-77Se) of the appropriate seleno derivatives 
[C24]
. Therefore, we reacted 
the phosphino ferrocenyl amidoamines 9-Fe and 5-Fe with selenium in dichloromethane at 
ambient temperature to obtain the appropriate seleno-phosphine derivatives 9-Fe-Se and 5-
Fe-Se (Figure C2) to classify the electronic properties of the immobilized phosphino ferro-
cenes and range them with conventionally phosphines. After appropriate work-up, 5-Fe-Se 
and 9-Fe-Se were isolated as orange solids in almost quantitative yield (Experimental Part). 
 
Figure C2. Seleno-phosphines 5-Fe-Se and 9-Fe-Se. 
The phosphorus-selenium coupling constants of 5-Fe-Se and 9-Fe-Se were determined to 
1
J(31P-77Se) = 720 Hz (5-Fe-Se) and 723 Hz (9-Fe-Se), being slightly decreased, when com-
pared with FcPh2P=Se (
1
J(31P-77Se) = 731 Hz) and Ph3P=Se (
1
J(31P-77Se) = 729 Hz) 
[C25]
. Ob-
viously, the immobilization on the scaffold has no negative impact on the  – donor proper-
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ties of the phosphines. Furthermore, the phosphorus-selenium coupling constants indicate no 
influence according to the number of the immobilized diphenylphosphino ferrocenyl frag-
ments. 
2.3. Catalysis with Heterobimetallic Iron-Palladium Amidoamine Dendrimers 
To enrich the family of existing Heck catalysts, we applied the above described heterobime-
tallic Fe-Pd phosphines 5-Fe-Pd – 9-Fe-Pd in vinylation reactions, as metal-containing phos-
phines and particularly those based on a ferrocene scaffold have played a very important role 
in many organic transformations catalyzed by palladium complexes 
[C26]
. In comparative stu-
dies these newly synthesized compounds showed to be efficient catalysts in the carbon-carbon 
cross coupling of iodobenzene with tert-butyl acrylate. The results obtained for dendrimers 6-
Fe-Pd – 9-Fe-Pd are compared with the parent model 5-Fe-Pd and are comparatively dis-
cussed in terms of the potential ability of the amidoamine scaffold stabilizing catalytic active 
palladium species. The homogeneous palladium-catalyzed vinylation was performed as de-
scribed by Boys and Butler 
[C27]
. Thus, the appropriate organic coupling reagents (3.0 mmol 
iodobenzene (10), 3.1 mmol tert-butyl acrylate (11)) were reacted in a toluene-acetonitrile 
mixture of ratio 1:1 (v/v), in the presence of NEt
i
Pr2 (3.1 mmol) as a base, [CuI] (two equiva-
lents) as reducing reagent 
[C27]
 and a (pre)catalyst loading of 0.5 mol% of palladium at a com-
parative mild reaction temperature (80 °C) (Reaction C1, Figure C3, Table C1, Experimental 
Part). The initial reaction rate, conversion, TON (= turn-over-number) and TOF (= turn-over-
frequency) data are reported. 
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Figure C3. Kinetic investigation of 5-Fe-Pd – 9-Fe-Pd in the Heck-Mizoroki carbon-
carbon cross-coupling reaction of iodobenzene (10) with tert-butyl acrylate (11) to give E-
tert-butyl cinnamate (12) (0.5 mol% (pre)catalyst; conversion time 0 – 6 hrs).  
 
Table C1. Results of the Heck-Mizoroki C,C-cross-coupling of iodobenzene with tert-
butyl acrylate by 5-Fe-Pd – 9-Fe-Pd. 
Compd. 5-Fe-Pd 6-Fe-Pd 7-Fe-Pd 8-Fe-Pd  9-Fe-Pd 
      
Yield of 12 [%] 
a
 44 48 61 63 88 
TON 
b
 88 96 122 126 176 
TOF [1/h] 
c
 20 24 80 88 90 
a
 Yields are determined by 
1
H NMR spectroscopy with acetylferrocene as standard 
relative to E-tert-butyl cinnamate (12), reaction time 24 hrs; 
b
 Mol product/mol [Pd]; 
c
 Mol product/mol [Pd])/2, determined after 1 h. 
 
From Figure C3 and Table C1 it can be seen that the best productivity is reached with cata-
lyst 9-Fe-Pd possessing the highest number of terminal heterobimetallic Fe-Pd-units. It can 
also be recognized that there is a positive synergistic effect most pronounced between 5-Fe-
Pd / 6-Fe-Pd, 7-Fe-Pd / 8-Fe-Pd and 9-Fe-Pd (Figure C3). As the electronic properties of all 
the compounds are similar (
1
J(31P-77Se), vide supra), the different catalytic activity is most like-
ly caused by cooperative effects between the catalytic active palladium-species formed and 
the amino groups of the amidoamine scaffold. The higher the number of terminal metal frag-
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ments and of intrinsic amino units, the higher is the catalytic activity for the embedded palla-
dium catalyst. Similar results of a positive "dendritic effect" on chemical yields, which means 
that the activity is improved by increasing the number of terminal metal-containing groups, 
have been reported recently 
[C3c, C16e, C28, C29]
. For all heterobimetallic Fe-Pd systems concomi-
tant precipitation of metallic palladium occurs during the catalytic reaction, which decreases 
in the series 5-Fe-Pd / 6-Fe-Pd > 7-Fe-Pd / 8-Fe-Pd > 9-Fe-Pd.  
By means of the Hg(0) drop test, reaction mixtures of iodobenzene (10), tert-butyl acrylate 
(11) and 0.5 mol% of 8-Fe-Pd as (pre)catalyst are quenched with metallic mercury (Figure 
C4) at certain times 
[C30]
. Quenching after the catalytically active system is formed (t = 45 
min) extinguishes the catalytic activity instantly, while adding mercury at the beginning of the 
catalysis (t = 0 min) even prevents the formation of a catalytic active palladium species.  This 
observations of poisoning implies heterogeneous Heck-Mizoroki reactions promoted by Pd(0) 
particles 
[C31]
.  
0 1 2 3 4 5 6
0
10
20
30
40
50
60
70
80
90
100
 
 
8-Fe-Pd (Hg)
8-Fe-Pd (Hg)
8-Fe-Pd (no Hg)
C
o
n
v
e
rs
io
n
 /
 %
time / h
addition of Hg
 
Figure C4. Hg(0) drop tests of 8-Fe-Pd in the Heck-Mizoroki reactions by addition of me-
tallic mercury at certain times (t = 0 min; t = 45 min) and without the addition of mercury for 
comparison. 
 
3. Conclusions 
The preparation and characterization of well-defined Fe-Pd phosphine functionalized amido-
amines N(CH2CH2C(O)NHCH2CH2NHC(O)(Fe(
5
-C5H4)(
5
-C5H4PPh2(Pd(
3
-C3H5)Cl))))3, 
[CH2N(CH2CH2C(O)NHCH2CH2NHC(O)(Fe(
5
-C5H4)(
5
-C5H4PPh2(Pd(
3
-C3H5)Cl))))2]2, 
(Fe((5-C5H4PPh2(Pd(
3
-C3H5)Cl))(
5
-C5H4))C(O)HNCH2CH2NHC(O)CH2CH2)N[CH2CH2-
N(CH2CH2C(O)NHCH2CH2NHC(O)(Fe(
5
-C5H4)(
5
-C5H4PPh2(Pd(
3
-C3H5)Cl))))2]2, (Fe-
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(5-C5H4(PPh2(Pd(
3
-C3H5)Cl))(
5
-C5H4C(O)NH
n
C3H7))) and [Fe(
5
-C5H4(PPh2(Pd(
3
-
C3H5)Cl))(
5
-C5H4C(O)NHCH2))]2, for comparison, using consecutive divergent growth me-
thodologies including addition, amidation and complexation reactions is described. These 
molecules are unique because they feature as end-grafted moieties heterobimetallic ferro-
cenyl-based palladium allyl chlorides. These individual metallodendrimers were successfully 
employed as homogeneous Heck catalysts in the vinylation of iodobenzene with tert-butyl 
acrylate to give E-tert-butyl cinnamate. The newly prepared Fe-Pd-catalysts are less active 
than the catalyst systems reported earlier with any combination of N-heterocyclic carbenes 
[C32]
, bulky electron-rich chelating bis(phosphines) 
[C33]
, palladacycles 
[C34]
, secondary phos-
phates or phosphonium salts 
[C29a, C35]
, however, the systems prepared show synergistic and 
cooperative effects resulting in higher yields and productivities with increasing numbers of 
end-grafted Fe-Pd phosphine moieties. Due to the larger organic matrix with its specific, in-
trinsic amine functionalities the amidoamine scaffold with the most immobilized heterobime-
tallic iron-palladium features is best suited for the stabilization of the catalytic active species. 
 
4. Experimental 
4.1. Materials and Methods 
Syntheses were performed under a dry and deoxygenated dinitrogen atmosphere using stan-
dard Schlenk techniques unless otherwise stated. All solvents were carefully dried by standard 
procedures over the appropriate drying agents and distilled immediately prior to use. The rea-
gents that where purchased commercially were used without further purification. (Diphenyl-
phosphino)ferrocenyl carboxylic acid (3) 
[C21b]
, [Pd(3-C3H5)Cl]2 (4) 
[C21c]
 and 5-Fe – 8-Fe 
[C16e]
 were prepared according to published procedures. 
1
H, 
13
C{
1
H} and 
31
P{
1
H} NMR spectra were recorded with a Bruker Avance III 500 MHz 
spectrometer. Chemical shifts  are given in ppm (parts per million) using the particular sol-
vent or H3PO4 as external standard as reference signal. Coupling constants J are given in 
Hertz (Hz). FT-IR spectra were recorded with a FT Nicolet IR 200 instrument in the range of 
500 to 4000 cm
-1
. The melting points were obtained using capillaries with an electro thermal 
melting point apparatus. Microanalyses were performed with a C,H,N-analyzer FLASHEA 
1112 Series (Thermo Inc.). 
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4.2. Preparation of H2NCH2CH2NHC(O)CH2CH2)N(CH2CH2N(CH2CH2C(O)NH-
CH2CH2NH2)2)2 (2) 
Poly(amidoamine)dendrimer 2 was synthesized by a preparation procedure firstly described 
by Tomalia et al. 
[C21a]
, in a two step synthesis methodology using 1.0 g (9.7 mmol) of diethy-
lenetriamine in 20 mL of methanol. After subsequent addition of methyl acrylate (10 g, 116 
mmol) at 25 °C an excess of ethylenediamine (33.5 mL, 0.5 mol) was added in a single por-
tion. After 3 days of stirring all volatiles were evaporated in oil-pump vacuum, whereby 2 was 
obtained as colorless oil (6.5 g, 99 %, based on diethylenetriamine). Anal. Calc. for 
C29H63N13O5 (673.9): C, 51.69; H, 9.42; N, 27.02. Found: C, 52.03; H, 9.67; N, 27.19. 
1
H 
NMR (, CDCl3): 1.45 (bs, 10 H, NH2), 2.37 (m, 10 H, CH2C(O)), 2.56 (br, 8 H, 
NCH2CH2N), 2.74 (t, 10 H, 
3
JHH = 6.9 Hz, NCH2CH2C(O)), 2.78 (t, 10 H, 
3
JHH = 6.3 Hz, 
CH2NH2), 3.25 (t, 10 H, 
3
JHH = 6.3 Hz, NHCH2), 7.66 (m, 5 H, C(O)NH). 
13
C{
1
H} NMR (, 
CDCl3): 32.1 (CH2C(O)), 41.3 (NHCH2), 42.3 (CH2NH2), 51.4 (NCH2CH2N), 52.0 
(NCH2CH2N), 54.2 (NCH2CH2C(O)), 168.4 (C(O)). FT-IR (NaCl, cm
-1
): 3365 (vs, NH2), 
1640 (vs, C(O), amide I), 1560 (s, C(O), amide II). 
4.3. Preparation of ((Fe(5-C5H4PPh2)(
5
-C5H4))C(O)HNCH2CH2NHC(O)CH2CH2)-
N[CH2CH2N(CH2CH2C(O)NHCH2CH2NHC(O)(Fe(
5
-C5H4)(
5
-C5H4PPh2)))2]2 
(9-Fe) 
300 mg (0.45 mmol) of 2 in 20 mL of dichloromethane was mixed with 950 mg (2.3 mmol) 
of (diphenylphosphino)ferrocenyl carboxylic acid (3) and 310 mg (2.3 mmol) of HOBT. After 
stirring for 1 h at 0 °C, 355 mg (2.3 mmol) of EDC in 30 mL of dichloromethane was slowly 
added. The resulting reaction mixture was stirred overnight at 25 °C and afterwards was sub-
sequently washed with 20 mL of an aqueous solution of ammonium chloride (0.5 M). After 
drying the organic layer over MgSO4 the solvents were removed under reduced pressure. The 
crude product was purified by column chromatography (column size: 10 x 3 cm, alumina) 
using dichloromethane as eluent. After evaporation of all volatiles in oil-pump vacuum mole-
cule 9-Fe was obtained as an air stable, orange colored solid (350 mg, 30 %, based on 2). Mp: 
125 °C. Anal. Calc. for C144H148Fe5N13O10P5 (2654.9): C, 65.15; H, 5.62; N, 6.86. Found: C, 
64.63; H, 5.23; N, 6.39. 
1
H NMR (, CDCl3): 2.09 (bs, 20 H, NCH2CH2C(O)), 2.51 (m, 8 H, 
NCH2CH2N), 3.31 (m, 20 H, HNCH2CH2NH), 4.00 (m, 10 H, H/C5H4PPh2), 4.07 (m, 10 H, 
H/C5H4C(O)), 4.29 (m, 10 H, H/C5H4PPh2), 4.64 (m, 10 H, H/C5H4C(O)), 7.18 – 7.31 (m, 
50 H, C6H5), 7.82 (m, 10 H, NH). 
13
C{
1
H} NMR (, CDCl3): 29.7 (CH2C(O)), 39.3 
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(HNCH2CH2NH), 40.4 (HNCH2CH2NH), 50.9 (NCH2CH2C(O)), 51.6 (NCH2CH2N ), 51.9 
(NCH2CH2N), 69.5 (C/C5H4C(O)), 71.9 (C/C5H4C(O)), 73.1 (d, 
3
JCP = 3 Hz, 
C/C5H4C(PPh2)), 74.4 (d, 
2
JCP = 13 Hz, C/C5H4C(PPh2)), 76.6 (Ci/C5H4C(O)), 77.5 (d, 
1
JCP 
= 8 Hz, Ci/C5H4C(PPh2)), 128.4 (d, 
3
JCP = 6 Hz, Cm/C6H5), 128.8 (Cp/C6H5), 133.5 (d, 
2
JCP = 
19 Hz, Co/C6H5), 138.5 (d, 
1
JCP = 10 Hz, Ci/C6H5), 170.9 (C(O)), 173.6 (C(O)). 
31
P{
1
H} NMR 
(, CDCl3): -17.9 (PPh2). FT-IR (KBr, cm
-1
): 3300 (m, NH), 1640 (s, C(O), amide I), 1540 (s, 
C(O), amide II). 
4.4. Preparation of (Fe(5-C5H4(PPh2(Pd(
3
-C3H5)Cl))(
5
-C5H4C(O)NH
n
C3H7))) (5-
Fe-Pd) 
180 mg (0.4 mmol) of (Fe(5-C5H4(PPh2)(
5
-C5H4C(O)NH
n
C3H7))) (5-Fe) were dissolved 
in dichloromethane (20 mL) and 75 mg (0.21 mmol) of [Pd(3-C3H5)Cl]2 (4) were added in a 
single portion. After 1 h of stirring at 25 °C, 5-Fe-Pd was purified by precipitation from dich-
loromethane (5 mL) by addition of 20 mL of n-hexane. The precipitate was washed twice 
with 10 mL portions of n-hexane. After appropriate work-up, the title compound was isolated 
as a bright yellow solid (230 mg, 90 %, based on 5-Fe). Mp: 150 °C. Anal. Calc. for 
C29H31ClFeNOPPd (638.3): C, 54.57; H, 4.90; N, 2.91. Found: C, 54.44; H, 5.12; N, 2.99. 
1
H 
NMR (, CDCl3): 0.96 (t, 3 H, 
3
JHH = 7.4 Hz, CH3), 1.65 (m, 2 H, CH2CH2CH3), 2.85 (m, 1H, 
CH-anti), 3.30 (m, 2 H, CH2CH2CH3), 3.78 (m, 1 H, CH-syn), 4.26 (m, 2 H, H/C5H4PPh2), 
4.57 (m, 2 H, H/C5H4C(O)), 5.02 (m, 2 H, H/C5H4PPh2), 5.15 (m, 2 H, H/C5H4C(O)), 5.55 
(m, 1 H, CH-centered), 7.18 (m, 1 H, NH), 7.31 – 7.78 (m, 10 H, C6H5). 
13
C{
1
H} NMR (, 
CDCl3): 11.7 (CH3), 23.2 (CH2CH2CH3), 41.5 (CH2CH2CH3), 61.9 (CH2-syn/anti), 70.3 
(C/C5H4C(O)), 71.9 (C/C5H4C(O)), 73.5 (d, 
3
JCP = 5 Hz, C/C5H4C(PPh2)), 74.3 (d, 
1
JCP = 
47 Hz, Ci/C5H4C(PPh2)), 76.4 (d, 
2
JCP = 16 Hz, C/C5H4C(PPh2)), 78.5 (Ci/C5H4C(O)), 118.2 
(CH-centered), 128.5 (d, 
3
JCP = 6 Hz, Cm/C6H5), 130.2 (Cp/C6H5), 133.1 (d, 
2
JCP = 12 Hz, 
Co/C6H5), 135.9 (d, 
1
JCP = 44 Hz, Ci/C6H5), 169.2 (C(O)). 
31
P{
1
H} NMR (, CDCl3): 11.6 
(PPh2). FT-IR (KBr, cm
-1
): 3315 (m, NH), 1645 (s, C(O), amide I), 1540 (s, C(O), amide II), 
1480 (w, 3-C3H5). 
4.5. Preparation of [Fe(5-C5H4(PPh2(Pd(
3
-C3H5)Cl))(
5
-C5H4C(O)NHCH2]2 (6-Fe-
Pd) 
Compound 6-Fe-Pd was synthesized in the same manner as 5-Fe-Pd, whereby 150 mg (0.18 
mmol) of [Fe(5-C5H4(PPh2))(
5
-C5H4C(O)NHCH2)]2 (6-Fe) were reacted with 70 mg (0.2 
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mmol) of [Pd(3-C3H5)Cl]2 (4). After appropriate work-up, 6-Fe-Pd was obtained as a bright 
yellow solid (200 mg, 92 %, based on 6-Fe). Mp: 160 °C. Anal. Calc. for 
C54H52Cl2Fe2N2O2P2Pd2 (1218.4): C, 53.23; H, 4.30; N, 2.30. Found: C, 53.46; H, 4.31; N, 
2.20. 
1
H NMR (, CDCl3): 2.67 (m, 2H, CH-anti), 3.59 (m, 4 H, CH2), 3.86 (m, 2 H, CH-syn), 
4.03 (m, 4 H, H/C5H4PPh2), 4.27 (m, 4 H, H/C5H4C(O)), 4.44 (m, 4 H, H/C5H4PPh2), 4.80 
(m, 4 H, H/C5H4C(O)), 5.68 (m, 2 H, CH-centered), 7.12 (m, 2 H, NH), 7.38 – 7.71 (m, 20 
H, C6H5). 
13
C{
1
H} NMR (, CDCl3): 40.6 (CH2), 61.7 (CH2-syn/anti), 70.2 (C/C5H4C(O)), 
72.6 (C/C5H4C(O)), 73.7 (d, 
3
JCP = 9 Hz, C/C5H4C(PPh2)), 74.5 (d, 
1
JCP = 44 Hz, 
Ci/C5H4C(PPh2)), 76.4 (d, 
2
JCP = 14 Hz, C/C5H4C(PPh2)), 77.5 (Ci/C5H4C(O)), 118.3 (CH-
centered), 128.6 (d, 
3
JCP = 9 Hz, Cm/C6H5), 130.3 (Cp/C6H5), 133.2 (d, 
2
JCP = 12 Hz, 
Co/C6H5), 135.4 (d, 
1
JCP = 44 Hz, Ci/C6H5), 170.7 (C(O)). 
31
P{
1
H} NMR (, CDCl3): 11.4 
(PPh2). FT-IR (KBr, cm
-1
): 3315 (m, NH), 1640 (s, C(O), amide I), 1535 (s, C(O), amide II), 
1485 (w, 3-C3H5). 
4.6. Preparation of N(CH2CH2C(O)NHCH2CH2NHC(O)(Fe(
5
-C5H4)(
5
-C5H4PPh2-
(Pd(3-C3H5)Cl))))3 (7-Fe-Pd) 
Compound 7-Fe-Pd was synthesized in the same way as 5-Fe-Pd, whereby 140 mg (0.09 
mmol) of N(CH2CH2C(O)NHCH2CH2NHC(O)(Fe(
5
-C5H4)(
5
-C5H4PPh2)))3 (7-Fe) were 
reacted with 50 mg (0.135 mmol) of [Pd(3-C3H5)Cl]2 (4). After appropriate work-up, 7-Fe-
Pd was obtained as a bright yellow solid (165 mg, 88 %, based on 7-Fe). Mp: 165 °C. Anal. 
Calc. for C93H99Cl3Fe3N7O6P3Pd3 (2096.9): C, 53.27; H, 4.76; N, 4.68. Found: C, 53.13; H, 
4.91; N, 4.52. 
1
H NMR (, CDCl3): 2.37 (m, 6 H, CH2C(O)), 2.72 (m, 6 H, NCH2CH2C(O)), 
2.97 (m, 3 H, CH-anti), 3.43 (bs, 12 H, HNCH2CH2NH), 3.84 (m, 3 H, CH-syn), 4.01 (m, 6 
H, H/C5H4PPh2), 4.29 (m, 6 H, H/C5H4C(O)), 4.53 (m, 6 H, H/C5H4PPh2), 4.99 (m, 6 H, 
H/C5H4C(O)), 5.64 (m, 3 H, CH-centered), 7.29 – 7.81 (m, 30 H, C6H5), 7.87 (m, 6 H, NH). 
13
C{
1
H} NMR (, CDCl3): 29.9 (NCH2CH2C(O)), 39.6 (HNCH2CH2NH), 39.9 
(HNCH2CH2NH), 50.0 (NCH2CH2C(O)), 59.9 (CH2-syn/anti), 69.9 (C/C5H4C(O)), 72.4 
(C/C5H4C(O)), 73.6 (d, 
3
JCP = 7 Hz, C/C5H4C(PPh2)), 73.9 (d, 
1
JCP = 43 Hz, 
Ci/C5H4C(PPh2)), 74.5 (d, 
2
JCP = 15 Hz, C/C5H4C(PPh2)), 77.5 (Ci/C5H4C(O)), 118.4 (CH-
centered), 128.3 (d, 
3
JCP = 10 Hz, Cm/C6H5), 130.3 (Cp/C6H5), 132.7 (d, 
2
JCP = 12 Hz, 
Co/C6H5), 135.6 (d, 
1
JCP = 42 Hz, Ci/C6H5), 170.6 (C(O)), 171.9 (C(O)). 
31
P{
1
H} NMR (, 
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CDCl3): 12.5 (PPh2). FT-IR (KBr, cm
-1
): 3300 (m, NH), 1640 (s, C(O), amide I), 1540 (s, 
C(O), amide II), 1480 (w, 3-C3H5). 
4.7. Preparation of [CH2N(CH2CH2C(O)NHCH2CH2NHC(O)(Fe(
5
-C5H4)(
5
-
C5H4PPh2 (Pd(
3
-C3H5)Cl))))2]2  (8-Fe-Pd) 
The title compound 8-Fe-Pd was synthesized by using the same synthesis methodology as 
5-Fe-Pd, whereby 275 mg (0.13 mmol) of [CH2N(CH2CH2C(O)NHCH2CH2NHC(O)(Fe(
5
-
C5H4)(
5
-C5H4PPh2)))2]2 (8-Fe) were reacted with 100 mg (0.27 mmol) of [Pd(
3
-C3H5)Cl]2 
(4). After appropriate work-up, 8-Fe-Pd was obtained as a bright yellow solid (240 mg, 65 %, 
based on 8-Fe). Mp: 170 °C. Anal. Calc. for C126H136Cl4Fe4N10O8P4Pd4 (2833.3): C, 53.41; H, 
4.84; N, 4.94. Found: C, 53.74; H, 4.96; N, 5.28. 
1
H NMR (, CDCl3): 2.34 (m, 8 H, 
CH2C(O)), 2.42 (m, 4 H, CH2N), 2.74 (m, 8 H, NCH2CH2C(O)), 2.84 (m, 4 H, CH-anti),  
3.38 (m, 16 H, HNCH2CH2NH), 3.81 (m, 4 H, CH-syn), 4.07 (m, 8 H, H/C5H4PPh2), 4.28 
(m, 8 H, H/C5H4C(O)), 4.55 (m, 8 H, H/C5H4PPh2), 5.01 (m, 8 H, H/C5H4C(O)), 5.61 (m, 4 
H, CH-centered), 7.28 – 7.78 (m, 40 H, C6H5), 8.18 (m, 8 H, NH). 
13
C{
1
H} NMR (, CDCl3): 
34.8 (CH2C(O)), 39.3 (HNCH2CH2NH), 40.4 (HNCH2CH2NH), 53.5 (NCH2CH2C(O)), 56.7 
(CH2N), 61.2 (CH2-syn/anti), 70.4 (C/C5H4C(O)), 72.4 (C/C5H4C(O)), 73.8 (d, 
3
JCP = 7 Hz, 
C/C5H4C(PPh2)), 74.5 (d, 
1
JCP = 48 Hz, Ci/C5H4C(PPh2)), 76.2 (C/C5H4C(PPh2)), 77.9 
(Ci/C5H4C(O)), 118.3 (CH-centered), 128.5 (d, 
3
JCP = 10 Hz, Cm/C6H5), 130.4 (Cp/C6H5), 
133.1 (d, 
2
JCP = 12 Hz, Co/C6H5), 133.6 (d, 
1
JCP = 48 Hz, Ci/C6H5), 169.9 (C(O)), 170.4 
(C(O)). 
31
P{
1
H} NMR (, CDCl3): 13.4 (PPh2). FT-IR (KBr, cm
-1
): 3300 (m, NH), 1645 (s, 
C(O), amide I), 1535 (s, C(O), amide II), 1480 (w, 3-C3H5). 
4.8. Preparation of ((Fe(5-C5H4PPh2(Pd(
3
-C3H5)Cl))(
5
-C5H4))C(O)HNCH2CH2-
NHC(O)CH2CH2)N[CH2CH2N(CH2CH2C(O)NHCH2CH2NHC(O)(Fe(
5
-
C5H4)(
5
-C5H4-PPh2(Pd(
3
-C3H5)Cl))))2]2 (9-Fe-Pd) 
Dendrimer 9-Fe-Pd was synthesized in the same manner as 5-Fe-Pd, whereby 150 mg (0.06 
mmol) of (Fe((5-C5H4PPh2)(
5
-C5H4))C(O)HNCH2CH2NHC(O)CH2CH2)N[CH2CH2N-
(CH2CH2C(O)NHCH2CH2NHC(O)(Fe(
5
-C5H4)(
5
-C5H4PPh2)))2]2 (9-Fe) were reacted with 
55 mg (0.15 mmol) of [Pd(3-C3H5)Cl]2 (4). After appropriate work-up, 9-Fe-Pd was ob-
tained as a bright yellow solid (180 mg, 85 %, based on 9-Fe). Mp: 170 °C. Anal. Calc. for 
C159H173Cl5Fe5N13O10P5Pd5 (3569.6): C, 53.50; H, 4.88; N, 5.10. Found: C, 54.02; H, 4.75; N, 
5.43. 
1
H NMR (, CDCl3): 2.31 (m, 20 H, NCH2CH2C(O)), 2.58 (m, 8 H, NCH2CH2N), 2.76 
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(m, 5 H, CH-anti), 3.31 (m, 20 H, HNCH2CH2NH), 3.79 (m, 5 H, CH-syn), 4.04 (m, 10 H, 
H/C5H4PPh2), 4.28 (m, 10 H, H/C5H4C(O)), 4.53 (m, 10 H, H/C5H4PPh2), 5.01 (m, 10 H, 
H/C5H4C(O)), 5.62 (m, 5 H, CH-centered), 7.27 – 7.76 (m, 50 H, C6H5), 7.89 (m, 10 H, NH). 
13
C{
1
H} NMR (, CDCl3): 34.6 (CH2C(O)), 39.5 (HNCH2CH2NH), 40.1 (HNCH2CH2NH), 
50.9 (NCH2CH2C(O)), 53.5 (CH2N), 61.3 (CH2-syn/anti), 70.3 (C/C5H4C(O)), 72.5 
(C/C5H4C(O)), 73.9 (d, 
3
JCP = 7 Hz, C/C5H4C(PPh2)), 74.5 (d, 
1
JCP = 46 Hz, 
Ci/C5H4C(PPh2)), 77.2 (C/C5H4C(PPh2)), 77.8 (Ci/C5H4C(O)), 118.4 (CH-centered), 128.5 
(d, 
3
JCP = 11 Hz, Cm/C6H5), 130.4 (Cp/C6H5), 133.2 (d, 
2
JCP = 11 Hz, Co/C6H5), 133.4 (d, 
1
JCP 
= 44 Hz, Ci/C6H5), 170.0 (C(O)), 170.8 (C(O)). 
31
P{
1
H} NMR (, CDCl3): 13.3 (PPh2). FT-IR 
(KBr, cm
-1
): 3295 (m, NH), 1640 (s, C(O), amide I), 1540 (s, C(O), amide II), 1480 (w, 3-
C3H5). 
4.9. Preparation of (Fe(5-C5H4(PPh2(Se))(
5
-C5H4C(O)NH
n
C3H7))) (5-Fe-Se) 
50 mg (0.11 mmol) of (Fe(5-C5H4(PPh2)(
5
-C5H4C(O)NH
n
C3H7))) (5-Fe) were dissolved 
in 10 mL of dichloromethane and 8 mg (0.11 mmol) of selenium were added in a single por-
tion. After 1 h of stirring at 25 °C, the suspension was filtered through a pad of Celite. After 
evaporation the title compound could be isolated as an orange solid (55 mg, 98 %, based on 5-
Fe). Anal. Calc. for C26H26FeNOPSe (534.3): C, 58.45; H, 4.91; N, 2.62. Found: C, 58.16; H, 
5.22; N, 2.54. 
1
H NMR (, CDCl3): 0.97 (t, 3 H, 
3
JHH = 7.3 Hz, CH3), 1.67 (m, 2 H, 
CH2CH2CH3), 3.33 (m, 2 H, CH2CH2CH3), 3.92 (m, 2 H, H/C5H4PPh2), 4.24 (m, 2 H, 
H/C5H4C(O)), 4.62 (m, 2 H, H/C5H4PPh2), 4.89 (m, 2 H, H/C5H4C(O)), 7.39 (m, 1 H, NH), 
7.45 – 7.68 (m, 10 H, C6H5). 
13
C{
1
H} NMR (, CDCl3): 11.8 (CH3), 23.2 (CH2CH2CH3), 41.4 
(CH2CH2CH3), 71.2 (C/C5H4C(O)), 71.5 (C/C5H4C(O)), 73.4 (d, 
3
JCP = 10 Hz, 
C/C5H4C(PPh2)), 75.1 (d, 
2
JCP = 12 Hz, C/C5H4C(PPh2)), 75.5 (d, 
1
JCP = 88 Hz, 
Ci/C5H4C(PPh2)), 79.1 (Ci/C5H4C(O)), 128.4 (d, 
3
JCP = 12 Hz, Cm/C6H5), 131.7 (Cp/C6H5), 
132.1 (d, 
1
JCP = 11 Hz, Ci/C6H5), 133.2 (d, Co/C6H5), 169.1 (C(O)). 
31
P{
1
H} NMR (, CDCl3): 
30.9 (
1
J(31P-77Se) =  720 Hz). FT-IR (KBr, cm
-1
): 3300 (m, NH), 1645 (s, C(O), amide I), 1540 
(s, C(O), amide II), 560 (s, P(Se)). 
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4.10. Preparation of ((Fe(5-C5H4(PPh2(Se)))(
5
-C5H4))C(O)HNCH2CH2NHC(O)-
CH2CH2)N[CH2CH2N(CH2CH2C(O)NHCH2CH2NHC(O)(Fe(
5
-C5H4)(
5
-C5H4-
(PPh2(Se)))))2]2  (9-Fe-Se) 
Compound 9-Fe-Se was synthesized as described for 5-Fe-Se using 55 mg (0.02 mmol) of 
(Fe((5-C5H4PPh2)(
5
-C5H4))C(O)HNCH2CH2NHC(O)CH2CH2)N[CH2CH2N(CH2CH2C(O)-
NHCH2CH2NHC(O)(Fe(
5
-C5H4)(
5
-C5H4PPh2)))2]2 (9-Fe) and 8 mg (0.11 mmol) of sele-
nium. After appropriate work-up, compound 9-Fe-Se was obtained as an air stable, orange 
colored solid (50 mg, 85 %, based on 9-Fe). Anal. Calc. for C144H148Fe5N13O10P5Se5 (3049.7): 
C, 56.71; H, 4.89; N, 5.97. Found: C, 56.31; H, 4.94; N, 6.02. 
1
H NMR (, CDCl3): 2.03 (m, 
20 H, NCH2CH2C(O)), 2.67 (m, 8 H, NCH2CH2N), 3.47 (m, 20 H, HNCH2CH2NH), 4.15 (m, 
10 H, H/C5H4PPh2), 4.32 (m, 10 H, H/C5H4C(O)), 4.59 (m, 10 H, H/C5H4PPh2), 4.88 (m, 
10 H, H/C5H4C(O)), 7.45 – 7.67 (m, 50 H, C6H5), 7.72 (m, 10 H, NH). 
13
C{
1
H} NMR (, 
CDCl3): 29.8 (CH2C(O)), 39.7 (HNCH2CH2NH), 40.5 (HNCH2CH2NH), 50.3 
(NCH2CH2C(O)), 51.6 (NCH2CH2N), 51.9 (NCH2CH2N), 70.1 (C/C5H4C(O)), 72.1 
(C/C5H4C(O)), 73.7 (d, 
3
JCP = 8 Hz, C/C5H4C(PPh2)), 75.4 (d, 
2
JCP = 11 Hz, 
C/C5H4C(PPh2)), 75.6 (d, 
1
JCP = 88 Hz, Ci/C5H4C(PPh2)), 78.2 (Ci/C5H4C(O)), 128.3 (d, 
3
JCP 
= 12 Hz, Cm/C6H5), 131.5 (Cp/C6H5), 132.2 (d, 
1
JCP = 11 Hz, Ci/C6H5), 133.2 (Co/C6H5), 170.1 
(C(O)), 173.2 (C(O)). 
31
P{
1
H} NMR (, CDCl3): 30.7 (
1
J(31P-77Se) =  723 Hz). FT-IR (KBr, cm
-
1
): 3300 (m, NH), 1645 (s, C(O), amide I), 1540 (s, C(O), amide II), 560 (s, P(Se)). 
4.11. General Procedure for the Heck-Reaction 
Iodobenzene (615 mg, 3.0 mmol), tert-butyl acrylate (395 mg, 3.1 mmol), EtN
i
Pr2 (410 mg, 
3.1 mmol) and acetylferrocene (114 mg, 0.5 mmol) were dissolved in 20 mL of a tolu-
ene/acetonitrile mixture (ratio 1:1, v/v) and loaded with the respective catalyst (6-Fe-Pd – 9-
Fe-Pd or 5-Fe-Pd, 0.5 mol% palladium). Two equivalents of [CuI] (6 mg, 0.0315 mmol) 
were added in a single portion. The reaction suspension was stirred at 80 °C and samples (1 
mL) were taken in periods of 1 h. The samples were filtered through a pad of Silica gel with 
diethyl ether as eluent. All volatiles were evaporated from the respective samples under re-
duced pressure. The conversions were determined by 
1
H NMR spectroscopy. 
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The issues presented in the subsequent section are the result of an inter-institutional coopera-
tion with the research group of ac. Prof. Dr. Petr Štěpnička at Charles University in Prague 
(Czech Republic). 
In this respect, the author of the present doctoral thesis synthesized and fully characterized 
the dendritic amidoamines 7 and (Sp,Sp,Sp)−5 under supervision of Prof. Dr. Heinrich Lang in 
Chemnitz. The syntheses of the remaining compounds as well as the catalytic tests were per-
formed by Martin Lamač, Jiří Tauchman and ac. Prof. Dr. Petr Štěpnička in Prague. The X-
ray crystallographic investigations were accomplished by Dr. Ivana Císařová. 
 
1. Introduction 
The use of dendrimeric molecules as supporting scaffolds to catalytic systems has recently 
gained considerable attention largely because it can lead to multifunctional catalysts, which 
can be recycled while often retaining high activity and selectivity of their corresponding ho-
mogeneous, low-molecular weight counterparts. Dendrimers for catalytic applications, mostly 
with phosphane donor sites, are typically prepared with a single functional moiety in (or close 
to) the core of the hyperbranched structure, or with several functional units attached at the 
periphery. The latter approach is particularly attractive as it may result in unique materials 
showing unusual reactivity due to the formation of specific microcompartments within the 
highly functionalized structures. 
[D1]
  
In view of our previous work aimed at the preparation, coordination behaviour and catalytic 
chemistry of ferrocene-based phosphanylcarboxylic acids 
[D2]
 and the corresponding carbox-
amide derivatives, 
[D3]
 we recently synthesized dendrimer like assemblies containing several 
covalently bonded terminal 1´-(diphenylphosphanyl)ferrocen-1-yl groups at the exterior. 
[D4]
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For the synthesis of the latter molecules, we made use of the amidation reaction between 1´-
(diphenylphosphanyl)ferrocene-1-carboxylic acid (Hdpf) 
[D5, D2a]
 and the terminal NH2 groups 
of first-generation poly(amidoamine) dendrimers (PAMAM). 
[D6, D7]
 Even these relatively 
simple compounds containing one to four phosphanylferrocenyl moieties exerted a distinct 
positive dendritic effect on the reaction rate in palladium-catalyzed Suzuki–Miyaura and 
Heck–Mizoroki reactions. This led us to design, prepare and study analogous compounds de-
rived from the planar-chiral isomer of Hdpf, viz. (Sp)-2-(diphenylphosphanyl)ferrocene-1-
carboxylic acid [(Sp)–1]. 
[D8]
  
With this contribution, we report on the preparation of several amides derived from (Sp)–1 
and small PAMAM-like amines or related model compounds (Scheme D1) and on their use as 
ligands in palladium-catalyzed asymmetric allylic alkylation. 
[D9]
 These newly prepared do-
nors not only widen the scope of the chiral phosphanyl-carboxamide ligands synthesized so 
far from (Sp)–1, 
[D3e, D8a, D8b, D10]
 but also further demonstrate the alternative approach towards 
the preparation of chiral phosphanylferrocenyl dendrimers. 
[D11]
 
 
2. Results and Discussion 
2.1. Syntheses and Characterization 
The series of phosphanylferrocenyl amides was designed comprising both simple monofer-
rocenyl derivatives analogous to the compounds studied earlier 
[D3e]
 and their larger PAMAM-
like congeners (Scheme D1). Compounds 2 – 5 were obtained by the reactions of (Sp)-2-
(diphenylphosphanyl)ferrocene-1-carboxylic acid [(Sp)–1] 
[D8]
 with appropriate terminal 
amines in the presence of peptide coupling agents 
[D12]
 (Scheme D1).  
The starting amines were synthesized as described in the literature (see Experimental) except 
for the precursor to compound 4, which was obtained via the coupling of N-Boc protected 
1,2-diaminoethane (8) and β-alanine (9) followed by removal of the protecting groups and 
was isolated as dihydrochloride 6 (Scheme D2). 
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Scheme D1. Preparation of phosphane-amide ligands 2 – 5 (EDC = 1-ethyl-3-[3-
(dimethylamino)propyl]carbodiimide, HOBT = 1-hydroxybenzotriazole). 
The amidation reactions with small amines proceeded very well and afforded the products in 
good to excellent isolated yields. In the case of larger molecules, however, the isolation was 
complicated by chemical similarity and overall high polarity of the main and side products, 
which resulted in relatively lower yields (cf. the synthesis of compound 5). Finally, an at-
tempted preparation of a penta(amidoferrocenyl) derivative from {H2N(CH2)2-
NHC(O)(CH2)2}2NCH2CH2N{(CH2)2C(O)NH(CH2)2NH2}CH2CH2N{(CH2)2C(O)NH(CH2)2
NH2}2 analogously to the synthesis of 5 was unsuccessful due to complications during the 
isolation step. 
Amido-phosphanes 2 – 5 were characterized by multinuclear NMR spectroscopy, electro-
spray (ESI) mass spectrometry and by optical rotation. In the 
1
H and 
13
C NMR spectra, they 
showed signals typical for 1,2-disubstituted ferrocene moieties and signals due to the amide 
substituents. The 
13
C NMR spectra further comprised resonances of the amide C═O groups 
due to the ferrocenyl-bound amide units (a doublet with 
3
JPC = 3 – 4 Hz) and the organic link-
ers (singlets), all in the narrow range δC ca 170.3 – 173.2. 
31
P{
1
H} NMR spectra of 2, 3 and 5 
displayed single resonances at δP around -20, whereas the unsymmetric diphosphane 4 expec-
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tedly showed two signals. On the other hand, the unsymmetric diphosphane 4 showed two 
signals at very similar positions (δP -19.7 and -19.8). In ESI mass spectra, compounds 2 – 5 
gave rise to characteristic pseudomolecular ions ([M + Z]
+
, Z = H, Na or K; [M - H]
-
). 
 
 
Scheme D2. Preparation of the starting amido-diamine dihydrochloride 6 (see legend to 
Scheme D1). 
 
2.2. Solid-State Structure of (Sp)–2 
The solid-state structure of (Sp)–2 was established by single-crystal X-ray diffraction analy-
sis. A view of the molecular structure is presented in Figure D1 together with selected geome-
tric data. The structure of (Sp)–2 is not unexpected and corroborates both the connectivity and 
chirality at the ferrocene moiety. Besides, the molecular geometry compares well with the 
structural data reported for (Sp)-1-(N-benzylcarbamoyl)-2-(diphenylphosphanyl)ferrocene 
[D3e]
 
and (Sp)-2-(diphenylphosphanoyl)-1-ferrocene-1-carboxylic acid. 
[D8c] 
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Figure D1. View of the molecular structure of (Sp)–2 showing the atom labeling scheme. 
Displacement ellipsoids are drawn at the 30 % probability level. Selected distances and an-
gles: Fe–Cg1 1.6443(7), Fe–Cg2 1.653(1), P–C2 1.826(1), P–C12 1.837(2), P–C18 1.850(2), 
C1–C11 1.487(2), C11–O 1.240(2), C11–N 1.343(2), N–C24 1.465(2) Å;<Cp1,Cp2 1.8(1), 
C2–C1–C11 124.7(1), C5–C1–C11 126.9(1), C1–C11–O 121.4(1), C1–C11–N 115.4(1), O–
C11–N 123.2(1), C11–N–C24 121.2(1), C1–C2–P 126.9(1), C3–C2–P 126.7(1), C2–P–C12 
103.23(6), C2–P–C18 97.60(7), C12–P–C18 99.29(7). The ring planes are defined as follows: 
Cp1 = C(1–5), Cp2 = C(6–10); Cg1 and Cg2 denote the respective ring centroids. 
The ferrocene moiety in (Sp)–2 exerts balanced Fe–Cg distances and negligible tilting [dihe-
dral angle of the mean cyclopentadienyl ring planes being 1.8(1)°]. As indicated by the rela-
tively minor differences in the pairs of adjacent C2/C5–C1–C11 and C1/C3–C2–P angles be-
ing 2.2 and 0.2°, respectively and further by the torsion angle C11–C1–C2–P being 0.6(2)°, 
the substituents bind symmetrically to the ferrocene scaffold without any notable torsional 
deformation. On the other hand, the carbamoyl group (C11,O,N) is rotated from the plane of 
its bonding cyclopentadienyl ring by as much as 20.5(2)° with its bulkier N(CH2)2CH3 moiety 
pointing above the ferrocene unit and away from the PPh2 group. In the crystal, individual 
molecules of (Sp)–2 aggregate into infinite chains by means of N–H· · ·O hydrogen bonds 
between proximal molecules related by crystallographic 21 screw axis (Figure D2). A similar 
packing arrangement has been noted in the structure of the aforementioned N-benzyl amide. 
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Figure D2. A section of the infinite hydrogen bonded chain in the structure of (Sp)–2. Only 
pivotal phenyl ring carbons and H-bonded hydrogen atoms are shown for clarity. Hydrogen 
bond parameters, N–H1N· · ·O´:N· · ·O´ = 3.006(2) Å, N–H1N· · ·O´ = 161° (prime-labeled 
atoms are generated by the (2 - x, y - 1/2, 1 - z) symmetry operation). 
 
2.3. Catalytic Tests 
Although asymmetric palladium-catalyzed allylic alkylation is both a valuable synthetic tool 
and a widely used benchmark test, 
[D9]
 there have been published only a few reports concern-
ing the use of chiral, dendrimer-supported phosphanes as ligands for this reaction. 
[D11d, D13]
 In 
the present case, we have employed asymmetric allylic alkylation because it allows for a 
comparison of the newly prepared multidonor phosphanylferrocene carboxamides with the 
related ligands. For testing, we used the alkylation of the symmetrical substrate 1,3-
diphenylprop-2-en-1-yl acetate (11) with in-situ generated malonate anion (Scheme D3). 
 
Scheme D3. The model asymmetric allyic alkylation reaction. 
The results summarized in Table D1 clearly show that there was only relatively minor varia-
tion in the ee upon increasing the number of the chiral 2-phosphanylferrocenyl units per li-
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gand molecule, the (R)–12 always being the major product. In terms of enantioselectivity, the 
reaction outcome was similar to or slightly better than that achieved with simple benzylic 
amides derived from acid (Sp)–1 
[D3e]
 and considerably better than that reported for analogous, 
donor-unsymmetric chiral-pocket bisamides. 
[D10a] 
Table D1. Application of the chiral phosphano-amides 2 – 5 to palladium-catalyzed enanti-
oselective allylic alkylation
a
. 
Entry Ligand Additive Conversion ee
b
 
1 (Sp)−2 None 65 82 
2 (Sp)−3 None 70 91 
3 (Sp,Sp)−4 None 7 87 
4 (Sp,Sp,Sp)−5 None 22 88 
5 (Sp)−3 LiOAc 13 84 
6 (Sp)−3 NaOAc 45 92 
7 (Sp)−3 KOAc 33 92 
8 (Sp)−3 RbOAc 57 93 
9 (Sp)−3 CsOAc 96 91 
     
a
 The results are an average of two independent runs. For detailed conditions, see Ex-
perimental.  
b
 (R)–12 was the dominating component of the enantiomeric mixture in all cases. 
On the other hand, the conversions achieved with ligands 2 – 5 were far from complete after 
24 hrs and varied greatly with the ligand structure, being lower with the larger ligands (Table 
D1). Fortunately, however, the conversion could be varied significantly upon adding alkali-
metal acetates a catalytic base additives to N,O-bis(trimethylsilyl)acetamide. With ligand 
(Sp)–3, which performed best in the series of ligands tested and caesium acetate as the base 
additive, the conversion was nearly complete within 24 hrs while the degree of asymmetric 
induction remained unaffected (Table D1). 
 
3. Conclusions 
Oligoamides bearing one to three (Sp)-2-(diphenylphosphanyl)ferrocen-1-yl pendant groups 
at the periphery are readily available via amide coupling of (Sp)-2-(diphenyl-
phosphanyl)ferrocene-1-carboxylic acid with appropriate terminal amines. When combined 
with bis[chlorido(η3-allyl)palladium(II)] as a metal source, these donors give rise to efficient 
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catalysts for asymmetric allylic alkylation of 1,3-diphenylallyl acetate. Whereas the enanti-
oselectivity varies only slightly with the ligand structure (maximum ee being 93 %), the reac-
tion rate changes considerably more, being lower with the larger donor molecules. However, 
the reaction can be improved by adding an appropriate alkalimetal acetate as a catalytic base 
additive. 
 
4. Experimental 
4.1. Materials and Methods 
All syntheses were performed under an argon atmosphere. Dichloromethane was dried over 
anhydrous potassium carbonate and distilled under argon. Acetone and methanol were distill-
ed under argon. Acid (Sp)–1, 
[D8c]
 N-(2-aminoethyl)acetamide, 
[D14]
 tert-butyl N-(2-
aminoethyl)carbamate (8) 
[D15]
 and 3-[(tert-butoxycarbonyl)amino]propanoic acid (9) 
[D16]
 
were prepared according to the literature procedures. 
NMR spectra were recorded on a Varian Unity Inova 400 spectrometer at 25 °C (
1
H, 399.95; 
13
C, 100.58 and 
31
P, 161.90 MHz). Chemical shifts (δ/ppm) are given relative to internal te-
tramethylsilane (
13
C and 
1
H) or to external 85 % aqueous H3PO4 (
31
P). Low-resolution elec-
trospray (ESI) mass spectra were measured with a Bruker Esquire 3000 spectrometer on me-
thanol solutions whereas the high-resolution data were obtained with a Thermo Fisher Scien-
tific LCQ Fleet spectrometer. Optical rotations were determined with an Autopol III automat-
ic polarimeter (Rudolph Research) at room temperature. 
 
4.2. Preparation of Simple Amides. A General Procedure 
N-(3-Dimethylaminopropyl)-N-ethylcarbodiimide (EDC) was slowly added to a mixture of 
acid (Sp)–1, 1-hydroxybenzotriazole (HOBT) and dry dichloromethane (10 – 15 mL) while 
cooling in an ice bath. The resultant mixture was stirred at 0 °C for 5 min, whereupon the sol-
ids dissolved to give a clear orange-red solution. The appropriate amine was introduced (dis-
solved in a small amount of dichloromethane) and stirring was continued at room temperature 
for 20 h. Then, the mixture was washed successively with 1 M HCl, saturated 
aqueous NaHCO3 solution and with brine. The organic phase was separated, dried over 
MgSO4 and evaporated under vacuum, leaving and orange residue, which was subsequently 
purified by column chromatography (silica gel, dichloromethane-methanol 20:1, v/v) to give 
the desired amide after evaporation under vacuum. 
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4.2.1. (Sp)-2-(Diphenylphosphanyl)-1-(N-n-propylcarbamoyl)ferrocene [(Sp)–2] 
Starting with (Sp)–1 (208 mg, 0.50 mmol), HOBT (76 mg, 0.51 mmol), EDC (0.15 mL, 0.75 
mmol) and n-propylamine (35 mg, 0.60 mmol), the general procedure afforded amide (Sp)–2 
as an orange oil, which slowly crystallized at 4 °C. Yield: 205 mg (91 %). [α]D = -201° (c = 
1.0, CHCl3); 
1
H NMR (CDCl3): δ = 0.87 (t, 
3
JHH = 7.5 Hz, 3 H, CH3), 1.50 (m, 2 H, CH2), 
3.30 (m, 2 H, CH2), 3.79 (m, 1 H, C5H3), 4.11 (s, 5 H, C5H5), 4.45 (m, 1 H, C5H3), 5.18 (m, 1 
H, C5H3), 7.12 – 7.59 (m, 11 H, PPh2 and NH); 
13
C{
1
H} NMR (CDCl3): δ = 11.45 (CH3), 
22.91, 41.37 (2 ∙ CH2), 70.79 (C5H5), 71.35 (C5H3 CH), 73.79 (d, JPC = 2 Hz, C5H3 CH), 
74.25 (d, JPC = 4 Hz, C5H3 CH), 74.72 (d, JPC = 9 Hz, C5H3 Cipso), 81.35 (d, JPC = 20 Hz, C5H3 
Cipso), 128.36 (d, 
3
JPC = 7 Hz, PPh2 CHm), 128.40 (PPh2 CHp) 128.43 (d, 
3
JPC = 6 Hz, PPh2 
CHm), 129.75 (PPh2 CHp), 132.10 (d, 
2
JPC = 17 Hz, PPh2 CHo), 135.13 (d, 
2
JPC = 21 Hz, PPh2 
CHo), 135.92, 137.84 (2 ∙ d, 
1
JPC = 6 Hz, PPh2 Cipso), 170.04 (d, 
3
JPC = 4 Hz, CONH); 
31
P{
1
H} 
NMR (CDCl3) = δ -20.1 (s); MS ESI
+
: m/z = 456 ([M + H]
+
), 478 ([M + Na]
+
), 494 ([M + 
K]
+
); MS ESI
-
: m/z = 454 ([M - H]
-
); HR MS (ESI
+
) calcd. for C26H27
56
FeNOP ([M + H]
+
) 
456.1174, found 456.1172. 
 
4.2.2. (Sp)-2-(Diphenylphosphanyl)-1-{N-[2-(acetylamino)ethyl]carbamoyl}ferrocene 
[(Sp)–3] 
Following the general procedure, acid (Sp)–1 (83 mg, 0.20 mmol), HOBT (30 mg, 0.22 
mmol), EDC (0.05 mL, 0.30 mmol) and N-(2-aminoethyl)acetamide (26 mg, 0.25 mmol) gave 
amide (Sp)–3 as an orange solid foam. Yield: 62 mg (62 %). [α]D = -147° (c = 1.0, CHCl3); 
1
H 
NMR (CDCl3): δ = 1.84 (s, 3 H, CH3), 3.25 – 3.59 (m, 4 H, CH2), 3.81 (m, 1 H, C5H3), 4.12 
(s, 5 H, C5H5), 4.47 (m, 1 H, C5H3), 5.11 (m, 1 H, C5H3), 6.02 (br s, 1 H, NHCOMe), 7.13 – 
7.58 (m, 11 H, PPh2 and C5H3CONH); 
13
C{
1
H} NMR (CDCl3): δ = 23.21 (CH3), 39.45, 40.87 
(2 ∙ CH2), 70.91 (C5H5), 71.65 (C5H3 CH), 73.18 (d, JPC = 2 Hz, C5H3 CH), 74.46 (d, JPC = 4 
Hz, C5H3 CH), 75.42 (d, JPC = 10 Hz, C5H3 Cipso), 80.41 (d, JPC = 18 Hz, C5H3 Cipso), 128.40 – 
128.55 (m, PPh2 CHm and CHp), 129.83 (PPh2 CHp), 131.87 (d, 
2
JPC = 17 Hz, PPh2 CHo), 
135.13 (d, 
2
JPC = 21 Hz, PPh2 CHo), 135.82, 138.18 (2 ∙ d, 
1
JPC ≈ 6 Hz, PPh2 Cipso), 170.66 
(CH3CONH), 171.70 (d, 
3
JPC ≈ 3 Hz, C5H3CONH); 
31
P{
1
H} NMR (CDCl3): δ = -19.8 (s); MS 
ESI
+
: m/z = 499 ([M + H]
+
), 521 ([M + Na]
+
), 537 ([M + K]
+
); MS ESI
-
: m/z = 497 ([M - H]
-
); 
HR MS (ESI
+
) calcd. for C27H27
56
FeN2O2P (M
+
) 498.1160, found 498.1156. 
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4.3. Preparation of 2-[N-(2-aminoethyl)carbamoyl]ethylamine dihydrochloride (6) 
A suspension of 3-[(tert-butoxycarbonyl)amino]propanoic acid (9; 1.89 g, 10.0 mmol) and 
HOBT (1.5 g, 11.0 mmol) in dichloromethane (100 mL) was cooled in an ice bath. EDC (2.2 
ml, 12.0 mmol) was slowly introduced and the mixture was stirred at 0 °C for 5 min. To the 
resulting clear solution, a solution of tert-butyl (2-aminoethyl)carbamate (8; 1.92 g, 12.0 
mmol) in dichloromethane (20 mL) was added and the reaction mixture was stirred at room 
temperature for 20 h. Then, it was washed with saturated aqueous citric acid and brine (50 mL 
each). The organic phase was dried over MgSO4 and evaporated under vacuum, leaving a pale 
yellow viscous oil. Subsequent purification by column chromatography (silica gel, dichloro-
methane-methanol, 10:1 v/v) gave 10 as a colourless solid. Yield: 2.96 g (89 %). 
1
H NMR 
(CDCl3): δ = 1.43, 1.44 (2 ∙ s, 9 H, CMe3), 2.39 (t, 
3
J = 5.8 Hz, 2 H, COCH2), 3.20 – 3.45 (m, 
6 H, CH2), 4.99, 5.21, 6.40 (3 ∙ br s, 1 H, NH); HR MS (ESI
+
) calcd. for C15H29N3NaO5 ([M + 
Na]
+
) 354.1999, found 354.2001. 
In the next step, the Boc-protected derivative 10 (500 mg, 1.51 mmol) was dissolved in ace-
tone (30 mL, in air) and dry HCl gas was bubbled through the stirred solution for 15 min, 
causing separation of a fine white precipitate. The mixture was stirred for another 2 hrs and 
then evaporated to dryness under vacuum. The resulting colourless solid was identified as 
pure dihydrochloride 6 and was used directly in the following synthesis without any further 
purification. 
1
H NMR (D2O): δ = 2.73 (t, 
3
J = 6.7 Hz, 2 H, CH2), 3.17 (t, 
3
J = 5.8 Hz, 2 H, 
CH2), 3.29 (t, 
3
J = 6.6 Hz, 2 H, CH2), 3.54 (t, 
3
J = 5.9 Hz, 2 H, CH2), 4.77 (br s, 6 H, NH3
+
); 
HR MS (ESI
+
) calcd. for C5H14N3O([6-H-2Cl]
+
, i.e. monodeprotonated cation) 132.1131, 
found 132.1130. 
 
4.4. Preparation of Compound (Sp,Sp)–4 
EDC (0.05 mL, 0.30 mmol) was added to a mixture of (Sp)–1 (83 mg, 0.20 mmol), HOBT 
(30 mg, 0.22 mmol) and dichloromethane (10 mL) with cooling in an ice bath. After stirring 
for 5 min, the resulting clear orange-red solution of the pre-formed active ester was added to a 
suspension of compound 6 (35 mg, 0.15 mmol) in triethylamine (0.1 mL, 0.72 mmol) and 
dichloromethane (10 mL). The heterogeneous mixture was stirred at room temperature for 
22 hrs and worked up in the same manner as described in the general procedure. Yield: 68 mg 
(74 %) of (Sp,Sp)–4; an orange solid foam. 
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4.5. Preparation of Amino-Amide 7 
Compound 7 was obtained by a two-step procedure as reported previously by Tomalia et al. 
[D17]
 Methyl acrylate (14.5 g, 0.168 mol) and excess 1,2-diaminoethane (49.0 g, 0.815 mol) 
were successively added to a solution of ammonia in methanol (4 mL, 0.028 mol) and the 
reaction mixture was stirred at room temperature for 72 h. Subsequent removal of the volatiles 
under vacuum yielded 7 as a colourless oil (10.0 g, 99 % based on the ammonia).  
 
4.6. Preparation of Compound (Sp,Sp,Sp)–5 
Acid (Sp)–1 (230 mg, 0.55 mmol) and HOBT (75 mg, 0.55 mmol) were added to a solution 
of 7 (64 mg, 0.18 mmol) in dichloromethane (20 mL) while cooling in an ice bath. After stir-
ring at 0 °C for 1 h, a solution of EDC (100 mg, 0.65 mmol) in dichloromethane (5 mL) was 
introduced slowly. The resulting mixture was stirred at room temperature overnight, washed 
with aqueous ammonium chloride solution (0.5 M), dried over MgSO4 and evaporated under 
reduced pressure. The product was isolated by column chromatography on alumina using 
dichloromethane-ethanol (100:1 v/v) as the eluent. Subsequent evaporation afforded amide 
(Sp,Sp,Sp)–5 as an orange amorphous solid. Yield: 150 mg (54 %). 1H NMR (CDCl3): δ = 
2.19 (unresolved t, 2 H), 2.44 – 2.69 (br m, 2 H), 3.18 – 3.37 (m, 4 H) (4 ∙ CH2); 3.78 (m, 1 H, 
C5H3), 4.13 (s, 5 H, C5H5), 4.42 (t, J = 2.6 Hz, 1 H, C5H3), 5.08 m, 1 H, C5H3), 7.07 (br unre-
solved t, 1 H, NH), 7.12 – 7.57 (m, 11 H, PPh2 + NH); 
13
C{
1
H} NMR (CDCl3): δ = 33.86 
(br), 39.61, 40.01 and 49.90 (4 ∙ CH2), 70.96 (C5H5), 71.51 (C5H3 CH), 72.51 (d, JPC = 2 Hz, 
C5H3 CH), 74.42 (d, JPC = 4 Hz, C5H3 CH), 80.37 (d, JPC = 17 Hz, C5H3 Cipso), 128.1 – 128.5 
(m, PPh2, four CHm + one CHp), 129.45 (PPh2 CHp), 132.04 (d, 
2
JPC = 18 Hz, PPh2 CHo), 
135.13 (d, 
2
JPC = 21 Hz, PPh2 CHo), 136.97, 138.98 (2 ∙ d, 
1
JPC = 8 Hz, PPh2 Cipso), 171.17 (d, 
3
JPC = 3 Hz, C5H3CONH), 173.2 (br, CH2CONH) (note: the signal due to C5H3 Cipso is proba-
bly obscured by another resonance); 
31
P{
1
H} NMR (CDCl3): δ = -19.6; MS ESI
+
: m/z = 1548 
([M + H]
+
), 1570 ([M + Na]
+
), 1586 ([M + K]
+
); HR MS (ESI
+
) calcd. for C84H85
56
Fe3N7O6P3 
([M + H]
+
) 1548.3817, found 1548.3818. 
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4.7. Asymmetric Allylic Alkylation. A General Procedure 
Ligand (12.5 μmol), [{Pd(η3-C3H5)Cl}2] (2.3 mg, 6.3 μmol) and alkali metal acetate (25 
μmol; if appropriate) were mixed with dry dichloromethane (3 mL) and the mixture was 
stirred at room temperature for 15 min. Racemic 1,3-diphenylprop-2-en-1-yl acetate (11; 63 
mg, 0.25 mmol) was introduced next, followed after stirring for another 5 min by N,O-
bis(trimethylsilyl)acetamide (BSA; 0.19 mL, 0.75 mmol) and dimethyl malonate (0.09 mL, 
0.75 mmol). The reaction mixture was stirred at room temperature for 24 hrs and then washed 
with saturated aqueous NH4Cl solution (2 ∙ 5ml). The organic layer was separated, dried over 
MgSO4 and concentrated under vacuum. Subsequent purification by flash chromatography 
(silica gel; hexane-ethyl acetate, 3:1 v/v) afforded the mixture of the alkylation product and 
the starting acetate 11. The conversions were determined by 
1
H NMR spectroscopy. Enanti-
omeric excesses were established from 
1
H NMR spectra recorded in C6D6 in the presence of 
the chiral lanthanide shift reagent tris(3-trifluoroacetyl-d-camphorato)-europium(III). The 
configuration of the major component was assigned on the basis of optical rotation of the mix-
ture. 
[D18] 
 
4.8. X-ray Crystallography 
Single-crystals of (Sp)–2 suitable for X-ray diffraction analysis were selected directly from 
the reaction batch (orange-brown block, 0.38 × 0.50 × 0.55 mm
3
). Full-set diffraction data (±h 
±k ±l; 2θ ≤ 55°) were collected with a Nonius KappaCCD image plate diffractometer 
equipped with a Cryostream Cooler (Oxford Cryosystems) at 150(2) K using graphite mo-
nochromatized MoKα radiation (λ = 0.71073 Å) and were analysed with the HKL program 
package. 
[D19]
 
The phase problem was solved by direct methods (SIR97 
[D20]
) and the structure was refined 
by full-matrix least squares procedure based on F
2
 (SHELXL97 
[D21]
). All non-hydrogen 
atoms were refined with anisotropic displacement parameters. The amide hydrogen atom 
(H1N) was identified on a difference density map and refined as a riding atom with Uiso(H1N) 
= 1.2 Ueq(N). The remaining hydrogen atoms were included in calculated positions and re-
fined as riding atoms with Uiso(H) assigned to a multiple of Ueq(C) of their bonding carbon 
atom. Geometric parameters and structural drawings were obtained with a recent version of 
PLATON program. 
[D22] 
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Crystallographic data: C26H26FeNOP, M = 455.3g mol
-1
, monoclinic, space group P21 (no. 
4), a = 9.6809(1), b = 9.6817(2), c = 11.8994(2) Å; β = 100.897(1)°, V = 1095.19(3) Å3, Z = 
2, D = 1.381 g mL
-1
, μ(Mo Kα) = 0.779 mm
-1
; 28 930 diffractions of which 5026 were unique 
and 4895 observed according to Io > 2ζ(Io) criterion (Rint = 1.65 %); 272 parameters, R (ob-
served diffractions) = 2.15 %, R (all data) = 2.26 %, wR (all data) = 5.31 %, Flack´s enantio-
morph parameter: 0.002(9). 
The crystallographic data for (Sp)-2 have been deposited at the Cambridge Crystallographic 
Centre as supplementary publication CCDC-749434. This data can be obtained free of charge 
from the Cambridge Crystallographic Centre, via http://www.ccdc.cam.ac.uk/data request/cif. 
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1. Introduction 
Transition metal nanoparticles (NPs) are of significant interest in physics, biology, chemi-
stry and material sciences 
[E1]
. As these materials have at least one dimension between 1 and 
100 nm, their unique physical and chemical properties are strongly affected by the particle 
size, size distribution, shape and particle-to-particle interaction 
[E2]
. In particular, group-11 
NPs play an important role in the field of optic 
[E3]
, catalytic 
[E4]
, electronic 
[E5]
, chemical sens-
ing 
[E6]
 and bio-medical approaches 
[E7]
. Nanostructured colloids can be obtained by Top-
Down and Bottom-Up processes 
[E8]
, resulting in the design of new generations of nanodevic-
es and smart materials to link the current technologies with future demands 
[E9]
. Various syn-
thetic strategies have been reported continuously to generate NPs of noble metals 
[E10]
, whe-
reas the chemical reduction of metal ions to zero-valent metal NPs in aqueous or organic sol-
vents in the presence of stabilizing agents is most common 
[E11]
. The organic coatings provide 
stabilization to the nanoparticles surface and act as protectives to prevent aggregation. As 
stabilizing components mostly ethylene glycol 
[E12]
, polymers/co-polymers 
[E13]
 or dendrimers 
[E14]
 with donating functionalities including N, O, P and S donor atoms are used. 
(Poly)amidoamine (PAMAM)-based dendrimers are outstanding candidates as templates and 
stabilizers because of their regular structure and chemical versatility 
[E15]
, having intrinsic 
amino and amido functionalities as well as terminal amino 
[E16]
, hydroxyl 
[E17]
 and 
(poly)ethylene glycol (PEG) 
[E18]
 groups or substituted saccharides 
[E19]
.  Originally, Tomalia 
[E20]
 and Crooks 
[E21]
 reported on an efficient encapsulation of copper NPs in a 
(poly)amidoamine matrix providing dendrimer-metal nanocomposites, followed by a number 
of reports dealing with the application of dendrimers for the formation of stable colloidal met-
al NP solutions, such as Ag 
[E22]
, Au 
[E23]
, Ni 
[E24]
, Pd 
[E25]
 and Pt 
[E26]
. Recently, the synthesis 
and structural analysis of heterobimetallic PdAu 
[E27]
, PtAu 
[E28]
 and NiAu 
[E29]
 dendrimer-
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encapsulated core-shell NPs for catalytic and magnetic applications have been reported as 
well. 
In all the above-mentioned investigations the dendritic (poly)amidoamine templates used for 
the stabilization of the appropriate NPs were dendrimers of 2
nd
 to 10
th
 generation 
[E30]
, having 
a large interior with tertiary amines binding to the corresponding metal centers. Although 
these dendritic networks are of particularly chemical elegance exhibiting a monodisperse and 
high radial symmetry their multifarious and time consuming synthesis as well as extensive 
purification make them less attractive for applications, due to economical reasons. Recently, 
in this respect Astruc showed the encapsulation and stabilization of Au NPs by an arene-cored 
(poly)ethylene glycol-terminated dendrimer formed by "click" chemistry providing 27, 81 and 
243 tethers (Gen. 0 to 2) 
[E14a]
. These dendritic precursors which are accessible after a plurali-
ty of complex synthetic steps allow the formation of 2 to 4 nm sized Au NPs. 
Herein, we report a two-step synthesis methodology for a novel series of well-defined 
(poly)amidoamine-based dendrimers of low-generation (Gen. 0) and related amidoamine 
model compounds functionalized with terminal ethylene glycol ethers of various chain lengths 
providing multiple donating functionalities. Our approach facilitates a straightforward and 
more time efficient access to flexible dendritic surfactants, whose identity and purity are still 
well characterisable (e.g. by NMR techniques) compared to other applied dendrimers 
[E14, E20, 
E21]
. Furthermore, our biocompatible organic coatings are also more effective than monoden-
tate stabilizers such as triphenylphosphine 
[E31]
 or alkanethioles 
[E32]
, as they provide more 
donating functionalities per gram. Bearing up to ten tentacles, the molecules described here 
act as promising templates in the formation of Au NPs using H[AuCl4] as gold source and 
Na[BH4] as reducing agent. The sufficient surfactant sizes and determination of the minimum 
requirements for (poly)ethylene glycol-based nanotemplates as well as temporal stability stu-
dies on inorganic and/or organic hybrid colloids are presented. 
 
2. Materials and Methods 
2.1. Synthesis of Stabilizers 
All synthesis procedures were performed under a dry and deoxygenated dinitrogen atmos-
phere using standard Schlenk techniques unless otherwise stated. All organic solvents were 
carefully dried by standard procedures over the appropriate drying agents and distilled imme-
diately prior to use. Hydrogen tetrachloroaurate(III) hydrate (12), sodium borohydride, ethy-
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lene glycol methyl ether acrylate (9) and poly(ethylene glycol) methyl ether acrylate (average 
Mn ca. 480 g ∙ mol
-1
) (11) were purchased from SIGMA ALDRICH and were used without 
further purification. Di(ethylene glycol) ethyl ether acrylate (10) was distilled prior to use. 
The poly(amidoamine)dendrimers N(CH2CH2C(O)NHCH2CH2NH2)3 (6), [CH2N-
(CH2CH2C(O)NHCH2CH2NH2)2]2 (7) and (H2NCH2CH2NHC(O)CH2CH2)N[CH2CH2N-
(CH2CH2C(O)NHCH2CH2NH2)2]2 (8) as well as the corresponding di(ethylene glycol) func-
tionalized amidoamine (R2NCH2CH2NHC(O)CH2CH2)N[CH2CH2N(CH2CH2C(O)-
NHCH2CH2NR2)2]2 (5b, R = CH2CH2C(O)O(CH2CH2O)2C2H5) were synthesized according 
to previously published procedures 
[E33, E34, E37]
. Detailed experimental instructions for 1, 2, 3a 
– 3c, 4 and 5a – 5c are given in the supplementary material available. 
 
2.2. Preparation Procedure for Gold Nanoparticles 
In-situ (dendrimer) stabilized Au NPs were prepared in solution 
[E11]
. This methodology in-
volves two steps: (a) The preparation of the corresponding (dendritic) amidoamine-based 
ethylene glycol Au(III) system, whereas the appropriate metallodendrimer was synthesized by 
combining the respective dendrimer (10 mL) with H[AuCl4] (10 mL) in tetrahydrofuran at 25 
°C in different ratios (dendrimer:Au(III) = 1:1 (2 mmol ∙ L-1: 2 mmol ∙ L-1), 1:5 (0.4 mmol ∙ 
L
-1: 2 mmol ∙ L-1), 1:10 (0.2 mmol ∙ L-1: 2 mmol ∙ L-1), 1:50 (0.04 mmol ∙ L-1: 2 mmol ∙ L-1) or 
1:100 (0.02 mmol ∙ L-1: 2 mmol ∙ L-1)). The resulting yellow colored mixture was stirred for 
additional 15 min followed by (b) the reduction of the respective Au(III) ions to zero-valent 
Au NPs. Therefore, freshly prepared saturated Na[BH4] in tetrahydrofuran was added drop-
wise under vigorous stirring. The mixture was further aged for 30 min, while the solution col-
or changed from yellow to intensive purple. 
 
3. Results and Discussion 
3.1. Dendritic Stabilizers 
The amidoamine-based dendrimers with end-grafted ethylene glycol ether tentacles (Chart 
E1) were prepared by a divergent consecutive synthesis procedure including Michael addition 
and amidation cycles, a method which was firstly described by Tomalia and coworkers 
[E33]
. 
This methodology was applied for the straightforward and more time efficient synthesis of 
(poly)ethylene glycol-functionalized dendrimers N(CH2CH2C(O)NHCH2CH2NR2)3 (3a, R = 
CH2CH2C(O)OCH2CH2OCH3; 3b, R = CH2CH2C(O)O(CH2CH2O)2C2H5; 3c, R = 
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CH2CH2C(O)O(CH2CH2O)9CH3), [CH2N(CH2CH2C(O)NHCH2CH2NR2)2]2 (4, R = 
CH2CH2C(O)O(CH2CH2O)2C2H5) and (R2NCH2CH2NHC(O)CH2CH2)N[CH2CH2N-
(CH2CH2C(O)NHCH2CH2NR2)2]2 (5a, R = CH2CH2C(O)OCH2CH2OCH3; 5b, R = 
CH2CH2C(O)O(CH2CH2O)2C2H5; 5c, R = CH2CH2C(O)O(CH2CH2O)9CH3).  
 
Chart E1. (Poly)ethylene glycol-functionalized PAMAM dendrimers 3a – 3c, 4, 5a – 5c 
and for comparison, amines 1 and 2. 
Michael addition of the terminal amino functionalities of dendritic molecules 
N(CH2CH2C(O)NHCH2CH2NH2)3 (6), [CH2N(CH2CH2C(O)NHCH2CH2NH2)2]2 (7) and 
(H2NCH2CH2NHC(O)CH2CH2)N[CH2CH2N(CH2CH2C(O)NHCH2CH2NH2)2]2 (8) to ethy-
lene glycol methyl ether acrylate (9), di(ethylene glycol) ethyl ether acrylate (10) and 
poly(ethylene glycol) methyl ether acrylate (11), respectively, gave the appropriate biocom-
patible dendrimers 3a – 3c, 4, 5a – 5c featuring 6, 8, or even 10 ethylene glycol ether-termini 
of various sizes and hence, feature multiple -donor capabilities (Chart E1) [E37]. Exemplarily, 
the synthesis of 3b is shown in Reaction E1.  
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After appropriate work-up, dendrimers 3a – 3c, 4 and 5a – 5c were isolated as odorless oils 
in almost quantitative yield (Experimental Section). For comparison, the di(ethylene glycol) 
ethyl ether-functionalized amines 1 and 2 were accessible using the same reaction conditions 
as described for the synthesis of 3 – 5 (Experimental Section). 
Molecules 1 – 5 were characterized by NMR (1H, 13C{1H}), FT-IR and UV/Vis spectrosco-
py as well as high resolution mass spectrometry. As the unimolecular amino compounds 1 and 
2 the 
1
H NMR spectra of 3a – 3c, 4 and 5a – 5c show single resonance signals for the 
CH2C(O)O ( ≈ 2.45 ppm), C(O)OCH2 ( ≈ 4.25 ppm), CH2OCH2 ( ≈ 3.60 ppm) and CH3 ( 
≈ 1.25 and 3.35 ppm, respectively) moieties. Furthermore, the amidoamine dendrimers exhibit 
a broad distinctive resonance signal at ca. 7.0 ppm for the C(O)NH unit. In the 
13
C{
1
H} NMR 
spectra of all compounds the carbonyl carbon atoms are observed between ca. 172 ppm, while 
the CH2, CH3 building blocks are found at 12 – 73 ppm. 
The progress of the reaction of attaching the (poly)ethylene glycols to the (amido)amine 
scaffold can be monitored by FT-IR spectroscopy, since as an evidence for the complete con-
sumption of the appropriate amino educts, the absorption band of the terminal NH2 group at 
ca. 3365 cm
-1
 (NH) disappears 
[E34]
. 
 
3.2. Dendritic Stabilized Gold Nanoparticles 
The nanotemplating properties of the synthesized (poly)ethylene glycol-functionalized 
amines 1 and 2 as well as the PAMAM-based dendrimers 3a – 3c, 4 and 5a – 5c featuring 
intrinsic tertiary amine and ether groups were examined for the stabilization of Au NPs in 
tetrahydrofuran solutions using consecutive steps. Based on the number of di(ethylene glycol) 
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termini, the addition of half equivalents of H[AuCl4] (12) to 1, 2, 3a – 3c, 4 and 5a – 5c re-
sulted in the formation of the appropriate intensively yellow colored Au(III) containing metal-
lodendrimers 3a-Au(III) – 3c-Au(III), 4-Au(III), 5a-Au(III) – 5c-Au(III), 1-Au(III) and 2-
Au(III), respectively. All the Au(III) loaded compounds 1-Au(III) – 5-Au(III) were then 
reduced chemically by addition of Na[BH4]. For completion of the reaction vigorously stirring 
for 30 min was required during the color changed from yellow to purple indicating the forma-
tion of zero-valent Au colloids 1-Au(0) – 5-Au(0) stabilized by the appropriate templating 
agent. 
 
3.3. Physical and Chemical Characterization  
The formation of Au NPs within the stabilizing system was examined by FT-IR spectroscop-
ic measurements. A bathochromic absorption shift of the C−O−C stretching vibration of ca. 
30 cm
-1
 compared to the appropriate non-coordinated species was thereby observed. Further-
more, electron diffraction patterns were taken, whereas the resulting pattern for the 5b-
stabilized Au NPs is exemplarily shown in Figure E1a. The displayed ring pattern can be in-
dexed as derived from (111), (002), (022), (222), (113), (024) and (133) lattice planes of gold 
(Figure E1b).  
 
 
 
 
 
 
(a)                                                                                      (b) (b)
 
Figure E1. Selected area diffraction patterns (a) and resulting Miller indices (b) derived 
from lattice planes of gold NPs obtained from 5b-Au(0). 
To investigate the optical properties of the hybrid materials UV/Vis spectroscopic studies of 
1-Au(0), 2-Au(0), 3b-Au(0), 4-Au(0) and 5b-Au(0) were carried out (Figure E2). The ob-
tained spectra show strong absorptions in the range of 450 – 700 nm due to plasmon oscilla-
tion modes of the electrons in the Au NPs 
[E35]
. The higher the number of end-grafted 
di(ethylene glycol) ethyl ether-functionalities, the stronger the absorption, the narrower the 
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curve´s shape and the more the absorption maximum is hypsochromic shifted (3b-Au(0): λmax 
= 541 nm; 5b-Au(0): λmax = 532 nm). As a result thereof, dendritic stabilizer 5b produces 
smaller NPs (Figure E2) 
[E36]
. 
For determination of the Full-Width-at-Half-Maximum (FWHM) of the plasmon band de-
convolution of the UV/Vis data was performed using four Gaussian shaped overlapping ab-
sorptions until the sum of the Gaussian functions closely matches the measured spectra. The 
FWHM of 5b-Au(0) is 2525 cm
-1
, whereas 3b-Au(0) possess a FWHM of 3450 cm
-1
 and 
hence, a broader NP size distribution than in 5b-Au(0). Furthermore, using 1 as stabilizing 
agent for Au NPs a very wide absorption was observed. Deposition of a gold layer occurs 
contemporary and proofs that molecule 1 cannot provide an adequate quantity of donor atoms 
to stabilize the surface of the Au colloids (1-Au(0)) 
[E14]
. As a conclusion of the UV/Vis stu-
dies (Figure E2) within this series of 1-Au(0) – 5b-Au(0), dendrimer 5b is the most suitable 
for the formation of Au NPs having smallest particle diameters as well as narrow size distri-
butions. 
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Figure E2. UV/Vis absorptions of di(ethylene glycol) ethyl ether-functionalized 1-Au(0), 
2-Au(0), 3b-Au(0), 4-Au(0) and 5b-Au(0) in tetrahydrofuran ( = 25 °C; c = 1.0 mmol ∙ L-1). 
Estimation of the maximum loading of stabilized Au NPs within the dendritic template was 
achieved by embedding various amounts of Au colloids in the organic matrix of 5b. The re-
sulting UV/Vis absorption spectra for 5b:Au ratios 1:1, 1:10, 1:50, or 1:100 are depicted in 
Figure E3. The spectra for the ratios 5b:Au of 1:1 (FWHM = 2345 cm
-1
) and 1:10 (FWHM = 
2870 cm
-1
), respectively, exhibit absorption peaks at about 525 and 530 nm. In addition, the 
absorbance of 5b-stabilized Au NPs increases concomitantly with the loading of zero-valent 
gold colloids from 5b:Au = 1:1 to 1:10. However, the curves for 5b:Au of 1:50 (FWHM = 
4695 cm
-1
) and 1:100 are very broad, caused by an exceeding of 5b´s stabilizing capacity re-
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sulting in enlarged particle sizes due to aggregation of Au NPs, which is in accordance with 
the experimental observations that metallic Au precipitated. These results correspond well 
with literature, where lower loadings yield smaller particles 
[E14]
.  
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Figure E3. UV/Vis absorption spectra of various 5b:Au ratios (1:1, 1:10, 1:50 and 1:100) 
in tetrahydrofuran (= 25 °C; c = 1.0 mmol ∙ L-1). 
To investigate the influence of different ethylene glycol chain lengths on the stabilization 
capability for Au NPs, tri- and penta-amino terminated PAMAM-dendrimers 6 and 8 were 
modified with ethylene glycol methyl ether acrylate (9) and poly(ethylene glycol) methyl eth-
er acrylate (11) to give 3a, 5a, 3c and 5c (Chart E1), using the same reactions conditions as 
described for the synthesis of 3b. Figure E4 shows the changes occurring in the absorption 
spectra, when Au NPs were stabilized by dendrimers 5a, 5b and 5c. The absorption patterns 
of the surface plasmon resonance derived from 5b-Au(0) and 5c-Au(0) are more sharp com-
pared to 5a-Au(0), exhibiting a FWHM value of 2715 cm
-1
. Furthermore, as the intensity of 
the absorption is increased, within this series dendritic templates 5b and 5c result in the for-
mation of small Au NPs (vide infra; Figures E6 and E7).   
In addition, we proceeded temporal stability studies of the ethylene glycol-terminated PA-
MAM-based dendrimers. From Figure E5 it can be seen that 5c is capable to encapsulate Au 
NPs for more than eight weeks and thus, prevents macroscopic particle aggregation. The 
UV/Vis spectra display absorption curves centered at ca. 530 nm after reduction with 
Na[BH4]. The curve´s shape becomes broader and the absorption´s intensity is slightly de-
creased after aging for 8 weeks, as the Au NPs agglomerate to macroscopic colloids. In com-
parison, Au NPs embedded in dendritic 5a and 5b, respectively, are stable for several hours to 
some days, only. 
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Figure E4. Comparison of the UV/Vis absorption spectra of Au NPs stabilized by 5a, 5b 
and 5c, respectively, bearing ethylene glycol units of different lengths (tetrahydrofuran;  = 
25 °C; c = 1.0 mmol ∙ L-1). 
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Figure E5. UV/Vis absorption spectra of 5c-Au(0) for long-term stability investigations 
(tetrahydrofuran;  = 25 °C; c = 1.0 mmol ∙ L-1). 
These UV/Vis spectroscopic results indicate that the poly(ethylene glycol) methyl ether at-
tached to the dendrimers periphery can result in the formation of well-grown Au NPs and in a 
high colloidal stability for several weeks. 
The actual particle size, size distribution and particle shape were determined by transmission 
electron microscopy (TEM) and verified by dynamic light scattering (DLS) studies. The data 
show the appearance of the formed Au NPs coated by (amido)amine stabilizer 5b and 1 for 
comparison (Figure E6). The colloidal gold solutions obtained at ambient temperature for 
stabilizer 5b showed well-defined particles. Apparently, the Au NPs sizes depend on the 
number of terminal groups. The particle sizes decrease concomitantly with the number of at-
tached di(ethylene glycol) ethyl ether functionalities. As already expected from UV/Vis and 
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FWHM analyses (vide supra), from Figure E6 it can be seen that Au NPs stabilized by 5b (Ø 
= 4.0 ( 0.9) nm) are smaller and exhibit a more narrow size distribution as compared to par-
ticles embedded in 3b (Ø = 6.8 ( 5.3) nm) and 1 (Ø = 37.3 ( 13.4) nm), respectively. On the 
basis of observations made by TEM and FT-IR spectroscopy, the particles might grow within 
the dendritic template and hence, a higher number of terminal ethylene glycol results in a bet-
ter encapsulation, preventing aggregation and precipitation of the Au NPs. Furthermore, the 
shape of the generated gold particles is affected by the number of terminal di(ethylene glycol) 
ethyl ether groups as well. While 5b forms more or less regular spherical shaped Au NPs, 
ligand 1 results in formation and short stabilization of enlarged anisotropic particles exhibit-
ing multiple morphologies, e.g. spheres, rods and prisms (Figure E6b). 
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Figure E6. TEM micrographs and particle size distribution of spherical Au NPs stabilized 
by 5b (Ø = 4.0 ( 0.9) nm) (a) and multiple shaped Au NPs stabilized by 1 (Ø = 37.3 ( 13.4) 
nm) (b). 
In addition, the chain length´s effect of the ethylene glycol-moiety attached on dendrimer´s 
periphery on the colloid size is not simple, i.e. the colloids formed by 5a (Ø = 9.4 ( 3.4) nm) 
are larger than those generated by template 5b (Ø = 4.0 ( 0.9) nm). For Au NPs stabilized 
using 5c slightly increased particle diameters of 7.6 ( 1.8) nm were found (Figure E7a). In 
agreement with literature dealing with low-generation dendrimers as colloid stabilizers, for 
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the interpretation of these results, for example, different (stable) conformers of the dendrimers 
in solution have to be considered. In dependence on the terminal ethylene glycol ether func-
tionality the structure and the flexibility of the corresponding dendrimer as Au NPs template 
is crucial for the resulting colloid size and shape 
[E13, E22]
. However, the applied dendritic sur-
factants with merely ten (poly)ethylene glycol tentacles are able to generate gold colloid sizes 
in the same range or only slightly increased to Astruc´s complex dendritic arene-cored 
(poly)ethylene glycol-terminated system providing 27, 81 or even 243 tethers 
[E14a]
. 
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Figure E7. TEM images and particle size distributions of (a) freshly prepared 5c-Au(0) (Ø 
= 7.6 ( 1.9) nm) and (b) 5c-Au(0) (Ø = 16.9 ( 3.8) nm) aged for 8 weeks. 
Moreover, to perform temporal stability studies long-term investigations of 5a-Au(0) – 5c-
Au(0) were examined by TEM. The study demonstrates that 5c encapsulated Au colloids aged 
for more than 8 weeks (Figure E7b) have an average diameter of 16.9 ( 3.8) nm and almost 
retaining spherical shape. 5c obviously offers the best "host-guest conditions" for a long term, 
whereas Au NPs embedded in dendritic 5a and 5b (Ø = 14.4 ( 3.2) nm; obtained after 3 
days) aggregate in a period of 8 hours up to 5 days. 
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Table E1. Particle sizes generated by dendrimer 5b and varied stabilizer:Au ratios. 
Entry Ratio 
(Stabilizer:Gold) 
Particle Size 
1 1:1 5.3 ( 1.1) nm 
2 
1:10 9.1 ( 1.7) nm 
3 1:50 58.5 ( 14.5) nm 
4 1:100 42.2 ( 8.7) nm 
 
It is well known that the particle diameter of the Au NPs can be controlled by the molar ratio 
of Au and the appropriate stabilizer 
[E15]
. This correlation was evaluated using stabilizing 
agent 5b loaded with various amounts of H[AuCl4] to achieve different molar ratios of 5b:Au 
(1:1, 1:10, 1:50, 1:100) (Table E1). In accordance with UV/Vis spectroscopic data reported 
(vide supra), transmission electron microscopy images implied, when the molar ratio of 5b 
and Au is sufficiently low (5b:Au = 1:1, 1:10) stable colloidal solutions of small uniform 
spherical shaped Au NPs are generated (5b:Au = 1:1; Ø = 5.3 ( 1.1) nm). Higher concentra-
tions of Au (5b:Au = 1:50, 1:100) resulted in irregular shaped Au NPs of increased average 
diameters (5b:Au = 1:100; Ø = 42.2 ( 8.7) nm). Macroscopic metal precipitation occurs upon 
reduction of the dendritic Au(III) complex. 
 
4. Conclusion  
A novel series of well-defined (poly)amidoamine-based dendrimers 
N(CH2CH2C(O)NHCH2CH2NR2)3, [CH2N(CH2CH2C(O)NHCH2CH2NR2)2]2 and 
(R2NCH2CH2NHC(O)CH2CH2)N[CH2CH2N(CH2CH2C(O)NHCH2CH2NR2)2]2 functionalized 
with terminal ethylene glycol methyl ether- (R = CH2CH2C(O)OCH2CH2OCH3), di(ethylene 
glycol) ethyl ether- (R = CH2CH2C(O)O(CH2CH2O)2C2H5) and poly(ethylene glycol) methyl 
ether moieties (R = CH2CH2C(O)O(CH2CH2O)9CH3) were prepared by a straightforward syn-
thesis methodology enabling a more time efficient access to low-generation (Gen. 0) dendritic 
surfactants providing multiple donating functionalities. However, among other complex syn-
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thesized, sterically demanding, high generation dendrimers used in this field by Astruc 
[E2b]
, 
Amis 
[E14b]
, Tomalia 
[E20b]
 and Crooks 
[E21b]
 the more flexible, versatile, biocompatible and 
well characterisable organics presented here can serve as readily accessible efficient stabiliz-
ers and templating agents for gold colloids.  
Using the in-situ reduction of the appropriate Au(III)-loaded metallodendrimers with 
Na[BH4] gave nascent, small sized Au NPs.  In dependence on the dendritic structure, the 
adjusted stabilizer:gold ratio and the reaction time gold colloids of spherical shapes and aver-
age particle sizes in the range of 4.0 ( 0.9) to 58.5 ( 14.5) nm are created.  
In summary, it can be stated that even small PAMAM-based dendritic stabilizers (low-
generation dendrimers) can act efficiently as templates for nanoparticle formation. 
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The following section´s results were generated in a multifarious collaboration between 
Chemnitz University of Technology and the Indian Institute of Technology Bombay (India). 
The applied dendritic stabilizers 1 – 4 and 5a – c were synthesized and completely characte-
rized in the Department of Inorganic Chemistry headed by Prof. Dr. Heinrich Lang in Chem-
nitz. During a DAAD granted research stay in India the author of the present doctoral thesis 
further prepared the appropriate dendrimer coated Fe3O4 nanoparticles under supervision of 
Dr. Sudeshna Chandra and Prof. Dr. Dhirendra Bahadur in the
 
Department of Metallurgical 
Engineering and Materials Science in Bombay. Subsequently, the chemical identity and par-
ticle properties of the obtained magnetite colloids were determined by the Solid Surfaces 
Analysis Group by Dr. Steffen Schulze and Prof. Dr. Michael Hietschold at the Institute of 
Physics in Chemnitz. The magnetic peculiarities were analyzed by Dr. Senoy Thomas, Dr. 
Denys Makarov and Prof. Dr. Manfred Albrecht of the Department of Surface and Interface 
Physics (TU Chemnitz). 
 
1. Introduction 
Magnetic nanoparticles (MNPs) have generated considerable interest in the scientific world 
especially in the area of biomedicine and technology, particularly, magnetic storage media 
[F1]
, magnetic inks for ink-jet printing 
[F2]
, biosensing 
[F3]
, targeted drug delivery 
[F4]
 and con-
trast agents in magnetic resonance imaging (MRI) 
[F5]
.  The importance of the NPs is attri-
buted to the fact that they represent a critical link between the current technology and future 
application due to their small size, large surface to volume ratio and size dependent properties 
like superparamagnetism 
[F6]
.  The superparamagnetic behavior of MNPs is of immense inter-
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est for in vivo applications, as they lose their magnetism after removal of the magnetic field. 
Thus, the potential benefit of MNPs is to use the localized magnetic field to attract the particle 
to the chosen site, to hold them until completion of the therapy and then remove them 
[F7]
.  
Iron oxide NPs are generally synthesized in either aqueous or organic solutions and thus re-
quire sophisticated coatings for stability under physiological conditions 
[F8]
.  The coatings 
provide stabilization to the MNPs against aggregation in both a biological medium and in a 
magnetic field. In general, NPs can be stabilized with monomeric stabilizers 
[F9]
 (carboxylates, 
phosphates and sulphates), polymers 
[F10]
 (dextran, PEG and chitosan), inorganic materials 
[F11]
 (silica), liposomes 
[F12]
 and dendrimers 
[F13]
. Out of many stabilizers, dendrimers have an 
added advantage of not only providing stability to the MNPs in solution but also help in bind-
ing various biological ligands to the surface of the colloids. The unique structural features of 
the dendrimers allow them to be used as stabilizers either as templates under fast reduction 
and nucleation chemistry or by entrapment under mild reduction condition. Moreover, the 
dendrimers have an added advantage of being capable for entrapping guest molecules or drugs 
within themselves and can also provide surface to guest molecules for attachment. Stable in-
ternal encapsulation of the drug is provided by the covalent scaffold of the dendrimers thus 
making them efficient drug carriers. Recent advances in dendrimer chemistry have shown that 
carboxyl-terminated (poly)amidoamine (PAMAM) dendrimers with folic acid modifications 
can be assembled onto the surface of iron oxide nanoparticles for intracellular uptake studies 
[F14]
. Recently, Saboktakin et al. 
[F15]
 reported superparamagnetic iron oxide nanoparticles 
(SPIONs) coated with acetylated PAMAM dendrimers as controlled release systems for pa-
rental administration of mesalamine drug. Efforts have been continuously made to demon-
strate the ability of dendritic molecules to deliver MNPs into cells, however, not much suc-
cess has been achieved. Martin et al. 
[F16]
 aimed at modulating the uptake of SPIONs by cells 
for in vitro labeling using polyester dendron having multiple peripheral guanidine groups. 
This dendritic guanidine was found to have good penetrating capability upon conjugation with 
SPIONs and also enhanced the cellular uptake. Folate targeted PEG conjugate of PAMAM 
dendrimers 
[F17]
 was used as drug delivery system for controlled release of antiarthiritic drug, 
indomethacin with reduced side effects and higher targeting efficiency. The application of 
PEGylated diaminobutane poly(propylene imine) dendrimers 
[F18]
 as drug carrier was eva-
luated for solubilizing and release of betamethasone corticosteroids.   
In spite of significant progress in the synthesis of magnetic nanoparticles, preventing agglo-
meration or precipitation of MNPs remains an important issue. Stability still is a crucial para-
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meter for almost any application of the magnetic nanoparticles. The main difficulty arises due 
to the susceptibility of the nanoparticles towards oxidation which increases with decrease in 
particle size 
[F19]
. Therefore, it is essential to develop efficient strategies for improving the 
chemical stability of the nanoparticles. This can be achieved by protecting the nanoparticles 
with an impenetrable layer which prevents the oxygen to reach the particle surface.  
Towards this direction, we report here on a straightforward and time efficient approach faci-
litating in-situ synthesis of dendritic stabilized MNPs using the chemical co-precipitation me-
thod. The readily accessible flexident biocompatible organic coatings with ethylene glycol-
based tentacles provide stability to the MNPs surface and hence, protect from particle coagu-
lation. The resulted MNPs were characterized with TEM, XPRD, TGA, FT-IR and SQUID-
VSM magnetometry. 
 
2. Materials and Methods 
2.1. Materials and Instruments 
All synthesis procedures were performed under dinitrogen atmosphere. Water was deoxyge-
nated prior to use. Iron (II) chloride tetrahydrate, iron (III) chloride hexahydrate, ammonium 
hydroxide solution and methanol were purchased from SIGMA ALDRICH and used without 
further purification. The (poly)amidoamine (PAMAM)-based dendrimers 3, 4 and 5a – 5c as 
well as amines 1 and 2 were synthesized according to previously published procedures 
[F20]
. 
Size and morphology of the magneto-dendrimer NPs were determined using TEM imaging, 
performed on a PHILIPS CM 20 operated at 200 kV, while the structure of  the powder sam-
ples was identified by X-ray powder diffraction (XRPD) on a STOE-STAD IP diffractometer 
with Cu-K (1.5405 Å) radiation. The surface coating was examined by FT-IR spectroscopy 
recorded with a FT Nicolet IR 200 instrument. Thermogravimetric experiments were per-
formed on a METTLER-TOLEDO TGA/DSC1 1100 system with an UMX1 balance. Mass 
spectrometry coupled thermogravimetric experiments were determined by using a METT-
LER-TOLEDO TGA/DSC1 1600 system with a MX1 balance coupled with a PFEIFFER 
VACUUM MS ThermoStar GSD 301 T2 mass spectrometer. Magnetic properties of the mag-
netite nanoparticles were studied by a QUANTUM DESIGN SQUID-VSM. Field cooled (FC) 
and zero field cooled (ZFC) magnetization measurements were performed in the temperature 
range 5 K to 300 K at two different magnetic fields of 100 Oe and 200 Oe. Field dependent 
magnetization measurements were also recorded for the samples at various temperatures be-
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tween 5 K and 300 K in the field range -70 kOe to +70 kOe. For ZFC measurements, the 
samples were cooled in a zero magnetic field from 300 K to 5 K and at 5 K a small magnetic 
field of ≈ 100 Oe or 200 Oe was applied. The magnetic moment was measured on warming 
the samples to 300 K (ZFC magnetization). Next, the magnetic moment was measured by 
cooling the sample from 300 K down to 5 K keeping the applied field unchanged (FC magne-
tization). 
 
2.2. Synthesis Procedure for Fe3O4 Nanoparticles 
In a typical experiment, in-situ dendritic stabilized Fe3O4 NPs were prepared by the chemi-
cal co-precipitation method in a 250 mL round bottom flask equipped with a mechanical stir-
rer, gas inlet and condenser.  [FeCl2∙4 H2O] and two equivalents of [FeCl3∙6 H2O] were dis-
solved in deoxygenated distilled water and kept at 70 °C for 15 min. N2 gas was kept passing 
through the aqueous mixture during the whole experimental process. While vigorously stir-
ring the reaction mixture, an appropriate amount (molar ratio stabilizer-to-Fe3O4 = 1:10, 
1:100, 1:1000) of the respective (dendritic) stabilizer dissolved in 3 mL of methanol was add-
ed in a single portion. After alkaline hydrolysis (pH 8.5) by adding a slight excess of NH4OH 
in solution (25 %), the appropriate Fe3O4 colloids were obtained as a black precipitate in vir-
tually quantitative yield and isolated by magnetoseparation, decantation and washed twice 
with 25 mL of distilled water and methanol. The products were dried at 25 °C for 24 hrs. 
Data for 1-stabilized colloids (1:Fe3O4 = 1:100): 10 mg (0.023 mmol) 1, 0.46 g (2.3 mmol) 
[FeCl2∙4 H2O] and 1.24 g (4.6 mmol) [FeCl3∙6 H2O] in 70 mL H2O. 
Data for 2-stabilized colloids (2:Fe3O4 = 1:100): 10 mg (0.012 mmol) 2, 0.24 g (1.2 mmol) 
[FeCl2∙4 H2O] and 0.66 g (2.4 mmol) [FeCl3∙6 H2O] in 40 mL H2O. 
Data for 3-stabilized colloids (3:Fe3O4 = 1:100): 10 mg (0.007 mmol) 3, 0.14 g (0.7 mmol) 
[FeCl2∙4 H2O] and 0.38 g (1.4 mmol) [FeCl3∙6 H2O] in 20 mL H2O. 
Data for 4-stabilized colloids (4:Fe3O4 = 1:100): 10 mg (0.005 mmol) 4, 0.1 g (0.5 mmol) 
[FeCl2∙4 H2O] and 0.27 g (1.0 mmol) [FeCl3∙6 H2O] in 15 mL H2O. 
Data for 5a-stabilized colloids (5a:Fe3O4  = 1:1000): 10 mg (0.005 mmol) 5a, 1.01 g (5 mmol) 
[FeCl2∙4 H2O] and 2.72 g (10 mmol) [FeCl3∙6 H2O] in 150 mL H2O.  
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Data for 5b-stabilized colloids (5b:Fe3O4 = 1:10): 150 mg (0.06 mmol) 5b, 120 mg 
(0.6 mmol) [FeCl2∙4 H2O] and 320 mg (1.2 mmol) [FeCl3∙6 H2O] in 18 mL H2O. 
Data for 5b-stabilized colloids (5b:Fe3O4 = 1:100): 75 mg (0.029 mmol) 5b, 580 mg 
(2.9 mmol) [FeCl2∙4 H2O] and 1.58 g (5.8 mmol) [FeCl3∙6 H2O] in 90 mL H2O. 
Data for 5b-stabilized colloids (5b:Fe3O4 = 1:1000): 10 mg (0.0039 mmol) 5b, 770 mg 
(3.9 mmol) [FeCl2∙4 H2O] and 2.11 g (7.8 mmol) [FeCl3∙6 H2O] in 120 mL H2O. 
Data for 5c-stabilized colloids (5c:Fe3O4 = 1:1000): 20 mg (0.0036 mmol) 5c, 720 mg 
(3.6 mmol) [FeCl2∙4 H2O] and 1.96 g (7.2 mmol) [FeCl3∙6 H2O] in 110 mL H2O. 
 
 
 
Chart F1. (Di)ethylene glycol-functionalized PAMAM-dendrimers 3 and 4 as well as 
amines 1 and 2, for comparison 
[F20]
. 
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3. Results and Discussion 
3.1. Preparation and Characterization of Dendrimer-Surfaced Fe3O4 Nanoparticles 
End-grafted ethylene glycol ether-functionalized amidoamine-based low-generation dendri-
mers 3, 4 (Chart F1) and 5a – 5c (Scheme F1) as well as amines 1 and 2 (Chart F1) were pre-
pared according to published procedures 
[F20]
. The obtained biocompatible PEGylated dendrit-
ic nanoreactors of type N(CH2CH2C(O)NHCH2CH2NR2)3 (3, R = CH2CH2C(O)O-
(CH2CH2O)2C2H5), [CH2N(CH2CH2C(O)NHCH2CH2NR2)2]2 (4, R = CH2CH2C(O)O-
(CH2CH2O)2C2H5) and (R2NCH2CH2NHC(O)CH2CH2)N[CH2CH2N(CH2CH2C(O)NH-
CH2CH2NR2)2]2 (5a, R = CH2CH2C(O)OCH2CH2OCH3; 5b, R = CH2CH2C(O)O-
(CH2CH2O)2C2H5; 5c, R = CH2CH2C(O)O(CH2CH2O)9CH3) as well as amines 1 and 2 were 
applied as surfactants during the formation of iron oxide NPs by the controlled co-
precipitation method from Fe
2+
 and Fe
3+
 salts in an alkaline medium 
[F21]
. 
The resulting black colored Fe3O4 colloids with dendrimer coating were stable in aqueous 
solution. No bulk precipitate was observed in the reactions performed using mild conditions 
with slightly elevated temperatures (70 °C). After separation from the supernatant solution, 
the functionalized Fe3O4 NPs were dried at ambient temperature for 24 hrs (Scheme F2). 
 
 
Scheme F1. Synthesis of (oligo)ethylene glycol ether-functionalized amidoamine-based 
low-generation dendrimers 5a – 5c [F20]. 
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The nature of the chemical bonding in the newly formed hybrid materials was investigated 
using FT-IR spectroscopy. Figure F1 shows the FT-IR spectra of 5b and 5b-coated Fe3O4 
nanoparticles. In the spectrum of 5b-stabilized MNPs the vibration bands at around 585 and 
440 cm
-1 
indicate the formation of Fe3O4 as these peaks result from symmetric Fe−O stret-
ching and antisymmetric Fe−O vibrations, respectively [F22]. 
 
 
Scheme F2. Schematic illustration of in-situ dendrimer-stabilized Fe3O4 NP formation by 
the co-precipitation method. 
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Figure F1. FT-IR spectra of pure 5b and 5b-coated Fe3O4 MNPs.   
As an evidence for surfacing the colloids by the applied dendritic stabilizers the strong band 
at around 1095 cm
-1
 can be cited attributing to the C−O−C vibrations of the terminal 
(poly)ethylene glycol ether units. This absorption is bathochromic shifted by approximately 
30 cm
-1
, when compared to the parent dendrimers 5a – 5c [F20]. Furthermore, the broad bands 
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between 1620 and 1700 cm
-1
 can be assigned to both the amide and the ester functionalities of 
the dendritic scaffold. 
The phase and crystalline nature of dendrimer stabilized Fe3O4  MNPs were confirmed by XPRD 
analysis of 5b-coated Fe3O4 colloids (5b:Fe3O4 = 1:100) as shown exemplarily in Figure F2. 
The revealed powder diffraction pattern is consistent with standard Fe3O4 reflections reported 
in literature and in Joint Committee on Powder Diffraction Standards (JCPDS Card No. 19-
629) 
[F23]
, confirming the formation of magnetite NPs with the space group Fd-3m. The char-
acteristic diffraction peaks could be well indexed to the inverse cubic spinel structure of Fe3O4. 
The crystallite size of magnetite as calculated by the Scherrer formula was found to be ≈ 8.2 nm 
[F23]
. From the color of the precipitate as well as from the XRPD and FT-IR results, it is justi-
fied to conclude that the formed nanoparticles are that of Fe3O4. However, further experi-
ments are necessary to exclude the presence of traces of Fe2O3, if any. 
30 35 40 45 50 55 60 65
 2 Theta (°)
In
te
n
s
it
y
 (
a
.u
.)
4
0
0
 
 
2
2
0
3
1
1
2
2
2
4
2
2
5
1
1
4
4
0
 
Figure F2. X-ray powder diffraction patterns derived from 5b-stabilized Fe3O4 NPs 
(5b:Fe3O4 = 1:100). 
The magneto-dendrimer NPs were imaged by TEM. Figure F3 depicts representative TEM 
images of Fe3O4 NPs stabilized by 1 (surfactant:Fe3O4 = 1:100; Ø = 10.1 ( 1.9) nm), 5b (sur-
factant:Fe3O4 = 1:10; Ø = 5.6 ( 1.4) nm) and 5b (surfactant:Fe3O4 = 1:100; Ø = 7.3 ( 1.3) 
nm). The mean particle diameters and standard deviations were determined from TEM micro-
graphs from the statistics of at least 300 particles. The corresponding particle sizes of 1 – 4 
and 5a – 5c-surfaced Fe3O4 NPs are presented in Table F1. Although negligible cluster aggre-
gation occurs in all specimens as a result of drying effects in the sample preparation, the here-
in implemented co-precipitation method gives reproducible, well-defined spherical magnetite 
NPs embedded in biocompatible organic coatings of slightly decreased sizes compared to 
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other approaches in literature 
[F24]
. To some extent the resulting particle sizes can be affected 
by variation of the donation capabilities of the applied dendritic protective coatings and the 
adjusted molar surfactant-to-Fe3O4 ratio 
[F20]
.  
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Figure F3. TEM images and particle size distributions of a) 1- (surfactant:Fe3O4 = 1:100; 
Ø = 10.1 ( 1.9) nm), b) 5b- (surfactant:Fe3O4 = 1:10; Ø = 5.6 ( 1.4) nm) and c) 5b- (surfac-
tant:Fe3O4 = 1:100; Ø = 7.3 ( 1.3) nm) coated Fe3O4 NPs. Note the difference in scale bar in 
3 c) compared to panels in a) and b)). 
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From Table F1 it can be seen that increasing the number of peripheral attached ether ten-
tacles, using longer ethylene glycol ether termini at the amidoamine-based stabilizer´s scaf-
fold as well as higher molar surfactant-to-Fe3O4 ratios led to the formation of smaller colloid-
al iron oxide composites as the dendritic-constrained nanoreactors provide a confinement that 
restricts particle nucleation and growth. However, the control of the particle size distribution 
is limited, because the crystal growth in co-precipitation method is mainly influenced by ki-
netic factors 
[F25]
. 
The TEM determined particle size for, e.g. 5b-surfaced Fe3O4 colloids (molar ratio surfac-
tant:Fe3O4 = 1:100) is in good accordance with the crystallite size obtained by line profile 
fitting of the XRPD using Scherrer equation (Figure F2). 
Table F1. Particle sizes generated by surfactants 1 – 4 and 5a – 5c for varied molar stabi-
lizer:Fe3O4 ratios. 
Surfactant Ratio Particle Size 
1 1:100 10.1( 1.9) nm 
2 1:100 9.8 ( 2.1) nm 
3 1:100 9.1 ( 2.6) nm 
4 1:100 8.2 ( 1.4) nm 
5a 1:1000 9.0 ( 1.7) nm 
5b 1:10 5.6 ( 1.4) nm 
5b 1:100 7.3 ( 1.3) nm 
5b 1:1000 8.8 ( 2.0) nm 
5c 1:1000 7.3 ( 1.9) nm 
 
The thermal decomposition of the hybrid-material 5b:Fe3O4 (1:100) was studied by thermo-
gravimetric experiments in a dinitrogen atmosphere and a temperature range of 40 °C – 700 
°C using a heating rate of 10 K min
-1
 (Figure F4). Decomposition and transformation 
processes of both the organics and the iron oxide material within the applied composite occur 
in various steps between 70 °C and 550 °C resulting in an overall mass diminution of 12.3 
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wt%. Furthermore, in mass spectrometry-coupled thermogravimetric studies only m/z = 44 
amu was detected during the decomposition process. This mass fragment can be assigned to 
[CO2]
+
, [CONH2]
+
 as well as [C2H4O]
+
 representing sample specific components of 5b:Fe3O4 
(1:100). 
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Figure F4. Thermogravimetric analysis of hybrid-material 5b:Fe3O4 (1:100) in a dinitro-
gen atmosphere (20 mL min
-1
) using a heating rate of 10 K min
-1
. 
 
3.2. Magnetic Characterization of Dendrimer-Coated Fe3O4 Nanoparticles 
Magnetic measurements were carried out on all samples in powder form using a SQUID-
VSM. FC and ZFC magnetization recorded at two different fields for colloids 5b:Fe3O4 = 
1:100 is, for example, shown in Figure F5.  
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Figure F5.  FC and ZFC magnetizations of colloids 5b:Fe3O4 = 1:100 as a function of tem-
perature recorded at magnetic fields H = 100 Oe and H = 200 Oe, respectively. 
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In the FC mode, the magnetization increases slightly as the temperature is swept from 300 K 
to 5 K, whereas the ZFC magnetization exhibits a maximum followed by a steady decrease of 
magnetization in the low-temperature regime. This type of magnetization behavior is expected 
for superparamagnetic particles which show ferrimagnetic characteristics at temperatures be-
low the blocking temperature TB. Here, TB is defined as TB = KV/kBln(τm/τ0) where K is the 
crystalline anisotropy constant, kB is the Boltzmann constant, V is the volume of the particle, 
τm is the measurement time (typically 100 s) and τ0 is the inverse of the attempt frequency 
associated with magnetic moments overcoming field-dependent energy barriers 
[F26]
.  
In the ZFC mode during cooling, for temperatures lower than TB, the magnetization of each 
particle aligns with the direction of the easy axes and because of the random orientation of 
easy axes of the nanoparticles, the total magnetization approaches zero at low temperatures. 
However, when the sample is warmed up to 300 K, an increasing number of particles will 
acquire thermal energy to switch their magnetization from the easy axes to the direction of the 
applied magnetic field. This leads to an increase in magnetization of the sample. At tempera-
tures higher than TB, the nanoparticles undergo superparamagnetic relaxation, where the mag-
netization of each particle fluctuates in between the easy axis. TEM investigations showed 
that there is a distribution in MNPs sizes. Hence, a distribution in blocking temperature is 
expected. In a system consisting of non-interacting magnetic nanoparticles, the derivative of 
(MZFC-MFC) with respect to temperature T is a representative of the blocking temperature dis-
tribution 
[F27]
. Here, MZFC is the ZFC magnetization and MFC is the FC magnetization. In order 
to investigate this, -d(MFC-MZFC)/dT as a function of temperature T, is plotted in Figure F6.  
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Figure F6. Derivative of difference in FC and ZFC magnetization of 5b:Fe3O4 = 1:100 
with respect to temperature plotted as a function of temperature.  
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It was found that for sample 5b:Fe3O4 = 1:100 there is a distribution in TB and mean TB was 
around 20 K. From this value, a rough estimate of the mean particle size can be obtained us-
ing the equation TB = KV/25kB 
[F28]
. Here, we assumed the anisotropy constant K as 1.35∙104 J 
m
-3
 that of bulk Fe3O4 
[F29]
. NPs diameters thus obtained are around 10 nm which is in the 
range of particle sizes found from the TEM images and the calculation by the Scherrer formula. 
Slight discrepancies in the sizes can be due to the assumption of bulk anisotropy constant for 
Fe3O4 nanoparticles as well as due to the dipole-dipole interactions between the nanoparticles.  
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Figure F7. M-H loops for sample 5b:Fe3O4 = 1:100 recorded at temperatures 5 K, 10 K, 
50 K and 300 K. 
Figure F7 shows M-H loops recorded for 5b:Fe3O4 = 1:100 at 5 K, 10 K, 50 K and 300 K.  
M-H loops at 5 K and 10 K show hysteretic behavior as expected for superparamagnetic na-
noparticles in a blocked state. The coercive field, Hc determined from the loop is 258 Oe and 
202 Oe for 5 K and 10 K, respectively. M-H loops recorded at 300 K shows negligible rema-
nence and coercivity, which is characteristic of magnetic nanoparticles where thermal fluctua-
tions are sufficient to overcome the anisotropy energy barrier, allowing the magnetization to 
spontaneously reverse direction. It has to be noted that the MNPs obtained in the present ex-
periment are in a size range well below 20 nm, a value often proposed as the superparamag-
netic limit for Fe3O4 particles. For a comparison, magnetic properties of dendrimer-coated 
Fe3O4 NPs obtained from different synthesis conditions are summarized in Table F2. Not 
much difference was observed in the coercivity and mean blocking temperature for the four 
samples except for the magnetization values. Magnetization of a composite consisting of den-
drimer-coated Fe3O4 nanoparticles is mainly influenced by the volume fraction of Fe3O4 NPs 
in the composite matrix and the differences in magnetization observed in the sample series are 
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in accordance with the composition analyzed using inductively coupled plasma mass spec-
trometry (ICP-MS). 
 
 
Table F2.  Magnetic properties of dendrimer-stabilized magnetite NPs. 
Sample 
5 K 300 K 
Mean TB (K) 
Hc (Oe) 
M @ 70 kOe 
(emu/g) 
Hc (Oe) 
M @ 70 kOe 
(emu/g) 
5a:Fe3O4 
(1:100) 
214±3 74.5 32±3 61.5 20±2 
5b:Fe3O4 
(1:10) 
232±3 88.9 33±3 75.4 20±2 
5b:Fe3O4 
(1:100) 
258±3 66.9 32±3 56.5 20±2 
5b:Fe3O4 
(1:1000) 
228±3 54.2 33±3 45.7 20±2 
 
4. Conclusion 
Fe3O4 nanoparticles stabilized by biocompatible low-generation (poly)amidoamine-based 
dendrimers modified with end-grafted ethylene glycol ether moieties of type 
(N(CH2CH2C(O)NHCH2CH2NR2)3 (R = CH2CH2C(O)O(CH2CH2O)2C2H5), 
[CH2N(CH2CH2C(O)NHCH2CH2NR2)2]2 (R = CH2CH2C(O)O(CH2CH2O)2C2H5) and 
(R2NCH2CH2NHC(O)CH2CH2)N[CH2CH2N(CH2CH2C(O)NHCH2CH2NR2)2]2 (R = 
CH2CH2C(O)OCH2CH2OCH3; R = CH2CH2C(O)O(CH2CH2O)2C2H5; R = CH2CH2C(O)-
O(CH2CH2O)9CH3) were synthesized using Fe
2+
 and Fe
3+
 mixed aqueous salt solutions in the 
chemical co-precipitation method. The implemented synthesis protocol yielded Fe3O4 MNPs 
of sizes in the range of 5 nm to 10 nm depending on the applied molar stabilizer-to-Fe3O4 
ratio = 1:10, 1:100, 1:1000 as well as the number of ethylene glycol tentacles and the intrinsic 
donation capabilities of the utilized stabilizer. TEM studies revealed that increasing the num-
ber of tentacles and donation capabilities as well as higher molar ratios of the applied dendrit-
ic surfactants results in the formation of ultrafine magnetite colloids. The obtained NPs are 
superparamagnetic at ambient temperatures and thus the present synthesis method is capable 
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of obtaining biocompatible well-defined dendrimer-embedded Fe3O4 colloids for potential 
medical applications. 
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The results in the succeeding Chapter were accomplished in a fertile inter-institutional col-
laboration with Dr. Sudeshna Chandra in the research group of Prof. Dr. Dhirendra Bahadur at 
the Indian Institute of Technology Bombay (India). 
Whereas the synthesis and characterization of amidoamine 1 and OEGylated 2 was per-
formed by the author of the present doctoral thesis in Chemnitz, drug loading of dendrimer 2 
with doxorubicin to give a dendrimer-drug conjugate and subsequent in vitro cell studies were 
realized by Dr. Sudeshna Chandra and Prof. Dr. Dhirendra Bahadur in Bombay. 
 
1. Introduction 
Exceptional structural properties such as monodispersity, high density peripheral functional 
groups, globular structure and multivalency of dendrimers 
[G1]
 make them an efficient nano-
device for controlled and targeted delivery of therapeutic compounds. Low-generation den-
drimers possess open conformations and empty internal cavities which make them possible to 
encapsulate drug molecules. 
[G2]
 They also have more functional groups at the periphery in 
comparison to conventional macromolecules which enhance the applications of the dendri-
mers in various ways. The surface functional groups on the dendrimers are responsible for 
high reactivity and thus a dendrimer can be suitably modified for conjugation and encapsula-
tion of drugs. 
[G3]
 However, out of many considerations like hemocompatibility, cytotoxicity, 
immunogenicity and biodistribution for in vivo use of any dendritic system, cytotoxicity re-
mains the most critical factor. The dendritic cytotoxicity is related not only to generations, but 
also to the charges of the surface groups and it has been well reported that the cytotoxicity of 
the dendrimers increases with the increase in generation and concentration. 
[G4] 
Among den-
drimers, the cationic dendrimers were found to be more toxic than the anionic ones due to the 
fact that the cationic dendrimers interact with the lipid bilayers thereby causing a disturbance 
in the electrolyte flux resulting in the cell death. 
[G5, G6]
 The toxicity from the dendrimers can 
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be used to enhance the therapeutic efficacy of a drug which when programmed carefully can 
be used to reduce the dosage of a toxic drug, increase the bioavailability and also provide sta-
bility to the drug. 
[G7]
 In this way, the dendrimer can act as a shell encapsulating the drug 
(dendrimer-drug conjugate), which can enhance the delivery of the cytotoxic drug by releas-
ing it in the target site as and when required while minimizing the collateral damage to the 
normal cells. The loading ability of the drug onto the dendrimers can be tuned by using differ-
ent linkers between the dendrimer and the drug and thus dendrimer based therapeutics can be 
formulated. Drugs can be appropriately attached to the dendritic nanodevices by various lin-
kages like ester or amide connectivity which can later be hydrolyzed inside the cell. However, 
when drugs are loaded non-covalently into the dendrimers, they are rapidly released which 
make them inefficient for targeted delivery. 
[G8]
 Thus, improvement in loading efficiency and 
release properties remain as major challenges in the dendrimer based drug delivery systems. 
Since a dendrimer can provide a single molecule character along with their low cost synthesis, 
toxicology profile and permeability, they can be used not only as a drug carrier but can also 
be used to facilitate improved internalization over free drug. 
Another important factor is the biodistribution of the dendrimers which has been widely stu-
died. Usually, smaller generation dendrimers show rapid renal elimination while higher gen-
eration dendrimers show accumulation in the liver. 
[G9, G10]
 Binding of the PEG units into a 
dendrimer scaffold not only helps in reducing toxicity but also increases circulation time in 
the blood thereby reducing its accumulation in the liver or kidney. This is due to the shielding 
of the positive charge on the dendrimer by the PEG chains. 
[G11]
 Further, enhanced permeation 
and retention (EPR) can be achieved if the drugs are encapsulated within the PEG moiety of 
the dendrimer. 
[G12]
 In addition to this, there are many reports which demonstrated that PEG 
chains, when grafted to the polymer micelles and liposomes, suppress their interaction with 
the plasma proteins cells thereby prolonging the circulation time in blood. 
[G13, G14]
 Thus, it is 
expected that the dendrimers covered with PEG entity make them attractive drug carriers in 
vivo. 
To this end, we wish to report an amidoamine dendrimer with an oligo(ethylene glycol) graft 
(OEG) in the periphery which serves not only as an efficient drug delivery vehicle by loading 
the drug, but also enhances the sensitivity of the cells towards the drug. Doxorubicin (DOX) 
was employed as drug molecule and its interaction with the dendrimer was characterized by 
NMR and HPLC. The release properties of the doxorubicin from the dendrimer-DOX conju-
gate were studied under hyperthermic condition. As a proof of concept, we also report hyper-
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thermia studies through a biphasic suspension 
[G15]
 of this dendrimer-drug conjugate. Further, 
their in vitro cell viability and cellular uptake of the dendrimer-DOX conjugate were studied 
for their potential in therapeutic applications. 
 
2. Experimental Section 
2.1. Materials and Methods 
Syntheses of dendrimers were performed under dry and deoxygenated N2 atmosphere using 
standard Schlenk techniques unless otherwise stated. All solvents were dried by standard pro-
cedures over the appropriate drying agents and distilled immediately before use. The reagents 
purchased commercially (Sigma Aldrich) were used without further purification. Di(ethylene 
glycol)ethyl ether acrylate was distilled prior to use. Dendrimer 1 was synthesized according 
to the published procedure. 
[G16]
 Doxorubicin hydrochloride was obtained from Sigma Al-
drich. 
1
H and 
13
C{
1
H} NMR spectra were recorded with a Bruker Avance III 500 MHz spectrome-
ter. Chemical shifts  are given in ppm (parts per million) using CDCl3 solvent as the refer-
ence signal. Coupling constants J are given in Hertz (Hz). FT-IR spectra were recorded with a 
FT Nicolet IR 200 instrument in the range of 500 to 4000 cm
-1
. UV/Vis spectra were obtained 
with a CECIL CE 3021 spectrophotometer in the wave length range of 200 to 600 nm. High 
resolution mass spectra were recorded using a micrOTOF QII Bruker Daltonite workstation. 
The surface charges on samples (pH = 6.6 ± 0.4) were measured using a zeta plus zeta poten-
tial analyzer (Brookhaven Instruments) at 25 °C. DLS measurements to determine the size of 
the OEGylated dendrimer and drug-loaded dendrimer were performed using a Malvern 4800 
Autosizer employing a 7132 digital correlator. The light source was an argon ion laser operat-
ed at 514.5 nm with a maximum output of 2 W. The concentrations of dendrimer and drug 
loaded dendrimer were 1 mg ∙ mL-1 in the 0.1 M PBS (pH 7.4). 
Evidence of the chemical stability of the drug and the interaction of the drug and dendrimer 
was followed using HPLC using a reversed phase Thermohypersil 28905-020 column (250 × 
4.6 mm 5  pore size BDS phenyl) operated at room temperature with a Perkin Elmer Series 
200 Pump equipped with an UV detector (Varian Prostar). A linear gradient mixture of wa-
ter/acetonitrile/methanol/H3PO4 (540:290:170:2, v/v/v/v) + 1 g SLS was used as a mobile 
phase at a flow rate of 1.5 mL ∙ min-1. Detection of DOX was done by measuring its UV ab-
sorbance at 485 nm. Samples of free DOX and DOX loaded dendrimer were analyzed and a 
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calibration curve was constructed using the area under the curve (AUC) method and the total 
amount of DOX was calculated by summing up all AUC, attributed to DOX and its degrada-
tion products. 
 
2.2. Synthesis of OEGylated Poly(amidoamine) Dendrimer 2 
Molecule 1 (0.9 g, 1.35 mmol) dissolved in 20 mL of methanol was mixed with 5 mL (5.0 g, 
27 mmol) of di(ethylene glycol)ethyl ether acrylate. The resulting reaction mixture was stirred 
for 15 days at 25 °C. After evaporation of all volatiles in oil-pump vacuum, dendrimer 2 
(Scheme G1) was obtained as pale yellow oil (3.4 g, 98 %, based on 1). 
1
H NMR (, CDCl3): 
1.20 (t, 30 H, 
3
JHH = 7.0 Hz, CH3), 2.35 (t, 10 H, 
3
JHH = 6.8 Hz, CH2CH2C(O)NH), 2.42 (t, 20 
H, 
3
JHH = 6.8 Hz, NCH2CH2C(O)), 2.54 (t, 10 H, 
3
JHH = 6.1 Hz, HNCH2CH2N), 2.56 (m, 8 H, 
NCH2CH2N), 2.74 – 2.78 (m, 30 H, NCH2CH2C(O) / CH2CH2C(O)NH), 3.25 (dd, 10 H, 
3
JHH 
= 5.9 Hz, 
3
JHH = 11.6 Hz, HNCH2CH2N), 3.53 (q, 20 H, 
3
JHH = 7.0 Hz, CH2CH3), 3.59 (m, 20 
H, CH2OCH2CH3), 3.67 (m, 20 H, CH2CH2OCH2CH3), 3.73 (m, 20 H, C(O)OCH2CH2), 4.24 
(m, 20 H, C(O)OCH2CH2), 7.15 (m, 5 H, C(O)NH). 
13
C{
1
H} NMR (, CDCl3): 15.1 (CH3), 
32.7 (NCH2CH2C(O)), 33.8 (CH2CH2C(O)NH), 37.2 (HNCH2CH2N), 49.3 (NCH2CH2C(O)), 
50.2 (CH2CH2C(O)NH), 51.6 (HNCH2CH2N), 53.0 (NCH2CH2N), 63.1 (C(O)OCH2CH2), 
66.7 (CH2CH3), 68.6 (C(O)OCH2CH2), 69.9 (CH2OCH2CH3), 72.5 (CH2CH2OCH2CH3), 
172.3 (C(O)NH), 173.0 (C(O)). FT-IR (NaCl, cm
-1
): 3330 (m, NH), 1735 (vs, C(O)), 1650 (s, 
C(O), amide I), 1540 (m, C(O), amide II), 1120 (s, COC). HR MS: m/z calcd. for 
C99H183N13O37: 2148.2942, found 2148.3087 [M - C20H40O8 + H]
+
. UV/Vis (C2H5OH) [λmax 
(ε)]: 231 (3500). 
 
Scheme G1. Synthesis of OEGylated poly(amidoamine) dendrimer 2. 
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2.3. Cell Viability Studies 
Cytotoxicity of dendrimer 2 and the dendrimer-drug conjugate were determined by 3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) 
assay. HeLa (cervical cancer cell line) and MCF-7 (breast cancer cell line) cells were cultured 
in MEM and DMEM respectively, supplemented with 10 % fetal bovine serum and penicil-
lin/streptomycin at 37 °C in a 5 % carbon dioxide atmosphere. For subculture, cells were 
washed once with phosphate buffer saline (PBS) and incubated with trypsin-EDTA solution 
(0.25 % trypsin, 1 mM EDTA) for 10 min at 37 °C to detach the cells. The complete medium 
was then added to the flask at ambient temperature to inhibit the effect of trypsin. The cells 
were re-suspended in the complete medium for reseeding and growth in the new culture me-
dium. Cell viability was determined through staining with Trypan blue and cells were counted 
using a hemocytometer. Cell density was estimated using a 0.9 mm
3
 counting 
chamber. 
For viability measurements, cells were plated at the density of 10
4
 cells per well in a flat bot-
tomed 96 well plates. Later they were incubated with different concentrations of dendrimers 
(in PBS) for 24 h. After this incubation, the cell viability was determined by MTS assay. In 
short, after the period of incubation, the medium was removed from each well and 90 L of 
the fresh medium and 10 L of the MTS assay (CellTiter 96® Aqueous One solution Reagent; 
Promega, Madison, WI) were added to each well according the manufacturer´s instructions. 
After 4 hrs in culture, the cell viability was determined by measuring absorbance at 490 nm 
using 1420 Multilabel counter, Victor V
3
 (Perkin Elmer). Results were plotted in reference to 
100 % control cells using the following Equation G1:  
                     
                            
                           
        (Eq. G1) 
where, control was the absorbance of 10 µL  CellTiter 96
®
 Aqueous One solution Reagent in 
100 µL culture medium. The same set of experiments was carried out with DOX loaded den-
drimer 2 and the half maximal inhibitory concentration (IC50) was determined by using Bio-
Data Fit website (www.changbioscience.com/stat/ec50.html). 
 
2.4. Doxorubicin Loading and Release 
Fluorescence spectroscopy was followed to evaluate the drug loading onto dendrimer 2 and 
was recorded by exciting the DOX solution at 490 nm and recording the emission at 500 – 
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800 nm (excitation slit: 5 nm; emission slit: 2.5 nm) on a Hitachi F-2500 Fluorescence Spec-
trophotometer. The calibration curve of DOX was obtained at 535 nm (Figure S1, ESI†) and a 
linear relationship was observed between enhanced fluorescence intensities and the concentra-
tions of doxorubicin in the range of 0.2 to 20 mM with a correlation coefficient of 0.9979. 
4 mg ∙ mL-1 stock solution of dendrimer 2 was prepared in PBS (pH 7.4). From this solution, 
250 mL of dendrimer 2 was taken out in the sample tube and the volume was made up to 1 
mL by adding 750 L of PBS. 100 L of the diluted solution of the dendrimer was added af-
ter every 15 min to the DOX solution (concentration: 10 mg mL
-1
). After each addition, the 
solution was mixed well and incubated at ambient temperature for 15 min. The addition of the 
dendrimer was continued till no further decrease in emission was observed. Once a constant 
emission was achieved, the sample from the vial was taken out and put under dialysis in PBS 
in reservoir-sink condition for 24 hrs to remove the unloaded drug. After 24 h, the sink was 
analyzed by measuring the fluorescence and the loading efficiency was calculated as follows 
(Equation G2):  
               
                               -                              
                              
        (Eq. G2) 
To assess the drug release profile of the DOX loaded dendrimer, we monitored the release of 
DOX in phosphate buffer (0.1 M, pH 7.4) and simulated body fluid (SBF, pH 7.4) using a 
dialysis membrane of 2.5 nm pore size under reservoir-sink condition. 
[G17]
 Specifically, a 
solution of DOX loaded dendrimer 2 was prepared using the encapsulation procedure de-
scribed before and the drug concentration in the solution was determined. The drug loaded 
dendrimer was then transferred to the dialysis membranes which were placed in 250 mL 
beakers containing 200 mL of release medium (PBS and SBF) to maintain the sink conditions. 
The beakers containing the dialysis bag were placed over a magnetic stirrer and continuously 
stirred over the entire period of the drug release experiment. The dialysis was carried out at 37 
°C and 43 ± 1 °C and samples (1 mL) from each sink were collected at predetermined time 
intervals of 1 h to 24 hrs with replacement of equal amount of the solutions. The amount of 
DOX released was quantified by the 1420 Multilabel Counter, Victor V
3
 (Perkin Elmer) UV 
spectrophotometer at 490 nm using a validated analytical method. Hyperthermia experiments 
were done as described earlier. 
[G18] 
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2.5. In Vitro Cellular Uptake of Dendrimer-DOX Conjugate 
HeLA cells were seeded in 24-well plates at 10
5
 cells per well having a cover slip and grown 
overnight. The media were discarded after 24 hrs and the cells were incubated for 3 hrs with 
DOX, dendrimer 2 and dendrimer-DOX conjugate. After incubation, the media were again 
discarded and the cells were washed with PBS three times. 1 mL of 10 % formalin was added 
to each well and kept for 10 min. The cover slip was mounted on glass slides with DPX 
mount and the photographs of the cells after incubation were taken in phase contrast and fluo-
rescence mode with fixed exposure time using Olympus Inverted Confocal Microscope Model 
IX 81. 
 
3. Results and Discussion 
3.1. Drug Loading and Release 
Fluorescence spectroscopy has been successfully used to study the interaction between DOX 
and its surrounding molecules. Figure G1a shows the fluorescence spectra of DOX and DOX 
loaded dendrimer 2 assemblies and significant differences are seen in these spectra. The con-
centration of DOX was kept constant and the concentration of the dendrimer was varied as 
mentioned in the Experimental section. The loading of DOX within dendrimer 2 is indicated 
by predominant quenching of the DOX fluorescence.  
560 580 600 620 640 660 680 700 720
0
2x10
3
4x10
3
6x10
3
8x10
3
1x10
4
P
3
P
1
 
 
F
lu
o
re
s
c
e
n
c
e
 I
n
te
n
s
it
y
 (
-)
Wavelength (nm)
P
2
(i)
(x)
(a)
 
525 550 575 600 625 650 675 700 725 750
0
2x10
3
4x10
3
6x10
3
8x10
3
1x10
4  
F
lu
o
re
s
c
e
n
c
e
 i
n
te
n
s
it
y
 (
-)
Wavelength (nm)
(i)
(ii)
(viii)
(b)
P
3
P
2
 
 
P
1
 
Figure G1. (a) Fluorescence spectra of (a) pure DOX (i) and DOX-dendrimer conjugate 
(10 g ∙ L-1 of DOX) recorded at initial (ii) and after 15 (iii), 30 (iv), 45 (v), 60 (vi), 75 (vii), 
90 (viii), 105 (ix) and 120 min. (x); (b) Gaussian profiles for the fluorescence spectra (i), (ii) 
and (viii). 
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It has been observed that the fluorescence intensity of DOX decreases monotonically on in-
creasing the interaction/loading time of DOX with the dendrimer till a saturation loading of 
DOX is achieved. The drug loading efficiency was calculated out to be 52 % where 10 g ∙ 
mL
-1
 of DOX was reacted with 450 g ∙ mL-1 of the dendrimer for 90 min, after which the 
intensity begins to remain constant. The loading was continued further for another 30 min till 
saturation is achieved. 
The fluorescence spectrum of DOX showed three emission bands at ca. 555 nm (P1 band), 
590 nm (P2 band) and 626 nm (P3 band). To understand the interaction between the DOX and 
the dendrimer, select fluorescence spectra were further analyzed by multiple peak Gaussian 
curve fitting analysis using Origin 7.2 data processing software. The area under each emission 
bands and correlation factor R
2
 values are shown in Figure G1b and Table S1 (see ESI†). Any 
change in the position of the peak maximum, spectral shape and ratios of area under the peak 
1 (A1) to peak 2 (A2) and peak 3 (A3) to peak 2 (A2) tells us about the nature of interaction be-
tween drug and dendrimer. When compared to pure DOX, A1/A2, A3/A2 values for DOX 
loaded dendrimer at t = 0 and t = 90 min show progressive increase which indicates that there 
is a significant interaction between the DOX and dendrimer 2. The ethylene glycol moiety of 
the dendrimer exhibits –  stacking interaction with the quinine portion of DOX developing 
hydrophobicity in the conjugate. In addition to this, the NH2 and the OH groups of DOX also 
participate in hydrogen bonding with the dendrimer. 
 
3.2. Surface Potential of the Dendrimer-Drug Assembly 
Zeta potential (-potential) is the difference in the electrical charge developed between the 
dense layers of ions surrounding the molecule and gives information about the overall surface 
charge of the particles thereby indicating their stability. The interactions between the mole-
cules play an important role in determining the colloidal stability and the -potential mea-
surements may be used to quantify such interactions. 
The values of -potential for unloaded and drug loaded dendrimer 2 are summarized in Ta-
ble G1 which clearly indicate that loading of doxorubicin onto dendritic arena increases posi-
tive potential of the entire molecule. The observed increase may be explained by the fact that 
drug molecules bear a positive charge and due to their loading onto the dendrimers, the posi-
tive charge increases which also supports the dendrimer-drug interaction. Further characteri-
zation of the structure of the drug-loaded dendrimer was carried out to investigate their size 
change before and after loading of DOX using dynamic light scattering measurements. Figure 
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S2 (ESI†) shows the size distributions of dendrimer and DOX loaded dendrimer. The effec-
tive diameter of the dendrimer increased from 215 to 432 nm after loading DOX. 
Table G1. Surface potential of the dendrimer-drug assembly, EMF data have been ex-
pressed as mean ± S.D. of at least three determinations. 
pH 
EMF / mV 
Buffer solution 
EMF / mV 
Unloaded 
EMF / mV 
Loaded 
1.4 275.2 258.4 283.3 
7.5 -34.2 -36.7 -20.7 
9.2 -80.4 -84.1 -43.2 
 
 
3.3. Structural Analysis of Dendrimer-DOX Conjugate 
FT-IR spectroscopy was used to confirm the successful loading of DOX into OEGylated 
dendrimer 2 (Figure G2). Doxorubicin exhibits characteristic FT-IR modes at 1742 cm
-1
 
(C═O stretching vibration at position C13), 1630 and 1552 cm-1 (stretching vibration of the 
C═O groups of the anthracene ring (C6, C12)), 1412 cm-1 (C–H bending), ≈ 1250cm-1 (skele-
ton vibration of the DOX molecule) and a band at 992 cm
-1
 (C–O bonds). [G19] The broad 
band appears in the range of 2800 – 3000 cm-1 which is attributed to the stretching vibrations 
of the C–H and OH groups of DOX along with a contribution of NH2 within this band.  
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Figure G2. FT-IR spectra of (a) dendrimer 2, (b) DOX and (c) dendrimer-drug conjugate. 
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In the FT-IR spectra of dendrimer-DOX conjugate, the shift of the 1735 cm
-1
 and 1742 cm
-1
 
bands of the dendrimer and the DOX molecule respectively to 1630 cm
-1
 gives an evidence of 
formation of mutual hydrogen bonds between the carbonyl group of DOX (which acts as an 
hydrogen acceptor) and NH groups (hydrogen donors) of the dendrimer and vice versa. In this 
way, there exists a mutual interaction between the host dendrimer and the guest doxorubicin. 
Further, the broad peak at ≈ 3400 cm-1 and the shift in the absorption peaks are attributed to 
the intermolecular interaction of the DOX molecule with the dendrimer. The proposed inte-
raction of the dendrimer with DOX is shown in Scheme G2. 
The interaction of DOX with the dendrimer was also investigated by comparing the UV/Vis 
spectra of dendrimer-DOX conjugate with those of the pure dendrimer and DOX (see ESI†, 
Figure S3). UV/Vis absorption spectra of the DOX showed absorption bands at 485, 275 and 
257 nm. Bands corresponding to n  * absorption of the carbonyl groups of DOX (275 and 
257 nm) exhibit blue shift in the UV/Vis spectra of the dendrimer-DOX conjugate. The ob-
served blue shift may be due to the formation of hydrogen bond between the dendrimer and 
the DOX molecule. 
 
Scheme G2. Proposed interactions of the dendrimer with doxorubicin. 
DOX in dendrimer 2 was analyzed by reverse phase HPLC which gave evidence that most 
of the DOX was loaded without degradation (Figure G3). Free DOX eluted as a single sharp 
peak at 7.0 min. After encapsulation within the dendrimer, one new peak appeared at 7.4 
along with a slight shift in the peak of the free DOX. It may be due to the fact that the dox-
orubicin is encapsulated within the dendritic arms with reduced polarity thereby increasing 
the elution time and appearing as the second peak. The intensity of the first peak reduced 
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which may be due to the unencapsulated DOX in solution. Thus, reverse phase HPLC demon-
strated the interaction between DOX and dendrimer 2. 
5 6 7 8 9
(b)
  
(a)
Elution time (min)
 
Figure G3. Reverse phase HPLC chromatogram of pure DOX (a) and dendrimer-drug con-
jugate (b). 
 
NMR is a real time, in-situ and one of the powerful tools to give information regarding load-
ing in a host-guest system in a surrounding electronic environment and helps in predicting the 
interactions in it. 
[G20]
 Any change in the electronic environment around the target nucleus 
caused by the inclusion of any guest will induce a shield/deshield effect for the nucleus. 
Therefore, it can directly predict the intramolecular/intermolecular interactions in the system. 
[G21, G22]
 NMR characterization of the drug loaded dendrimer 2 was carried out to establish the 
loading of the drug within the dendrimer. The 
1
H NMR spectra of the dendrimer-drug conju-
gate in CDCl3 showed prominent resonance peaks at 7.2 – 7.6 and 1.6 – 2.5 ppm correspond-
ing to aromatic protons of the anthraquinone ring and the proton signals from the sugar moie-
ty of doxorubicin. In addition to this, the signals of the ethylene glycol group (OCH2CH2O) at 
≈ 3.1 to 3.5 ppm of the OEG moiety of dendrimer 2 were also seen (see ESI†, Figure S4). 
DOX is inherently less hydrophobic due to its polar hydroxyl and amino groups and thus is 
likely to be entrapped within dendrimer 2 by hydrogen bond interactions. 
Evidence for the chemical stability of doxorubicin contained in dendrimer 2 was further re-
vealed by visible spectroscopy (Figure G4). The absorbance of the free doxorubicin at 485 nm 
showed a decrease in absorbance from 0.25 to 0.045 over a period of 240 hrs (10 days), prob-
ably due to chemical degradation of pure DOX. 
[G23]
 However, the absorbance of DOX loaded 
onto dendrimer 2 was essentially constant over the same period of time. It showed negligible 
decrease in the absorbance from 0.20 to 0.17. This may be due to the fact that the cavities of 
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the dendrimer encapsulate the DOX molecules thereby preventing the hydrolytic reaction of 
DOX. This, in turn, gives an evidence of the dendrimer-drug interaction. Besides, giving the 
evidence of chemical stability of DOX and the interaction of the dendrimer with drug, the 
visible spectroscopy also suggests that the DOX is not released under the same experimental 
conditions. This suggests that some external stimuli are required for the release of the drug 
from the dendritic carrier. 
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Figure G4. Chemical stability of pure DOX and dendrimer–DOX conjugate over a period 
of time. 
 
 
3.4. In Vitro DOX Release Profile from Dendrimer-Drug Conjugate 
In vitro release profiles of DOX from DOX loaded dendrimer 2 in PBS (pH 7.4) and SBF 
(pH 7.4) as a function of time were studied at temperatures of 37 and 43 °C (Figure G5a and 
b). It is encouraging to note that while at the physiological temperature at 37 °C, the release is 
limited to about 10 % over a period up to 1400 min, this goes up to about 90 % at 43 °C, a 
possible hyperthermic temperature. An initial fast and burst release of DOX was observed at 
43 °C probably due to the breaking of the hydrogen bridge formed between DOX and the 
dendrimer. The burst release was observed within 1 h in both the release media (PBS and 
SBF), thereafter a slow release was observed for another 2.5 h. About 85 % of the DOX was 
released in 5 hrs in PBS after which a plateau was attained; the release in SBF was slightly 
higher (90 %) than in PBS medium. The release was monitored for 24 hrs and no change was 
observed in the release percentage and hence, complete release was not achieved. The release 
observation may prove to be very beneficial as a certain initial burst drug release is preferable 
to achieve sufficient initial dosage of the anticancer drug to inhibit the tumor cell growth for 
Chapter G  
 
115 
 
further treatment. For the cancer cells that are not inhibited by the initial stage of the DOX 
release, the slow DOX release is necessary to prevent their further proliferation. Therefore, 
based on the release profile of the conjugate, it is inferred that the dendrimer 2 makes it a 
promising candidate for tumor treatment. The next step of our studies will be devoted to the in 
vitro assessment of the cytotoxic activity of the dendrimer. 
The release fraction of DOX was plotted against the square root of time to assess the release 
mechanism of DOX from DOX loaded dendrimer 2. As it can be seen from the inset of Figure 
G5a and b, a linear relationship between the drug release and t
1/2
 is obtained in the first stage 
which shows that the DOX release process is diffusion-controlled. In the second stage also, a 
linear relationship between the drug release and the square root of time is observed, however, 
the slope of the second line is much less than the first stage. This indicates that the release rate 
was slower in the second stage probably due to the fact that the DOX loaded within the den-
dritic cavity took a longer time to get released. The results of DOX release indicate that the 
drug is not only encapsulated within the ethylene glycol moiety of the dendrimer 2, but also 
may be entrapped within matrix of the dendrimer. In this case, the triggering of the drug re-
lease is initiated by change in temperature, which acts as an external stimulus. The hydrogen 
bonds formed between the dendrimer and the DOX molecule break at higher temperature, 
which instantly release the DOX. Due to the presence of amide backbones in the OEGylated 
PAMAM dendrimers, degradation takes place only at harsh conditions and not in the physio-
logical conditions. OEGylated dendrimers are possibly degraded into smaller units and are 
easily eliminated from the body. 
[G24]
 The linking chemistry in the dendrimer-drug conjugate 
governs the drug release thereby enhancing the therapeutic index. 
0 200 400 600 800 1000 1200 1400
0
20
40
60
80
100
0 5 10 15 20 25 30
0
20
40
60
80
100
 
 
 %
 D
ru
g
 R
e
le
a
s
e
Square root of time (min
1/2
)
 
 
%
 D
O
X
 r
e
le
a
s
e
Time (min)
 37
 o
C
 43
 o
C
(a)
 
Figure G5. Drug release profile of DOX from dendrimer-drug conjugate in PBS (a) and 
SBF (b) at 37 °C and 43 °C. Inset shows curves of (a) and (b) replotted against the square root 
of time at 43 °C. 
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In view of the interesting observation of a large difference in the drug release between phy-
siological conditions (37 °C) and hyperthermic condition (43 °C), we were motivated to carry 
out some preliminary in vitro hyperthermic experiments through a biphasic suspension of the 
dendrimer-drug conjugate and a ferrofluid, which is an aqueous suspension of iron oxide 
magnetic nanoparticles. 
[G18]
 Magnetic fluids generate heat when exposed to the AC magnetic 
field and thus the induction heat is not only useful for hyperthermia treatment but also acts as 
driving force for drug release. Keeping this in mind, the release of the drug from the dendri-
mer-drug conjugate assisted by the magnetic fluid (iron concentration 10 mg ∙ mL-1 with a 
SAR value of 19 W ∙ g-1 Fe) was studied under AC magnetic field through a biphasic suspen-
sion consisting of dendrimer-drug conjugate and the magnetic fluid. This was taken in a fal-
con tube which was put inside a circular coil attached to a RF generator at 423 kHz fixed fre-
quency and 10 kA ∙ m-1 field and was exposed to AC magnetic field. It took only 4 minutes to 
raise the temperature of the suspension to 43 °C, which could be a possible temperature for 
magnetic hyperthermia. Figure G6 shows the release of DOX from the solution triggered by 
on–off switching of the AC magnetic field. In this experiment, the percentage of cumulative 
release DOX was calculated using the formula (Equation G3): 
    
  
  
             (Eq. G3) 
where Ci is the initial amount of the DOX and Cf is the cumulative amount of released DOX. 
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Figure G6. Controlled release of DOX from the conjugate by switching the AC magnetic 
field on-off. 
 
It is interesting that DOX gets released during application of the field (switch on mode) and 
it stops on removal of the field (switch off mode). It has been found that ≈ 70 % DOX is re-
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leased on application of AC magnetic field for 35 minutes. The sigmoidal profile of the graph 
shows that there is a fast release during the first 15 minutes under "switch on" mode of AC 
magnetic field and later on, the release is slow. This allows the controlled release of the DOX 
from the conjugate to its delivery to remote tumor locations. Moreover, the heat generated can 
be used for magnetic hyperthermia treatment and also for enhancing the drug effect (chemo-
therapy). 
[G25] 
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Figure G7. Viabilities of MCF-7 and HeLa cells incubated with MEM media containing 
(a) dendrimers and (b) dendrimer-drug conjugate. 
 
3.5. Cell Viability Studies of the Dendrimer-DOX Conjugate 
The cell viability of the dendrimer 2 and the dendrimer-DOX conjugate is shown in Figure 
G7. The MTS assay showed that about 90 % of the HeLa and the MCF-7 cells were viable 
after 24 hrs of incubation with dendrimer concentration of 0.25 mg ∙ mL-1, however, they are 
affected by the presence of the dendrimers above this limit. The IC50, defined as the concen-
tration of the material which results in a 50 % inhibition of cellular process, was found to be 
0.87 M and 0.76 M for HeLa and MCF-7 cells, respectively. The in vitro cytotoxicity of 
DOX-dendrimer conjugate was found to decrease the IC50 of DOX for HeLa cells to 0.711 
M (the reversal fold was 1.2) and for MCF-7 to 0.37 M (reversal fold was 2.0) indicating 
that dendrimer 2 can enhance the sensitivity of the cancer cells (HeLa and MCF-7) to DOX. 
Cytotoxicity experiments performed led to the conclusion that the toxicity from the dendrimer 
can also be used for formulation of a therapeutic drug specific to the cancer cells. 
[G26]
 How-
ever, as with the formulation of any drug, biological activity is not the sole determinant, 
hence, based on the in vitro results, detailed in vivo experiments will be designed to evaluate 
the therapeutic potential of the proposed dendrimer-drug conjugate in due course of time. 
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3.6. Cellular Uptake by the Dendrimer-DOX Conjugate 
Confocal microscopy was performed on the HeLa cells following 3 hrs incubation with free 
DOX, dendrimer 2 and the dendrimer-DOX conjugate at 37 °C. The control cells did not 
show any fluorescence under same microscopic settings (Figure G8a and b), while the cells 
exposed to free DOX showed nuclear internalization as the DOX has an inherent property to 
fluoresce (Figure G8c).  
 
 
Figure G8. Cellular uptake as evidenced by confocal microscopy images: (a) control cells 
showing no fluorescence, (b) phase contrast image of the control cells, (c) HeLa cells incu-
bated with free DOX and (d) cells incubated with dendrimer-DOX conjugate. All the cells 
were grown on sterilized cover slips and incubated for 24 h. Magnification is 60×. 
 
The conjugation of the DOX with the dendrimer also enables confocal microscopic imaging 
of the cellular uptake. The cells treated with the dendrimer-DOX conjugate displayed fluores-
cence signals, which are associated with the uptake of the dendrimer-DOX conjugate in to the 
cytoplasm as well as on the membrane of the cells within 3 hrs (see Figure G8d). The intensi-
ty of the fluorescence is, however, less in the cell nuclei when they were incubated with the 
dendrimer-DOX conjugate which suggests that the drug is still intact and does need some 
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trigger for the release. During this period of study, no toxicity was observed from the dendri-
mer-drug conjugate. Based on the confocal images, it was possible to determine the intracellu-
lar location of the dendrimer-DOX conjugate, however, further detailed microscopy will be 
carried out to ascertain the effects of cell type, incubation period and fixation. 
 
3.7. Protein Adsorption Studies 
Oligomers of ethylene glycol moieties are known to provide protein resistance in aqueous 
medium where the oxygen of the ethylene glycol forms hydrogen bonds with water thereby 
preventing hydrophobically driven protein adsorption. The chain mobility of the ethylene gly-
col segments results in steric hindrances which are also responsible for resistance to protein 
adsorption. To study the nonspecific protein adsorption onto the oligo(ethylene glycol)-
grafted amidoamine dendrimer, bovine serum albumin (BSA) and immunoglobulin (IgG) was 
used as test proteins and  potentials were recorded. The dendrimer (0.125 mg ∙ mL-1) was 
incubated with the test proteins, BSA (0.5 mg ∙ mL-1) and IgG (0.25 mg ∙ mL-1) in PBS at 
room temperature for 2 h. The  potential of pure dendrimer, pure BSA and pure IgG was -9.8 
± 3.0 mV, -11 ± 1.8 mV, -16.0 ± 3.8 mV respectively, in PBS (pH 7.4). The  potential of the 
incubated dendrimer-BSA and dendrimer-IgG sample was found to be -7.5 ± 4.7 and -13.5 ± 
3.2 mV, respectively; the change in  potentials are significantly small (≈ 4 mV) depicting 
resistance of the dendrimer to BSA and IgG adsorption. 
 
4. Conclusions 
The present study reports synthesis of a novel OEGylated dendrimer and its conjugate with 
doxorubicin. An important observation of the present work is that dendrimer 2 is not only an 
efficient carrier for the cancer drug, doxorubicin, as could be seen from the results of fluores-
cence spectroscopy in terms of the quenching of fluorescence intensity as well as the change 
in band positions and spectral shapes, but also an effective therapeutic. The IC50 of the den-
drimer-DOX conjugate towards the HeLa and MCF-7 cell lines were lowered suggesting that 
the loading of DOX in dendrimer increased its potency. Further, the dendrimer encapsulate 
the doxorubicin molecule without altering its chemical integrity as evidenced by HPLC, 
which is also an important aspect for drug delivery. The uptake by HeLa cells of the dendri-
mer-DOX conjugate is also promising for use as scaffolds in the development of drug carriers. 
The combined effect of loading and release pattern of DOX from the dendritic carrier and the 
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enhanced potency of the dendrimer-drug conjugate will certainly make them an efficient sys-
tem for cancer treatment. It is also interesting to observe the release of the DOX from the con-
jugate using a biphasic suspension with magnetic fluid under AC magnetic field. This study 
exhibits a strong potential for a combination therapy involving chemotherapy and hyperther-
mia. However, additional studies are required to establish the precise in vivo action of the 
dendrimer-drug conjugate and also to ascertain whether the dendrimer-DOX conjugate be-
haves as potent antitumor agent when acting on larger tumors. 
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H Summary 
1. Summary 
The present work describes the synthesis, characterization and application of 
(poly)amidoamine-based low-generation dendrimers. The main emphasis is focused on spe-
cific peripheral organometallic, metal-organic as well as biochemical modifications. The ver-
satility of thus dendritic architectures formed is reflected in various applications, as e.g. cata-
lysts in homogeneous cross-coupling reactions, templates for metal/metal oxide nanoparticles 
formation and drug delivery vehicles for therapeutic anticancer drugs.   
The results gained in this work can be subdivided into five topics according to the following 
Chapters:     
 
Chapter C: Amidoamine-based Dendrimers with End-grafted Pd-Fe Units: Synthe-
sis, Characterization and Their Use in the Heck Reaction 
Chapter D: A Preparation of Planar-Chiral Multidonor Phosphanylferrocene Car-
boxamides and Their Application as Ligands for Palladium-Catalyzed 
Asymmetric Allylic Alkylation 
Chapter E: Au Nanoparticles Stabilized by PEGylated Low-Generation PAMAM 
Dendrimers: Design, Characterization and Properties 
Chapter F: Design, Characterization and Magnetic Properties of Fe3O4-
Nanoparticle Arrays Coated with PEGylated-Dendrimers 
Chapter G: Dendrimer-Doxorubicin Conjugate for Enhanced Therapeutic Effects 
for Cancer 
 
The most relevant results are discussed below. 
 
Chapter C 
The synthesis and characterization of amidoamine-based metallodendrimers with heterobi-
metallic end-grafted amidoferrocenyl-palladium-allyl chloride units is described. The dendrit-
ic starting materials as well as the corresponding metallodendrimers were prepared by a con-
secutive divergent synthesis methodology including addition-amidation cycles, standard pep-
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tide coupling and coordination procedures (Scheme H1). Using [Pd(3-C3H5)Cl]2 as palla-
dium source the heterobimetallic metallodendrimers 7-Fe-Pd − 9-Fe-Pd as well as (ami-
do)amine-functionalized model compounds 5-Fe-Pd and 6-Fe-Pd were synthesized (Figure 
H1). 
 
Scheme H1. Synthesis of heterobimetallic 9-Fe-Pd. 
The individual heterobimetallic Fe-Pd phosphines 5-Fe-Pd – 9-Fe-Pd were applied as ho-
mogeneous Heck-catalysts in carbon-carbon cross coupling reactions of iodobenzene with 
tert-butyl acrylate. The highest productivity was achieved with catalyst 9-Fe-Pd possessing 
five terminal heterobimetallic Fe-Pd-units. Furthermore, synergistic and cooperative effects 
resulting in higher yields and productivities can be recognized most pronounced between me-
tallodendrimers 5-Fe-Pd / 6-Fe-Pd, 7-Fe-Pd / 8-Fe-Pd and 9-Fe-Pd. 
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Figure H1. Heterobimetallic amidoamines 5-Fe-Pd – 8-Fe-Pd. 
 
Chapter D 
A series of oligoamides bearing one to three (Sp)-2-(diphenylphosphanyl)ferrocen-1-yl pen-
dant groups at the periphery were designed by the amide coupling reactions of (Sp)-2-
(diphenylphosphanyl)ferrocene-1-carboxylic acid [(Sp)–1] with appropriate terminal amines in 
the presence of peptide coupling agents (Scheme H2). 
The obtained chiral dendrimer-supported phosphines 2 – 5 were combined with [Pd(3-
C3H5)Cl]2 as a metal source and applied for asymmetric palladium-catalyzed allylic alkylation 
reactions. Therein, the alkylation of the symmetrical 1,3-diphenylprop-2-en-1-yl acetate with 
in situ generated malonate anion was employed. The results indicate only relatively minor 
variation in the ee upon increasing the number of the chiral 2-phosphanylferrocenyl units per 
ligand molecule. Furthermore, the conversions achieved after 24 hrs for the applied ligands 2 
– 5 varied greatly, being lower for donor molecules exhibiting a larger dendritic scaffold. 
 
Chapter E 
In a two-step synthesis methodology a series of well-defined low-generation 
(poly)amidoamine-based dendrimers and related (amido)amine model compounds functiona-
lized with terminal ethylene glycol ethers of various chain lengths were prepared (Chart H1). 
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Scheme H2. Preparation of phosphane-amides 2 – 5 (EDC = 1-ethyl-3-[3-
(dimethylamino)propyl]carbodiimide, HOBT = 1-hydroxybenzotriazole). 
 
Chart H1. Synthesized (poly)ethylene glycol-functionalized PAMAM dendrimers 3a – 
3c, 4, 5a – 5c and for comparison, amines 1 and 2. 
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The obtained biocompatible dendritic architectures 3a – 3c, 4, 5a – 5c featuring 6, 8, or 10 
ethylene glycol ether-termini of various sizes provide multiple donating capabilities. The in-
trinsic nanotemplating properties were examined for the stabilization of Au NPs. Therefore, 
the appropriate templates 1, 2, 3a – 3c, 4 and 5a – 5c were loaded with H[AuCl4]. Subsequent 
reduction of the respective metallodendrimers with Na[BH4] produced dendrimer encapsu-
lated gold colloids. The dendritic scaffold, the length of the ethylene glycols, the adjusted 
stabilizer to gold ratio and the duration of reaction time affected the morphology and the aver-
age Au NPs diameter in a range of 4.0 ( 0.9) to 58.5 ( 14.5) nm. Characterization by trans-
mission electron microscopy (TEM), dynamic light scattering (DLS), UV/Vis and FT-IR 
spectroscopy revealed that Au NPs are formed and protected inside the dendrimer scaffold. 
  
Chapter F 
Stable magnetic magnetite nanoparticles (Fe3O4 NPs) were synthesized using the chemical 
co-precipitation method of ferrous (Fe
2+
)/ferric (Fe
3+
) mixed aqueous salt solutions in pres-
ence of well-defined biocompatible low generation (poly)amidoamine (PAMAM)-based den-
drimers with end-grafted n (oligo)ethylene glycol ether (n = 1, 2, 9) moieties, accessible by 
means of straightforward consecutive divergent synthesis methodologies including addition 
and amidation cycles (Scheme H3).  
 
Scheme H3. Schematic illustration of in-situ dendrimer-stabilized Fe3O4 NP formation by 
the co-precipitation method. 
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The structural properties of Fe3O4 NPs were analyzed by FT-IR spectroscopy, thermogravi-
metry (TGA), X-ray powder diffraction (XRPD) and transmission electron microscopy 
(TEM) experiments.  
Magnetic measurements, performed in the temperature range of 5 K to 300 K and at magnet-
ic fields of -70 kOe to +70 kOe, were carried out on Fe3O4-magnetodendrimers using a SQU-
ID-VSM to record field cooled (FC) and zero field cooled (ZFC) magnetizations. The deter-
mination revealed superparamagnetic metal oxide colloids, possessing ferrimagnetic characte-
ristics at temperatures below the blocking temperature TB (≈ 20 K). 
 
Chapter G 
The (oligo)ethylene glycol grafted amidoamine dendrimer 2 was synthesized, characterized 
and evaluated as drug delivery vehicle for therapeutic doxorubicin (DOX). While fluores-
cence spectroscopy was performed to monitor the drug loading process onto dendrimer 2, the 
successful loading was confirmed by FT-IR spectroscopy, displaying characteristic vibration 
modes of the resulting dendrimer-DOX conjugate (Scheme H4). 
 
Scheme H4. Proposed interactions of the dendrimer with doxorubicin. 
Temperature stimulated in vitro release studies of DOX from DOX-loaded dendrimers were 
carried out. An initial fast and burst release of DOX was observed in hyperthermic conditions 
at 43 °C, achieved by breaking off the intermolecular hydrogen bonds formed. The dendri-
mer-DOX conjugate´s efficacy was evaluated in vitro against HeLa and MCF-7 cancer cell 
lines and the IC50 was estimated, indicating an enhancement in cytotoxicity DOX loaded on 
dendrimer 2. 
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2. Zusammenfassung 
Die vorliegende Arbeit befasst sich mit der Darstellung, Charakterisierung und Anwendung 
(Poly)amidoamin-basierender Dendrimere kleiner Generationen. Den Mittelpunkt des Interes-
ses stellt dabei die gezielte Modifikation der dendritischen Peripherie durch das Einführen 
von metallorganischen, komplexchemischen und biochemischen Funktionalitäten dar. Die 
Vielseitigkeit der auf diesem Wege erhaltenen dendritischen Strukturen spiegelt sich in einer 
Vielzahl von Einsatzmöglichkeiten wie bspw. als Katalysatoren in homogen-katalytisch ge-
führten C,C-Kreuzkupplungsreaktionen, als Template für die Metall- bzw. Metalloxid-
Nanopartikelgenerierung sowie als spezifische Wirtsmoleküle für Zytostatika wieder. 
Die Ergebnisse, welche im Rahmen dieser Promotionsarbeit erzielt wurden, sind in fünf ein-
zelne Themengebiete unterteilt und in den entsprechenden Kapiteln ausgewiesen: 
 
Kapitel C: Amidoamine-based Dendrimers with End-grafted Pd-Fe Units: Synthe-
sis, Characterization and Their Use in the Heck Reaction 
Kapitel D: A Preparation of Planar-Chiral Multidonor Phosphanylferrocene Car-
boxamides and Their Application as Ligands for Palladium-Catalyzed 
Asymmetric Allylic Alkylation 
Kapitel E: Au Nanoparticles Stabilized by PEGylated Low-Generation PAMAM 
Dendrimers: Design, Characterization and Properties 
Kapitel F: Design, Characterization and Magnetic Properties of Fe3O4-
Nanoparticle Arrays Coated with PEGylated-Dendrimers 
Kapitel G: Dendrimer-Doxorubicin Conjugate for Enhanced Therapeutic Effects 
for Cancer 
 
Kapitel C 
In diesem Kapitel wird die Darstellung und Charakterisierung Amidoamin-basierender 
Metallodendrimere mit heterobimetallischen, endständigen Amidoferrocenyl-Palladium-
allylchlorid-Funktionalitäten vorgestellt. Mittels konsekutiver, divergenter Synthesestrategien 
konnten sowohl die dendritischen Ausgangsverbindungen als auch die entsprechenden 
Metallodendrimere zugänglich gemacht werden. Durch Zugabe von [Pd(3-C3H5)Cl]2 wurden 
die heterobimetallischen Metallodendrimere 7-Fe-Pd − 9-Fe-Pd als auch die (Amido)amin-
funktionalisierten Modellsysteme 5-Fe-Pd und 6-Fe-Pd erhalten (Schema H1, Figur H1). 
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Schema H1. Darstellung des heterobimetallischen Dendrimers 9-Fe-Pd. 
 
Figur H1. Heterobimetallische Amidoamine 5-Fe-Pd – 8-Fe-Pd. 
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Nachfolgend fanden die entsprechenden heterobimetallischen Systeme 5-Fe-Pd – 9-Fe-Pd 
Einsatz als Präkatalysatoren in einer C,C-Kreuzkupplungsreaktion nach Heck. Bei der homo-
gen-katalytisch geführten Umsetzung von Iodbenzol mit tert-Butylacrylat zeigte Verbindung 
9-Fe-Pd mit fünf terminalen heterobimetallischen Fe-Pd-Einheiten die höchste Produktivität. 
Darüber hinaus konnte das Auftreten gesteigerter Umsätze als Resultat synergistischer, ko-
operativer Effekte für die Metallodendrimere 5-Fe-Pd / 6-Fe-Pd, 7-Fe-Pd / 8-Fe-Pd, und 9-
Fe-Pd beobachtet werden. 
 
Kapitel D 
Eine Oligoaminserie mit peripherer Mono-, Di- und Tri-Funktionalisierung durch (Sp)-2-
(Diphenylphosphan)ferrocen-1-yl-Substituenten konnte mittels Peptidknüpfungsreaktionen 
ausgehend von (Sp)-2-(Diphenylphosphan)ferrocen-1-carbonsäure [(Sp)–1] und den entspre-
chenden terminalen Aminen in Gegenwart geeigneter Peptidkupplungsreagenzien dargestellt 
werden (Schema H2).  
 
Schema H2. Darstellung der Phosphanamid-Moleküle 2 – 5 (EDC = 1-Ethyl-3-[3-
(dimethylamino)propyl]carbodiimid, HOBT = 1-Hydroxybenzotriazol). 
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Die erhaltenen chiralen, Dendrimer-geträgerten Phosphane 2 – 5 wurden mit [Pd(3-
C3H5)Cl]2 zur Reaktion gebracht und im Anschluss als Präkatalysatoren in einer asymmetri-
schen Palladium-katalysierten allylischen Substitutionsreaktion eingesetzt. Die Ergebnisse der 
Umsetzung von 1,3-Diphenylprop-2-en-1-yl-acetat mit Malonat zeigen eine relativ geringe 
Veränderung des ee in Bezug auf die Anzahl chiraler 2-Phosphanylferrocenyl-Einheiten. Wei-
terhin sind die erhaltenen Umsätze nach 24 Stunden stark verschieden, wobei größere 
Dendrimerstrukturen geringere Umsätze zur Folge haben.   
 
Kapitel E 
Über eine zweistufige Synthesestrategie wurde die Darstellung einer Serie von 
(Poly)amidoamin-basierenden Dendrimeren sowie entsprechender (Amido)amin-
Modellverbindungen mit terminal funktionalisierten Ethylenglykolethern unterschiedlicher 
Kettenlänge ermöglicht (Abbildung H1). 
 
Abbildung H1. Dargestellte (Poly)ethylenglykol-funktionalisierte PAMAM 
Dendrimere 3a – 3c, 4, 5a – 5c und Modellverbindungen 1 und 2. 
Die erhaltenen, biokompatiblen dendritischen Strukturen 3a – 3c, 4 und 5a – 5c mit sechs, 
acht und zehn Ethylenglykolether-Endgruppen verschiedener Kettenlänge weisen eine große 
Anzahl von Donoratomen auf. Folglich wurden die intrinsischen koordinativen Eigenschaften 
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bei der Stabilisierung von Gold-Nanopartikeln eingehend untersucht. Die jeweiligen Template 
1, 2, 3a – 3c, 4 und 5a – 5c wurden mit H[AuCl4] zur Reaktion gebracht, und durch anschlie-
ßende Reduktion mit Na[BH4] konnte die Generierung der entsprechenden Dendrimer-
stabilisierten Goldkolloide realisiert werden. Es zeigte sich, dass neben der dendritischen 
Struktur selbst, auch die Größe der  Ethylenglykolether-Funktionalitäten, das eingestellte Sta-
bilisator-Gold-Verhältnis sowie die Reaktionszeit einen erheblichen Einfluss auf die Morpho-
logie und den durchschnittlichen Goldpartikeldurchmesser haben. Die Charakterisierung der 
Dendrimer-Gold-Hybridmaterialien mittels Transmissionselektronenmikroskopie (TEM), 
dynamischer Lichtstreuung (DLS), UV/Vis- und FT-IR-Spektroskopie belegen die Bildung 
4.0 ( 0.9) nm bis 58.5 ( 14.5) nm großer Goldkolloide innerhalb der dendritischen Struktu-
ren.   
 
Kapitel F 
Stabile, magnetische Magnetitnanopartikel (Fe3O4) konnten durch Anwendung der 
Mitfällungsmethode ausgehend von wässrigen Fe
2+
/Fe
3+
-Lösungen in Gegenwart entspre-
chender biokompatibler (Poly)amidoamin-basierender Dendrimere mit endständigen 
Ethylenglykolether-Einheiten erhalten werden (Schema H3). 
 
Schema H3. Schematische Darstellung der in-situ Generierung Dendrimer-stabilisierter 
Fe3O4-Nanopartikel durch die Mitfällungsmethode. 
Die strukturellen Besonderheiten der Dendrimer-stabilisierten Fe3O4-Kolloide wurden mit-
tels FT-IR-Spektroskopie, Thermogravimetrie (TGA), Röntgenpulverdiffraktometrie (XRPD) 
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und Transmissionselektronenmikroskopie (TEM) bestimmt. Magnetische Messungen wurden 
bei verschiedenen Temperaturen (5 K bis 300 K) und variierten magnetischen Feldern (-70 
kOe bis +70 kOe) an ausgewählten Fe3O4-Magnetodendrimeren durchgeführt. An einem 
SQUID-VSM-Gerät konnten die FC- (field cooled) und ZFC- (zero field cooled) Magnetisie-
rungen der Metalloxid-Proben ermittelt werden. Aus den erhaltenen Ergebnissen wird ein 
superparamagnetisches Verhalten der Kolloide oberhalb einer Blocking-Temperatur von TB ≈ 
20 K deutlich.  
 
Kapitel G 
Das (Oligo)ethylenglykol-funktionalisierte Amidoamin-Dendrimer 2 konnte erfolgreich 
dargestellt und charakterisiert werden. Bei einer anschließenden biochemischen Evaluierung 
erwies es sich als geeignete Wirtsverbindung für das Zytostatikum Doxorubicin (DOX). Mit-
tels Fluoreszenzspektroskopie wurde die Beladung des Dendrimers 2 mit DOX verfolgt. Cha-
rakteristische Schwingungsbanden im anschließend aufgenommenen FT-IR-Spektrum bestä-
tigten die Bildung eines Dendrimer-DOX-Konjugates (Schema H4). 
 
Schema H4. Postulierte intermolekulare Wechselwirkungen im Dendrimer-DOX-Konjugat. 
In vitro Untersuchungen zur temperaturgesteuerten Wirkstoffabgabe des Doxorubicins aus 
dem Konjugat zeigen eine schnelle Freisetzung des Therapeutikums unter hyperthermischen 
Bedingungen von 43 °C in Folge des Aufbrechens intermolekularer Wasserstoff-Brücken-
Bindungen. Die Wirksamkeit des Dendrimer-DOX-Konjugates bei der Behandlung von He-
La- und MCF-7-Krebszellen konnte durch die Bestimmung der jeweiligen IC50-Werte nach-
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gewiesen werden. Es zeigte sich eine erhöhte Zytotoxizität des Doxorubicin-beladenen Dend-
rimers 2 gegenüber des ungeträgerten Wirkstoffes. 
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I Appendix 
1. Appendix Chapter C 
Amidoamine-based Dendrimers with End-grafted Pd-Fe Units: 
Synthesis, Characterization and Their Use in the Heck Reaction 
Sascha Dietrich, Anja Nicolai and Heinrich Lang 
 
(Published in J. Organomet. Chem. 2011, 696, 739 – 747.) 
 
Technische Universität Chemnitz, Fakultät für Naturwissenschaften, Institut für Chemie, 
Lehrstuhl für Anorganische Chemie, Straße der Nationen 62, 09111 Chemnitz (Germany) 
 
Abstract 
The synthesis and characterization of novel amidoamine-based metallodendrimers with hete-
robimetallic end-grafted amidoferrocenyl-palladium-allyl chloride units is described. Dendri-
mer (Fe((5-C5H4PPh2)(
5
-C5H4))C(O)HNCH2CH2NHC(O)CH2CH2)N[CH2CH2N(CH2CH2-
C(O)NHCH2CH2NHC(O)(Fe(
5
-C5H4)(
5
-C5H4PPh2)))2]2 (9-Fe) and the corresponding me-
tallodendrimer (Fe((5-C5H4PPh2(Pd(
3
-C3H5)Cl))(
5
-C5H4))C(O)HNCH2CH2NHC(O)-
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CH2CH2)N[CH2CH2N(CH2CH2C(O)NHCH2CH2NHC(O)(Fe(
5
-C5H4)(
5
-C5H4PPh2(Pd(
3
-
C3H5)Cl))))2]2 (9-Fe-Pd) were prepared by a consecutive divergent synthesis methodology 
including addition-amidation cycles, standard peptide coupling and coordination procedures. 
For comparative reasons also the monomeric and dimeric molecules (Fe(5-C5H4(PPh2)(
5
-
C5H4C(O)NH
n
C3H7))) (5-Fe) and [Fe(
5
-C5H4(PPh2))(
5
-C5H4C(O)NHCH2)]2 (6-Fe) as well 
as N(CH2CH2C(O)NHCH2CH2NHC(O)(Fe(
5
-C5H4)(
5
-C5H4PPh2)))3 (7-Fe) and [CH2N-
(CH2CH2C(O)NHCH2CH2NHC(O)(Fe(
5
-C5H4)(
5
-C5H4PPh2)))2]2 (8-Fe) were prepared 
from Fe(5-C5H4(PPh2))(
5
-C5H4CO2H) (3). Using [Pd(
3
-C3H5)Cl]2 (4) as palladium source 
heterobimetallic metallodendrimers (Fe(5-C5H4PPh2(Pd(
3
-C3H5)Cl))(
5
-C5H4C(O)-
NH
n
C3H7)) (5-Fe-Pd), [Fe(
5
-C5H4(PPh2(Pd(
3
-C3H5)Cl))(
5
-C5H4C(O)NHCH2))]2 (6-Fe-
Pd), N(CH2CH2C(O)NHCH2CH2NHC(O)(Fe(
5
-C5H4)(
5
-C5H4PPh2(Pd(
3
-C3H5)Cl))))3 (7-
Fe-Pd) and [CH2N(CH2CH2C(O)NHCH2CH2NHC(O)(Fe(
5
-C5H4)(
5
-C5H4PPh2(Pd(
3
-
C3H5)Cl))))2]2 (8-Fe-Pd) were synthesized. Additionally, seleno-phosphines of 5-Fe-Se and 
9-Fe-Se, respectively, were prepared by addition of elemental selenium to 5-Fe or 9-Fe to 
estimate their  - donor properties. 
The palladium-containing amidoamine supports are catalytically active in the Heck-
Mizoroki cross-coupling of iodobenzene with tert-butyl acrylate. The catalytic data are com-
pared to those obtained for the appropriate mononuclear and dinuclear compounds 5-Fe-Pd 
and 6-Fe-Pd. This comparison confirms a positive cooperative effect. The mercury drop test 
showed that (nano)particles were formed during catalysis, following on heterogeneous car-
bon-carbon cross-coupling. 
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2. Appendix Chapter D 
A Preparation of Planar-Chiral Multidonor Phosphanyl-
Ferrocene Carboxamides and Their Application as Ligands for 
Palladium-Catalyzed Asymmetric Allylic Alkylation 
Martin Lamač, Jiří Tauchman, Sascha Dietrich, Ivana Císařová, Heinrich Lang and 
Petr Štěpnička 
 
(Published in Appl. Organometal. Chem. 2010, 24, 326 – 331.) 
 
Technische Universität Chemnitz, Fakultät für Naturwissenschaften, Institut für Chemie, 
Lehrstuhl für Anorganische Chemie, Straße der Nationen 62, 09111 Chemnitz (Germany) 
 
Charles University in Prague, Faculty of Science, Department of Inorganic Chemi-
stry, Hlavova 2030, 128 40 Prague (Czech Republic) 
 
Abstract 
Amide coupling of (Sp)-2-(diphenylphosphanyl)ferrocene-1-carboxylic acid with appropriate 
terminal amines mediated by 1-hydroxybenzotriazole and a carbodiimide affords multi-donor 
amides terminally functionalized with planar-chiral (Sp)-2-(diphenyl-phosphanyl)ferrocen-1-
yl moieties in good to excellent yields. Palladium catalysts based on these ligands efficiently 
promote asymmetric allylic alkylation of 1,3-diphenylallyl acetate with in-situ generated di-
methyl malonate anion to give the C-alkylated product with ees up to 93 % at room tempera-
ture. 
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3. Appendix Chapter E 
Au Nanoparticles Stabilized by PEGylatedLow-
Generation PAMAM Dendrimers: Design, Characterization and 
Properties 
Sascha Dietrich, Steffen Schulze, Michael Hietschold and Heinrich Lang 
 
(Published in J. Colloid Interface Sci. 2011, 359, 454 – 460.) 
 
Technische Universität Chemnitz, Fakultät für Naturwissenschaften, Institut für Chemie, 
Lehrstuhl für Anorganische Chemie, Straße der Nationen 62, 09111 Chemnitz (Germany) 
 
 
Abstract 
The preparation and characterization of a series of well-defined low-generation 
(poly)amidoamine (PAMAM)-based dendrimers with end-grafted ethylene glycol ether moie-
ties of type N(CH2CH2C(O)NHCH2CH2NR2)3 (3a, R = CH2CH2C(O)OCH2CH2OCH3; 3b, R 
= CH2CH2C(O)O(CH2CH2O)2C2H5; 3c, R = CH2CH2C(O)O(CH2CH2O)9CH3), 
[CH2N(CH2CH2C(O)NHCH2CH2NR2)2]2 (4, R = CH2CH2C(O)O(CH2CH2O)2C2H5)  and 
(R2NCH2CH2NHC(O)CH2CH2)N[CH2CH2N(CH2CH2C(O)NHCH2CH2NR2)2]2 (5a, R = 
CH2CH2C(O)OCH2CH2OCH3; 5b, R = CH2CH2C(O)O(CH2CH2O)2C2H5; 5c, R = 
CH2CH2C(O)O(CH2CH2O)9CH3) and their application for the stabilization of gold nanopar-
Appendix  
 
141 
 
ticles (Au NPs) is described. These dendrimers were prepared by a consecutive divergent syn-
thesis methodology including Michael addition and amidation cycles. For comparison, ami-
doamine related model compounds N(C3H7)R2 (1, R = CH2CH2C(O)O(CH2CH2O)2C2H5) and  
[CH2NR2]2 (2, R = CH2CH2C(O)O(CH2CH2O)2C2H5) were also synthesized to estimate the 
minimum required donating capabilities of the stabilizer. Loading the appropriate dendritic 
templates with H[AuCl4] (12) and subsequent reduction of the respective metallodendrimers 
with Na[BH4] produced dendrimer encapsulated gold colloids. The dendrimeric scaffold, the 
length of the ethylene glycols, the adjusted stabilizer:gold ratio and the duration of reaction 
time affects the average Au particle diameter in a range of 4.0 ( 0.9) to 58.5 ( 14.5) nm. 
Furthermore, depending on the nature of the stabilizer, nanoparticles were formed having 
spherical or multiple morphologies. Characterization by transmission electron microscopy 
(TEM), dynamic light scattering (DLS), UV/Vis and FT-IR spectroscopy revealed that Au 
NPs are formed and protected inside the dendrimer scaffold. 
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4. Appendix Chapter F 
 
Design, Characterization and Magnetic Properties of Fe3O4-
Nanoparticle Arrays Coated with PEGylated-Dendrimers 
Sascha Dietrich, Sudeshna Chandra, Colin Georgi, Senoy Thomas, Denys Makarov, 
Steffen Schulze, Michael Hietschold, Manfred Albrecht, Dhirendra Bahadur and Hei-
nrich Lang 
 
(Submitted to Mat. Chem. Phys. 2011.) 
 
Technische Universität Chemnitz, Fakultät für Naturwissenschaften, Institut für Chemie, 
Lehrstuhl für Anorganische Chemie, Straße der Nationen 62, 09111 Chemnitz (Germany) 
 
 
Abstract 
Stable magnetic magnetite nanoparticles (Fe3O4 NPs) were synthesized using the chemical 
co-precipitation method of ferrous (Fe
2+
)/ferric (Fe
3+
) mixed aqueous salt solutions in pres-
ence  of well-defined biocompatible low-generation (poly)amidoamine (PAMAM)-based 
dendrimers with end-grafted n ethylene glycol ether (n = 1, 2, 9) moieties, accessible by 
means of straightforward consecutive divergent synthesis methodologies including addition 
and amidation cycles. Addition of NH4OH to the respective dendritic nanoreactor containing 
iron salt solution produced dendritic stabilized uniform shaped magnetite nanoparticles. The 
structural and magnetic properties of Fe3O4 NPs were analyzed by FT-IR spectroscopy, ther-
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mogravimetry (TGA), X-ray powder diffraction (XRPD), transmission electron microscopy 
(TEM) and superconducting quantum interference device (SQUID) vibrating sample magne-
tometry (VSM). The coherence of affecting the average magnetite particle diameter in range 
of 5.6 ( 1.4) nm to 10.1 ( 1.9) nm by the dendritic scaffold, the number and length of the 
attached ethylene glycol ether termini as well as the adjusted stabilizer-to-Fe3O4 ratio is dis-
cussed along with their magnetic peculiarities. 
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5. Appendix Chapter G 
 
Dendrimer – Doxorubicin Conjugate for Enhanced  
Therapeutic Effects for Cancer 
 
Sudeshna Chandra, Sascha Dietrich, Heinrich Lang and Dhirendra Bahadur 
 
(Published in J. Mater. Chem. 2011, 21, 5729 – 5737.) 
 
Abstract 
An oligo(ethylene glycol)-grafted amidoamine dendrimer was synthesized and characterized 
by FT-IR, MS, 
1
H and 
13
C NMR. The dendritic scaffold was evaluated for its potential to load 
doxorubicin and its release, thereafter. The interaction between drug and the dendrimer was 
reviewed by  potential, HPLC, NMR and FT-IR spectroscopy. The drug encapsulation effi-
ciency was as high as 52 %. The temperature stimulated release characteristics of the DOX 
loaded dendrimers were studied in PBS and SBF at 37 °C (physiological temperature) and 43 
°C (hyperthermic temperature). A biphasic suspension of the dendrimer-drug conjugate and a 
magnetic fluid entitles release of the drug under AC magnetic field which can simultaneously 
be used for hyperthermia treatment of cancer. The efficacy of dendrimer-DOX conjugate was 
evaluated in vitro against cancer cell lines and the IC50 was estimated. 
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